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ABSTRACT
The microvascular endothelium serves as the barrier between the blood and perfused
tissues. Proper function of the endothelium is dependent on the ability of the
endothelial cells to produce nitric oxide and form tight junctions between themselves.
Dysfunction occurs when stresses overwhelm the endothelial cell, with oxidative stress
being a leading cause. Intracellular metabolism of purine nucleosides and nucleobases
has been implicated in the production of oxidative stress. Nucleosides (e.g. adenosine)
and nucleobases (e.g. hypoxanthine) are moved across cell membranes by a specialized
family of proteins called equilibrative nucleoside transporters (ENTs).
We characterized primary human cardiac microvascular endothelial cells (MVECs) for
expression, function, and regulation of nucleoside and nucleobase transporters. It was
discovered that nucleobase transport in these MVECs was mediated by a novel, purine
selective transporter that was insensitive to inhibitors of ENTs, which we named
equilibrative nucleobase transporter 1 (ENBT1). ENBT1 and the nucleoside selective
transporter ENT1 were differentially regulated by a number of intracellular protein
kinases, vascular endothelial growth factor, and oxidative stress.
The role of nucleoside and nucleobase transport in the physiology of MVECs was also
studied, using primary MVECs isolated from wild-type (WT) and ENT1-/- mice. Altered
gene expression of adenosine metabolizing enzymes and adenosine signaling was
identified and confirmed at the protein level, however, there was no compensatory
changes in other nucleoside or nucleobase transporters. Coinciding with the loss of
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adenosine transport capabilities, ENT1-/- mice had elevated adenosine plasma
concentrations compared to WT and lowered blood pressure.
Unexpectedly, the ENT1-/- began to develop hind limb paralysis at about 12 months old.
Post-mortem analysis revealed abnormal mineralization on the spine leading to spinal
cord compression. MicroCT analysis was used to determine a time course of
development, with mineralization being apparent as early as 2 months old. The pattern
of mineralization resembled the human condition known as diffuse idiopathic skeletal
hyperostosis (DISH).
Nucleoside and nucleobase transporters are important in the regulation of
cardiovascular effects of purines, with special consideration to oxidative stress and
blood pressure. We may have also discovered a novel role for ENT1 in the development
of DISH.

Keywords: adenosine, hypoxanthine, microvascular endothelium, transporters,
metabolism, reactive oxygen species, regulation, ischemia-reperfusion injury,
hypotension, diffuse idiopathic skeletal hyperostosis
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CHAPTER ONE
INTRODUCTION
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The work presented in this thesis was focused on understanding the function,
regulation, and physiological roles of nucleoside and nucleobase transporters expressed
in microvascular endothelial cells (MVECs). Following a brief introduction and
information on the hypotheses addressed in this thesis, research will be presented in
two main sections. The first section, which includes Chapters Three and Four, discuss
the expression, function, and regulation of nucleoside and nucleobase transporters in
primary human MVECs. The second section, which includes Chapters Five and Six, focus
on mouse models for nucleoside and nucleobase transport and with the aid of a
nucleoside transporter deficient mouse, it aims to help further the understanding of the
physiological importance of nucleoside and nucleobase transporters. The thesis will
conclude with a concise chapter pulling together all the information discussed and
provide clear concepts that can be derived from the work as a whole.
1.1 The Endothelium
The bulk of the research presented in this thesis was conducted with endothelial cells.
The following section will highlight the importance of this cell type and the unique
properties of the endothelium as a tissue. The endothelium is the specialized lining of
both the cardiovascular and lymphatic systems. It is estimated to cover 350 m 2 in the
average person and is the barrier between the blood and tissues (44). The endothelium
is also an important regulator of vascular tone and other important biological processes
including angiogenesis (the formation of new blood vessels), fluid and solute transport,
and inflammation (44). The endothelium can perform these multiple functions because
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rather than being one single identical sheet, there is a great deal of heterogeneity across
organs and even within continuous vascular beds(44).
1.1.1 Classifications of Endothelia
The simplest distinction of endothelia is based on the size of the vasculature where they
are found. There are two classifications: macrovasculature and microvasculature.
Macrovasculature includes any vessel 500 µm or greater in diameter. This includes
major arteries like the aorta, and major veins, like the superior vena cava. Everything
else is thus considered microvasculature, the major component of which is the
capillaries, which have a diameter of 10 µm or less. The microvasculature can also
include smaller arterioles and venuoles (55).
The other important classification of endothelia is based on the cellular morphology,
which also determines permeability. There are three types of morphologies: continuous,
fenestrated, and discontinuous (44). Continuous endothelium is the least permeable,
with cells forming tight junctions between themselves. Continuous endothelium exists
where controlling exchange between the blood and tissue is most important, for
example at the blood-brain barrier. Fenestrated endothelia have very fine pores
(fenestrae) less than 100 nm in diameter that are sealed with a semi-permeable
diaphragm. This design allows for increased permeability of hydrophilic, low-molecular
weight molecules and water. Fenestrated endothelium is found in locations were
absorption and secretion are important, for example in the kidney glomerulus or in
endocrine glands. Finally, discontinuous endothelium is the most permeable, with larger
fenestrae (up to 1 µm in diameter). However these fenestrae lack the diaphragm seen in
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fenestrated endothelium, and are also either lacking a basement membrane or the
basement membrane is also porous. Discontinuous endothelium is commonly found in
organs like the liver and spleen where they act as less selective filters for
macromolecules or aid in filtering the blood, respectively (44).
1.1.2 The Endothelial Cell
1.1.2.1 Identification and Function
Endothelial cells, the specialized cell type that makes up the endothelium tissue, can be
identified by several unique characteristics. These characteristics contribute to the
normal functioning of the endothelial cell, and therefore the endothelium tissue as a
whole.
The endothelial cell is most well known for the expression of endothelial nitric oxide
synthase (eNOS). eNOS produces nitric oxide (NO) from the amino acid L-arginine, which
can then alter transcription of genes in the endothelial cell and reduce vascular tone by
promoting the relaxation of smooth muscle cells through the activation of soluble
guanylate cyclase.
An important feature of the endothelial cell is the endothelial glycocalyx, a layer of
gylcoproteins and proteoglycans about 100 nm thick on the surface of the endothelial
cell. Of the proteoglycans in the glycocalyx, up to 90% are heparin sulphate
proteoglycans. These heparin sulphate proteoglycans bind antithrombin III, and this
combination is what gives the endothelial surface its anti coagulation properties (44).
The endothelial surface layer also limits mechanical stress both on the circulating red
blood cells and the endothelial cell itself. The loss of the endothelial surface layer can
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alter blood clotting, red blood cell life-span, blood flow dynamics through capillaries,
and mechanical damage to endothelial cells (44).
Endothelial cells can also be identified by the presence of specific proteins they express.
These proteins include eNOS, vascular endothelial growth factor receptor 2, von
Willebrand factor, vascular endothelial cadherin, and E-selectin (28).
1.1.2.2 Endothelial Dysfunction
Endothelial dysfunction is a blanket term that covers any change that prevents the
endothelial cell from functioning normally. However, in practice, endothelial
dysfunction is most commonly used to describe the decreased ability of the endothelial
cell to produce NO, leading to increased smooth muscle tone and hypertension.
Additionally, endothelial dysfunction may refer to a loss of the barrier function, resulting
in vascular leakage. The inability to prevent coagulation, leading to the formation of
clots is also a type of endothelial dysfunction. Ultimately, dysfunction may lead to the
loss of endothelial cells through cellular death.
Endothelial dysfunction can be caused a number of different factors including
inflammation (43) and reactive oxygen species (ROS) (59; 63), or conditions that
promote inflammation or ROS production such as hypertension (9) and diabetes (18).

1.2 Ischemia and Reperfusion
Ischemia is the lack of blood flow to a tissue. The area affected by ischemia is
characterized by reduced oxygen concentrations, known as hypoxia, and nutrient
supply. There is also an accumulation of metabolic products that cannot be removed
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due to the lack of blood flow. It is important to know that hypoxia can occur without
ischemia. Reperfusion is the return of oxygenated blood flow to the tissue that was
previously ischemic.
1.2.1 Cardiovascular Ischemia
Ischemia in the cardiovascular system is a life threatening condition. Cardiac ischemia
can cause a myocardial infarction, or heart attack. The length and severity of the
ischemic attack can influence the extent of cardiomyocyte death (30).
1.2.2 Reperfusion and the Microvasculature
The return of oxygenated blood flow to an ischemic tissue, especially in the heart, is
mandatory for survival of the cardiomyocytes. However, reperfusion is the start of a
second wave of damage, one that affects the microvascular endothelium. Perhaps the
best evidence that the microvasculature can be damaged as a result of ischemia is the
‘no-reflow’ phenomenon seen in cardiac angiograms 24 hours after reperfusion. Noreflow is the lack of the return of blood flow to the microvasculature in a previously
ischemic area of the heart, usually in correlation to the infarct zone (7; 47).
1.2.2.1 Reperfusion-Induced Inflammation
During ischemia the lowered oxygen concentrations lead to the release of P-selectin and
the activation of the transcription factor NF-κB, which in turn increases the expression
of adhesion molecules on the endothelial cell surface (7). With reperfusion, the
returning blood brings white blood cells, including leukocytes. The leukocytes are
attracted to the adhesion molecules expressed on the endothelial cell and are slowed
down, a process called leukocyte rolling. Once the leukocytes have slowed enough, they
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will adhere to the endothelial cell and then migrate through inter-endothelial spaces
into the surrounding tissue. At this time the leukocytes are activated and release ROS
damaging the endothelial cells ultimately leading to endothelial dysfunction and the noreflow phenomenon (7; 23).
1.2.2.2. Reperfusion and ROS
In addition to the ROS produced by recruited leukocytes, intracellular processes
contribute to the production of ROS and endothelial damage. The return of oxygen
allows mitochondria and intracellular oxidation proteins to function again. However,
mitochondrial electron transport processes are uncoupled, leading to more ROS
production and the opening of the mitochondria permeability transition pore, which
leads to cellular apoptosis (12). Increased ROS formation through NADPH oxidase and
xanthine oxidase interfere with the proper functioning of eNOS and directly react with
NO, effectively reducing NO bioavailability and thus contributing to endothelial
dysfunction (12; 23; 30).
1.2.3 Purines and Cardiovascular Ischemia
As mentioned above, the purine metabolizing enzyme xanthine oxidase, is capable of
producing ROS during reperfusion. This thesis will focus on the role of purine
transporters and metabolism in the microvascular endothelium in the context of
ischemia-reperfusion. The following sections of this chapter will introduce the necessary
concepts of purines, purine metabolism, and purine transport required to appreciate
the work presented in subsequent chapters.
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1.3 Nucleobases, Nucleosides, and Nucleotides
Nucleobases (also known as nitrogenous bases) are the building blocks of some of the
most important molecules in life. The bases are classified in two types, purine or
pyrimidine. Purine bases have a double ring structure compared to the pyrimidine single
ring structure. In fact, purine bases are pyrimidine rings fused to an imidazole ring.
Nucleosides are nucleobases bound to a ribose or deoxyribose sugar through an Nglycosidic bond. Nucleosides, especially the purine adenosine, have important biological
roles. Nucleosides can also have phosphate groups added to them to become
nucleotides. Nucleotides are the monomers of DNA and RNA. Nucleotides are also used
as cellular energy molecules and in intracellular signalling cascades. Figure 1.1 outlines
the relationship between these molecules.
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Figure 1.1. Nucleobase, nucleosides, and nucleotides.
A schematic showing the relationship between nucleobases, nucleosides, and
nucleotides. Purine and pyrimidine nucleobases are shown in blue on the right hand
side of the figure. On the bases, R represents the location of where the base is attached
to the sugar moiety by the glycosidic bond. The yellow sugar in the middle of the figure
can vary at the 2’ position, where the presence of an OH group defines a ribose, where
as if there is only an H, the sugar is a deoxyribose, and thus a nucleoside or
deoxynucleoside respectively. When phosphate groups, shown in red, are bound to a
nucleoside, a nucleotide is formed. The number of phosphate groups determines the
type of nucleotide.
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1.4 Adenosine
The purine nucleoside adenosine is one of the most important molecules in biology. In
addition to well known roles as the starting point of the cellular energy molecule
adenosine triphosphate (ATP), free adenosine can regulate the physiology of a variety of
different systems including the CNS (sleep, anxiety, addiction), cardiovascular, renal, and
immune system (4; 11; 27; 56). Adenosine is also important in pathophysiology, acting
as a protector of cardiac and neuronal tissue during ischemic insult (33; 36; 40; 46). To
accomplish these feats, adenosine must be present in the extracellular space to interact
with specific adenosine receptors.
1.4.1 Adenosine Bioactivity
Adenosine mediates cellular effects through the family of P1 purinergic G protein
coupled receptors, more commonly referred to as adenosine receptors. To date, 4
adenosine receptor subtypes have been identified and cloned: A1, A2A, A2B, and A3 (20).
A1 and A3 receptors have been shown to signal through Gi, inhibiting cAMP production
by adenlyate cyclase, where as the A2 subtypes signal through Gs, stimulating cAMP
production (20).
1.4.2 Adenosine in Ischemia-Reperfusion
During ischemia adenosine is released from cardiomyocytes and local extracellular
concentrations can rise from nanomolar to micromolar levels (26). Adenosine is formed
in cardiomyocytes during ischemia from two major sources: breakdown of ATP and sadenosylhomocystine catabolism (26; 32).
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1.4.2.1 Adenosine and Cardioprotection
The release of adenosine during ischemia is a defensive mechanism to reduce cardiac
infarct size.
The A1 receptor subtype has been the most extensively studied and is the key player in
the ability of adenosine to protect cardiac myocytes from infarction following an
ischemic insult (10; 40; 66; 69). In fact, A1 receptor agonism with pharmacological
ligands can also confer cardioprotection (29; 60; 65). However, vascular endothelial
cells, which are also susceptible to damage from ischemia/reperfusion, do not express
A1 receptors; the A2 subtypes are the predominant receptors (16; 19; 51).
1.4.2.2 Endothelial Adenosine Metabolism
While adenosine is initially cardioprotective – reducing infarct size – this excess
adenosine will eventually accumulate in the microvasculature. The surrounding cardiac
microvascular endothelium acts as a ‘sink’ removing approximately 65% of released
adenosine from the interstitium (8).
Adenosine is metabolized intracellularly by two distinct pathways: a high affinity
pathway via adenosine kinase, producing adenosine-5`-monophosphate, and a low
affinity pathway via adenosine deaminase, producing the nucleoside inosine (32).
Under normal conditions, adenosine kinase works below its Km value due to low
intracellular free adenosine concentrations.

However, during ischemia, the excess

adenosine leads to adenosine kinase saturation and inactivation, thus shifting
metabolism to adenosine deaminase, increasing intracellular inosine concentrations.
Inosine is metabolized by purine nucleoside phosphorylase to form the purine
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nucleobase hypoxanthine. Xanthine oxidase then catalyzes the conversion of
hypoxanthine to xanthine and xanthine to uric acid (Figure 1.2) (38). These reactions
result in the production of superoxide anion which is converted to hydrogen peroxide by
superoxide dismutase. Hydrogen peroxide can either be detoxified to water and oxygen
through the enzymes catalase and glutathione peroxidase or can be used to form strong
oxidizing chemicals such as hypochlorous acid by myeloperoxidase (5). In addition to
enzymatic reactions, hydrogen peroxide can spontaneously form hydroxyl radicals in the
presence of ferrous iron by the Fenton reaction. Hydroxyl radicals are extremely
reactive and will oxidize almost any cellular target. In endothelial cells, nitric oxide
produced by endothelial nitric oxide synthase can also react with hydrogen peroxide to
form the reactive peroxynitrite anion radical. Xanthine oxidase mediated superoxide
production is thought to contribute to cellular damage upon reperfusion, when the
return of oxygen allows the enzyme to metabolize the hypoxanthine that accumulated
during ischemia. In fact ROS generated by xanthine oxidase have been implicated in
microvascular endothelial dysfunction (5; 48).
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Figure 1.2. Endothelial purine metabolism during ischemia-reperfusion.
During cardiac ischemia, adenosine is released from cardiomyocytes and accumulates
within the surrounding endothelial cells. This schematic highlights the deamination
pathway of adenosine metabolism that is enhanced when the adenosine kinase enzyme
becomes saturated. Adenosine is metabolized to inosine by enzyme 1, adenosine
deaminase. Enzyme 2, purine nucleoside phosphorylase, catalyzes the formation of the
nucleobase hypoxanthine from inosine. This pathway will not progress until reperfusion
and the return of oxygen. During reperfusion, enzyme 3, xanthine oxidase, is capable of
metabolizing hypoxanthine to xanthine, and xanthine to uric acid. Xanthine oxidase
mediated oxidation of hypoxanthine and xanthine produces ROS, specifically superoxide
anion, which contributes to endothelial damage and dysfunction.
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1.5 Nucleoside Transporters
Regulation of extra- and intracellular nucleoside concentrations is important in
controlling energy balance as well as cellular signalling in response to physiological
stimuli. However, nucleosides are hydrophilic and therefore are incapable of crossing
the plasma membrane. Two families of the solute carrier (SLC) superfamily of
membrane transporters specialize in the transmembrane flux of nucleosides; the
concentrative nucleoside transporters (SLC28A) and the equilibrative nucleoside
transporters (SLC29A).
1.5.1 Concentrative Nucleoside Transporters
Concentrative nucleoside transporters (CNTs) are a family of sodium-dependent
transporters. CNTs move substrates against their concentration gradients into a cell,
while co-transporting sodium ions. CNTs require energy from ATP to function, however
the energy is used indirectly as CNTs do not catalyze ATP hydrolysis. Since CNTs require
sodium as a co-transported ion, they depend on larger extracellular sodium
concentrations compared to intracellular. This gradient is achieved by the sodiumpotassium ATPase (24).
To date, three CNTs have been cloned: CNT1-3. CNT1 transports pyrimidines, CNT2
purines, and CNT3 is broadly selective (24). CNTs have very specialized expression, with
CNT1 being localized to the kidney and liver and CNT2 having highest expression in the
intestine (41).
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1.5.2 Equilibrative Nucleoside Transporters
Equilibrative nucleoside transporters (ENTs) are sodium-independent, facilitative
diffusion transporters. As such, ENTs mediate the transmembrane flux of nucleoside
down their concentration gradient, either in to or out of the cell. Currently four
members of the family have been identified and cloned; ENT1-4. All members share a
common 11 membrane spanning domain topology with an intracellular N-terminus, and
extracellular C-terminus, a large glycosylated extracellular loop between TMD1 and
TMD2, and a large intracellular loop between TMD6 and TMD7. The orientation of the
termini and loops was confirmed by the work of Sundaram and colleagues in 2001 (57).
(Figure 1.3).
1.5.2.1 ENT1
ENT1 is the most widely distributed and most studied of the ENTs. Before the gene was
cloned, ENT1 was defined pharmacologically as the nucleoside transport system that
was

sensitive

to

nanomolar

concentrations

of

the

nucleoside

analogue

nitrobenzylmercaptopurine riboside (NBMPR). Consequently, this transporter was
referred to as es, or equilibrative sensitive (1; 68). ENT1 is also inhibited by vasoactive
drugs dipyridamole, draflazine, and dilazep (62). Inhibition of ENT1 by these drugs
promotes local increases in adenosine concentrations, leading to enhanced adenosine
receptor signalling and a vasodilation response (34).

ENT1 is also exploited in

chemotherapy to mediate the uptake of nucleoside analogue drugs in to tumour cells
(13; 25; 61), or cells infected with parasites (e.g. malaria) (61; 68) or viruses (e.g. HIV)
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(21; 35; 45). The level of expression of ENT1 in various cancers has been linked to
chemotherapy resistance and survival rates (17; 42).
The human ENT1 transporter was first cloned in 1997 (25), followed by the mouse in
2000 (31). Interestingly, the mouse ENT1 differed from human in respect to a variety of
splice variants that produced three different proteins, mENT1a, mENT1b, and
mENT1∆11(31). The mENT1a and 1b variants differed in the number of protein kinase
CKII consensus sites, which resulted in a sensitive (1b) or insensitive (1a) transporter to
the effects of inhibiting CKII with the compound TBB(6). The human ENT1 is more like
the mENT1b variant (6). The mENT1∆11 variant lacked the last three transmembrane
domains. Interestingly, the protein was still made and fully functional, but lacked the
ability to be irreversibly linked to NBMPR via photoaffinity labelling (50).
1.5.2.2 ENT2
ENT2 varies from ENT1 in several key ways. First, ENT2 is insensitive to NBMPR, leading
to the early identifier of ei, equilibrative insensitive. Chimeric proteins of rat ENT1 and
ENT2 identified transmembrane regions 3-6 as the site of NBMPR sensitivity (58). In
studies using human transporters, two glycine residues, G154 and G179, in
transmembrane domains 4 and 5 respectively, were identified as conferring NBMPR
sensitivity to ENT1 (53; 54). In fact, in ENT2, the residue at position 154 is a serine,
which may contribute to the lack of NBMPR sensitivity (54). Second, ENT2 is capable of
transporting nucleobases, in addition to nucleosides. This feature of ENT2 will be
discussed in Section 1.6.
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ENT2 also has a more discrete expression profile compared to ENT1, with the highest
level of expression in skeletal muscle (41). Other tissues that express ENT2 at notable
levels are kidney, small intestine, stomach, and pituitary gland (41).
1.5.2.3 ENT3
Unlike ENT1 and ENT2, ENT3 is not found on the plasma membrane (68). Instead, ENT3
is localized to lysosomes due to a endosomal/lysosomal targeting motif in the Nterminal of the protein (2). ENT3 is broadly selective for nucleosides and is capable of
transporting the nucleobase adenine, but not hypoxanthine (2). Additionally, ENT3
differs from ENT1 and ENT2 by requiring an acidic pH of 5.5 to operate optimally (2).
1.5.2.4 ENT4
ENT4 was originally identified as a monoamine transporter in the brain and named
plasma membrane monoamine transporter (PMAT) (15; 70). Substrates were
neurotransmitters such as serotonin and dopamine, and the neurotoxin MPP + (14).
However, it was subsequently found that ENT4 was expressed in the heart and gained
the ability to transport adenosine at acidic pH, whereas serotonin transport was
insensitive to pH (3). To date, no other nucleoside (or nucleobase) substrates of ENT4
have been identified (68).
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Figure 1.3. Predicted 2-dimensional structure of ENT proteins.
The predicted 2-dimenstional structure of ENT proteins with the intracellular Nterminal, extracellular C-terminal, and 11 transmembrane domains. A large gylcosolated
extracellular loop can be found between transmembrane domains 1 and 2. Between
transmembrane domains 6 and 7 there is a large intracellular loop. The circle represents
the location of the endosomal/lysosomal targeting motif found in ENT3. The solid
square highlights the regions of transmembrane domains 4 and 5 where G154 and G179
are found that confer NBMPR sensitivity to ENT1. The dashed line box around
transmembrane domains 5 and 6 represent the part of ENT2 that is responsible for
conferring the ability to transport nucleobases.
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1.6 Nucleobase Transporters
As with nucleosides, nucleobases are unable to cross the plasma membrane without
specialized transport proteins to facilitate the process. However, unlike nucleoside
transport, nucleobase transport in mammalian cells not been highly studied.
1.6.1 ENT2
As mentioned in Section 1.3.2.2, the nucleoside transporter ENT2 is also capable of
transporting nucleobases. Substrates recognized include the purine nucleobase
hypoxanthine (39; 49), the pyrimidine nucleobase uracil (67), and the chemotherapeutic
nucleobase analogues 6-mercaptopurine and 6-thioguanine (37). Uptake of nucleobases
by ENT2 is sodium-independent and can be inhibited by excess nucleobases and
nucleosides (67). Additionally, the nucleoside transport inhibitors NBMPR and
dipyridamole prevent hypoxanthine uptake through ENT2 at concentrations of 10 µM
(49; 67).
The affinity of ENT2 for nucleobases varies in the literature. Recombinant human ENT2
and rat ENT2 expressed in Xenopus oocytes have reported Km values for hypoxanthine of
700 ± 100 µM and 1000 ± 100 µM respectively (67). In primary rat microvascular
endothelial cells (MVECs), the reported Km value for hypoxanthine was 300 ± 100 µM
(49).
In addition to uptake, ENT2 is capable of releasing nucleobases from cells. In primary
rat MVECs, hypoxanthine was released from cells with a Km of 189 ± 67 µM, very similar
to the reported uptake affinity in the same cells (49). The efflux of hypoxanthine was
inhibited by dipyridamole (49).
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Using chimeras of rat ENT1 and ENT2 proteins, it was found that ENT1 gained the ability
to transport hypoxanthine when transmembrane regions 5 and 6 were replaced with
the corresponding regions from ENT2 (Figure 1.3) (67).
1.6.2 SLC23a4/Sodium-dependent nucleobase transporter 1 (SNBT1)
Recently, a novel nucleobase transporter was cloned from rat small intestine (64). This
transporter belonged to the SLC23 family, the sodium-dependent ascorbic acid
transporter (SVCT) family, and was predicted to have 12 transmembrane domains.
Recombinant SNBT1 expressed in HEK293 cells was able to transport guanine,
hypoxanthine, xanthine, thymine, and uracil. Notably, SNBT1 was unable to transport
adenine or ascorbic acid. Transport of xanthine and uracil was sodium-dependent and of
high affinity, with Km values of approximately 80 µM and 20 µM respectively (64).
Uptake could be inhibited by nucleobase analogues 5-fluorouracil and 6mercaptopurine, as well as the ENT inhibitor dipyridamole. Nucleosides had no effect on
SNBT1-mediated transport of nucleobases, nor did another ENT inhibitor, NBMPR (64).
A human ortholog was found by in silico analysis; however the human gene for SNBT1
contained seven exons instead of the twelve exons found in the rat gene. The exons
missing corresponded to highly conserved, transmembrane domain encoding regions in
the rat gene (64). Reverse-transcriptase polymerase chain reaction (RT-PCR) was
performed and it was determined that the human SNBT1 gene is in reality a
pseudogene, and thus does not produce a functional protein (64).
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1.6.3 SVCT/Nucleobase-ascorbate Transporter (NAT)
It seems strange to discuss ascorbic acid transporters in a section on nucleobase
transporters, as the chemical structure of ascorbic acid resembles a sugar more so than
a nucleobase (52). Moreover, there is no evidence that SVCTs can transport nucleobases
at all.
As mentioned in the previous section, SVCTs belong to the SLC23 family of transport
proteins. In humans, the SLC23 members are SVCT1 and SVCT2 (52). However, in lower
organisms like bacteria, fungi, and plants, NATs are common and actually transport
nucleobases (although they may not necessarily transport ascorbic acid) (22). The most
well known transporters, UrpA, UrpC, and UraA are fungal uric acid-xanthine
transporters found in Aspergillus nidulan, and bacterial uracil transporter of Escherichia
coli respectively.
In fungi, NATs are thought to be scavengers of uric acid and xanthine as a source of
nitrogen. Bacteria, on the other hand, use NATs to scavenge uracil for nucleoside
synthesis, which can then be used for nucleotide and DNA/RNA production.
It is not understood how or why the evolutionary progression of NATs in lower
organisms resulted in the SVCT proteins in humans that are incapable of transporting
nucleobases.
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CHAPTER TWO
RESEARCH QUESTIONS, GENERAL HYPOTHESES, AND COMMON METHODOLOGIES
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2.1 Research Questions
The microvasculature has been an understudied tissue with respect to nucleoside and
nucleobase transport. Human umbilical vein endothelial cells have been a popular
model to study nucleoside transport, however these cells are derived from a
macrovessel. Nucleobase transport in humans is even less studied and those studies
that have been conducted tend to focus on infection or cancer, as there are a variety of
nucleobase analogues used as chemotherapeutic agents, including 5-FU, 6-MP, and 6-TG
(18; 29; 31).
Thus, to understand nucleoside and nucleobase transport and metabolism in the human
microvasculature, the most direct approach is to use human primary microvascular
endothelial cells. What purine transporters are expressed in MVECs? Are MVECs capable
of transporting nucleobases? These are the kinds of basic questions that were
addressed early on in this work.
Once those basic questions are answered, the focus turns to regulation of the
transporters. ENT1 regulation is an area of extensive research, however the models
used are generally cancer cells lines, artificial over-expression systems, non-human cell
lines, and even non-mammalian organisms. While important for general understanding
of ENT1 regulation, these data may not be readily extrapolated to normal human cells.
Does ENT1 respond in the same manner to intracellular kinase activity in primary cells as
compared to cancerous or artificial cell lines? How are nucleobase transporters
regulated? Additionally, questions regarding how nucleoside and nucleobase
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transporters are affected by reactive oxygen species and hypoxia/ischemia have not
been addressed.
Finally, the role of ENT1 in the regulation of purine homeostasis is still not completely
understood. By using an ENT1 null animal, questions regarding compensatory
mechanisms in purine handling can be addressed. As well, given the important
cardiovascular role of adenosine, questions about the cardiovascular health and
functionality of animals with comprised adenosine handling can also addressed.

2.2 Hypotheses
2.2.1 Chapter 3 – Human Primary MVEC Characterization
As outlined in Chapter 1, movement of nucleosides and nucleobases across the cell
membrane requires specialized transport proteins. Both ENT1 and ENT2 contribute to
nucleoside transport, and as in the case with primary rat MVECs from skeletal muscle,
ENT2 can contribute up to 50 % of nucleoside transport capacity (3). Nucleobases, on
the other hand appear to be transported only by ENT2 as other known nucleobase
transporters do not exist in human cells (39; 40). Therefore it is hypothesized that:


Uptake of nucleosides, as measured with 2-[3H]chloroadenosine, in human
MVECs is mediated by ENT1 and ENT2. ENT2 will contribute up to 50 % of total
uptake capacity.



Nucleobase uptake, as measured with [3H]hypoxanthine, is facilitated by ENT2,
not ENT1 in human MVECs.
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2.2.2 Chapter 4 – Regulation of purine transporters in human primary MVECs.
Evidence has been amassed in other cell types that support the regulation of ENT1
function by a variety of molecular mechanisms, including intracellular kinases PKA (10),
PKC (9; 21), CKII (4; 35), adenosine A2 receptors(15; 32), and a receptor tyrosine kinase
(RTK) (37). Transcriptional regulation of ENT1 has also been studied and found to be
altered by hypoxia inducible factor 1 alpha (1; 13), elevated glucose (33), and nitric
oxide (16; 17). ENT1 and ENT2 function has been shown to decrease in response to
hypoxia in a variety of models (5; 6; 19; 27; 28). However, ENT2 may not be affected by
elevated glucose (2). Additionally, adenosine uptake has been affected by peroxynitrite
treatment (36). Therefore it was hypothesized that:


Both ENT1 and ENT2 function is regulated by the activation and/or inhibition of
the intracellular kinases PKA, PKC, or CKII.



Nucleoside and nucleobase uptake is diminished after hypoxia, ischemia, or
oxidative stress.



Nucleoside and nucleobase uptake is sensitive to regulation by vascular
endothelial growth factor (VEGF), a major protein produced during hypoxia that
acts through a family of RTKs (41).

2.2.3 Chapter 5 – MVECs from ENT1-/- Mice
The ENT1-/- mouse generated by Choi and colleagues (8) has been studied at the level of
the central nervous system (7; 8; 30; 38), the heart (34), kidney (22), and anti-viral
pharmacokinetics (14). No studies on the vasculature have been conducted. Given the
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importance of nucleosides in the vasculature, MVECs were isolated from wild-type and
ENT1-/- mice and characterized.
It was hypothesized that:


As previously found in rat MVECs, mouse primary MVECs from skeletal muscle
will express ENT1 and ENT2, with ENT2 accounting for up to 50% of total
nucleoside uptake capacity.



ENT2 expression or other ENT subtypes will be up-regulated in ENT1-/- MVECs to
compensate for the lack of the primary nucleoside transporter ENT1.



Genes related to metabolism, and/or signalling would have altered expression
levels to compensate for changes in cellular purine metabolite concentrations.



Mouse ENT1 and ENT2 would respond in a similar manner to hypoxia, ischemia,
and oxidative stresses compared to human ENT1 and ENT2.

2.2.4 Chapter 6 – Additional Phenotypes of ENT1-/- Mice
The ENT1-/- mouse appeared phenotypically normal, however only ethanol consumption
and anxiety behaviour was examined (7; 8). No in-depth phenotype profile was
generated. An independent laboratory generated their own ENT1-/- mouse and found
altered gene expression with quantitative PCR that was different between tissues (20).
Adenosine accumulates in extracellular spaces during times of stress, otherwise the
amount of free adenosine is minimal (11).
Therefore it was hypothesized that:


Circulating adenosine concentrations will be reduced in resting ENT1-/- mice
relative to wild-type.

35



Organs will have altered expression of genes related to purine transport and
metabolism

2.3 Common Methodologies
Many of the experiments relied on a common set of techniques and methods. In the
interest of clarity and readability, the basics of those techniques are described here,
allowing the unique details of each experiment to stand out without being lost in
repetition.
2.3.1 Mammalian Cell Culture
The most common cell type used was primary human cardiac microvascular endothelial
cells obtained from Lonza (Walkersville, MD). These cells were used between passage 47 and cultured in EGM2-MV medium as supplied by the manufacture. Medium was
changed 24 hr following seeding and then every 48 hr thereafter. Generally, MVECs
were passaged at a ratio of 1:7 as determined by cell counting to seed 5,000 cells/cm2
growth area as instructed by the supplier.
Additional cell types used when required are described in the appropriate chapter. All
cultured cells were maintained in a humidified atmosphere of 95% air-5% CO2 at 37°C.
2.3.1.1 Cell Harvesting
All [3H]NBMPR binding assays and transport assays were conducted with cell
suspensions to achieve the short incubation times required for transport kinetic
analysis. All cell types were harvested in the same manner. Cells were first washed with
phosphate-buffered saline (PBS: in mM: 137 NaCl, 6.3 Na2HPO4, 2.7 KCl, 1.5 KH2PO4, 0.9
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CaCl2·2H2O, 0.5 MgCl2·6H2O; pH 7.4) followed by trypsinization with 0.05% trypsin-0.53
mM EDTA. Trypsinized cells were then diluted 4-fold in 500µg/ml trypsin inhibitor in PBS
and collected by centrifugation at ~220 x g for 5 minutes. Pellets were washed in the
desired assay buffer, re-centrifuged, and resuspended in the same buffer for immediate
use in the assay.
2.3.2 [3H]NBMPR Binding Assay
To measure the amount of ENT1 protein present on the cell membrane, radioligand
binding using [3H]NBMPR was employed. NBMPR is a high affinity, non-transported
ligand that is selective for ENT1. Assays were conducted in 13x100 mm boroscillicate
glass tubes in duplicate. A working stock of [3H]NBMPR at a desired concentration
(usually 1.5 or 5 nM) was made by diluting stock [ 3H]NBMPR PBS and adjusted to the
required disintegrations per minute (DPM) as dictated by the specific activity of the
stock. Volumes of [3H]NBMPR were added to give the desired concentration in a final
volume of 1 ml. PBS was added to a volume of 925 µl and the reaction was started by
adding 75 µl of cell suspension. To determine non-specific binding, a set of tubes
included 10 µM nitrobenzylthioguanine riboside (NBTGR) or dipyridamole. Reactions
were incubated at room temperature (~22°C) for 45 min to allow equilibrium to be
achieved. Assays were terminated by filtration using a 24-port Brandell Cell Harvester
with ice cold 10 mM Tris buffer (pH 7.4) and collected on Whatman A-937 grade filter
paper strips. Perforated filter paper circles were placed in scintillation vials, mixed with
5 ml of liquid scintillation cocktail and incubated overnight (≥12 hr) before counting on a
liquid scintillation analyzer.
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Data were obtained as DPM and converted to pmol using the equation:
pmol = DPM/specific activity (DPM/fmol)/1000.
Specific binding was defined as the difference between total binding (no inhibitor
present) and non-specific binding (in the presence of 10 µM inhibitor). Equilibrium free
concentrations of [3H]NBMPR were determined for each condition (total, specific, nonspecific) by subtracting pmol bound from pmol added and dividing by the assay volume
of 1 ml. Since one molecule of [3H]NBMPR binds to one ENT1 protein (23; 24), specific
bound pmol [3H]NBMPR were converted to ENT1 per cell using the equation ENT1/cell =
pmol/cells ml-1 * 6.023x1011 molecules pmol-1. Cell concentrations were obtained using
a haemocytometer or a Bio-Rad TC-10 automated cell counter.
2.3.3 Oil-Stop Transport Assay
To measure accurately the transport kinetics of transporters a reliable, reproducible,
efficient stopping technique is required. To achieve this, the oil-stop method was
employed. A schematic overview of the technique is presented in Figure 2.1.
2.3.3.1 [3H]Substrate Preparation
In contrast to [3H]NBMPR binding, much higher concentrations of substrate are required
for transport assays. To reduce the amount of [ 3H]substrate required, the desired
concentrations of substrate were established with non-radioactive versions of the
substrate. These non-radioactive substrate concentrations were then spiked with small
amounts of radioactive substrate to allow the accumulation of substrate inside the cell
to be measured by liquid scintillation counting. Standards of the spiked substrate were
taken to determine the specific activity of each concentration using the equation:
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specific activity = dpm/[substrate]*volume of standard
2.3.3.2 Transport Assay Setup – Nucleoside Substrate
A mixture of Dow 550 silicone oil was mixed with light mineral oil in a 21:4 v/v ratio. This
mixture had a specific gravity of 1.04, allowing aqueous solutions to be layered on top of
the oil. Transport assays were performed in 1.5 ml microcentrifuge tubes, in which 200
µl of oil was added. On top of the oil cushion, 250µl of 2-[3H]chloroadenosine (prepared
as described in Section 2.3.3.1) was placed. Tubes were centrifuged briefly to establish a
clean aqueous-oil interface. Cells were harvested as described in section 2.3.1.1 and
divided into lots for ‘total’ uptake and ‘non-mediated’ uptake. ‘Non-mediated’ uptake
cells were pretreated with 10 µM NBMPR and 10 µM dipyridamole for 15 min at room
temperature, whereas ‘total’ uptake cells were treated with an equal volume of DMSO
(vehicle control). To initiate uptake, a 250µl aliquot of cell suspension was added to the
microcentrifuge tube and incubated at room temperature for a desired time point
(range 3-180 s). 2-Chloroadenosine is an agonist at adenosine receptors and thus there
is a potential that uptake may be affected by adenosine receptor signaling. Peak cyclic
AMP production by 2-chloroadenosine varies on cell type and has been reported in the
range of 30 s to 5 min (12; 25; 26). Since the most common time point used in uptake
studies was 10 s, contribution of adenosine receptor activation was expected to be
negligible. Following incubation the tube was centrifuged at ~10,000 x g for 10 s to
pellet the cells in the oil layer of the tube while the aqueous [ 3H]substrate remains
above the oil. This removal of the cells from the substrate stops transport. The aqueous
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Figure 2.1. Schematic of the Oil-Stop Method.
A [3H]labelled substrate was layered on top of Dow 550 silicone oil was mixed with light
mineral oil (21:4 v/v). Cells harvested by trypsinization were resuspended in buffer. An
aliquot of cells was added to the tube and incubated with the [ 3H]substrate for the
desired treatment time. Uptake was terminated by centrifugation at ~10,000 x g for 10 s
to pellet the cells in the oil layer. The aqueous [3H]substrate was removed and the oil
layer was washed with ddH2O before removal. The cell pellet was digested overnight in
1 M sodium hydroxide. The following day, the cell digest was transferred to a liquid
scintillation vial and mixed with liquid scintillation fluid for determination of [ 3H] content
by liquid scintillation counting.
(Original schematic drawn by Kevin Robillard)
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[3H]substrate was then removed by aspiration and the top of the oil was washed with
ddH2O.
Subsequently, the water and oil were removed by aspiration to expose the cell pellet.
Cells were digested overnight in 250µl of 1 M NaOH at room temperature. A 220 µl
aliquot of cell digest was then transferred to a scintillation vial, mixed with 5 ml of liquid
scintillation cocktail and allowed to sit overnight before counting on a liquid scintillation
analyzer.
2.3.3.3 Transport Assay Setup – Nucleobase Substrate
The set up for nucleobase transport was essentially the same as nucleoside uptake
except for one key difference. Most experiments were performed with a competing,
non-radioactive nucleobase for the non-mediated condition. Since this competitor could
also be transported and metabolized by cells, pre-incubation with the cells was not a
possibility. Therefore, a high concentration of the competing nucleobase had to be
included with the [3H]substrate in the microcentrifuge tube. The most common inhibitor
was adenine, where 25 µl of 20 mM adenine was added to uptake tubes for nonmediated uptake; total uptake tubes received 25 µl of buffer. To maintain the a final
volume of 500 µl in the uptake tube after the addition of cells, only 225 µl of cell
suspension was added to the uptake tubes to initiate uptake. From the addition of cells
on, nucleobase transport assays were treated identically to the nucleoside uptake tubes,
with the exception of longer incubation times to account for slower transport rates.
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2.3.3.4 Intracellular Volume
Uptake of substrates was normalized to the amount of intracellular water volume. To
determine total volume of the cell pellet, cells were incubated with 3H2O for 3 min at
room temperature and then processed as described in section 2.3.3.2. To determine
extracellular volume of the pellet, non-mediated uptake was extrapolated back to zero
time to estimate the dpm present on the outside of the cells. Volume was then
determined with the equation:
Extracellular volume = dpmt=0/specific activity (dpm/µl)
Intracellular volume was then defined as the difference between total volume and
extracellular volume.
2.3.3.5 Transport Data Analysis
Mediated uptake, that is, the uptake of substrate for which the transporter is directly
responsible, was defined as total uptake (in the absence of inhibitors) minus nonmediated uptake (in the presence of inhibitors) in pmol/µl of intracellular water volume.
Using GraphPad Prism software the Michaelis-Menten equation: Y=Vmax*X/(Km+X),
where X was the concentration of substrate, was used to fit each curve and derive
kinetic parameters.
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CHAPTER THREE

NUCLEOSIDE AND NUCLEOBASE TRANSPORTERS OF PRIMARY HUMAN CARDIAC
MICROVASCULAR ENDOTHELIAL CELLS: CHARACTERIZATION OF A NOVEL TRANSPORTER1

1

A version of this chapter has been published:

Bone, DBJ and Hammond JR. Nucleoside and nucleobase transporters of primary human
cardiac microvascular endothelial cells: Characterization of a novel nucleobase
transporter. Am J Physiol Heart Circ Physiol. Dec; 293(6):H3325-32. Epub: 2007 Oct 5.
doi:10.1152/ajpheart.01006.2007
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3.1 Introduction
The transmembrane flux of hydrophilic nucleosides and nucleobases is mediated by
integral membrane proteins, including equilibrative nucleoside transporters (SLC29;
ENTs) and concentrative nucleoside transporters (SLC28; CNTs) (4; 17). These nucleoside
transporters (NTs) have roles in salvaging endogenous nucleosides, such as adenosine,
and have been exploited for cancer chemotherapy and treatments for viral infection
(21). The CNTs are Na+-dependent transporters that facilitate movement of nucleosides
against their concentration gradient. Three members of the CNT family have been
cloned, each with distinct substrate specificity. CNT1 transports adenosine and
pyrimidine nucleosides, CNT2 transports purine nucleosides and uridine, and CNT3 is
broadly selective for both purine and pyrimidine nucleosides (27). The ENTs, on the
other hand, are Na+-independent facilitative diffusion transporters that rely on the
concentration gradient of the substrate and thus are capable of mediating both influx
and efflux of nucleosides. The two classical ENTs have been identified as being sensitive
(ENT1) or insensitive (ENT2) to the nucleoside analog nitrobenzylmercaptopurine
riboside (NBMPR) (36). ENT2 is also able to transport nucleobases like hypoxanthine
(26). Recently, two more ENT family members have been identified: ENT3 is associated
with intracellular acidic environments (19), and ENT4 was initially discovered as a
monoamine transporter in the brain (15).
The purine nucleoside adenosine is an important compound in the vasculature. Acting
through a variety of G-protein-coupled receptors, adenosine mediates physiological
actions such as, among others, vasodilation, bradycardia, and inhibition of platelet
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aggregation (33). NTs play a role in regulating adenosine levels in the vasculature by
facilitating its removal from the extracellular environment (23). In fact, cardiovascular
drugs like dipyridamole inhibit NTs, thereby extending the lifespan of adenosine in the
vasculature (30). Analogs of NBMPR (38) and dipyridamole (22) are now being designed
and tested for the potential to act as cardioprotective agents, thus highlighting the
importance of vascular NTs as potential therapeutic targets.
Investigations of NTs in the vasculature have primarily utilized models derived from the
macrovasculature, with a particular focus on umbilical vein endothelial cells, due to the
ease of obtaining the source tissue. However, the majority of exchange between the
blood and peripheral tissues occurs in the microvasculature, in which microvascular
endothelial cells (MVECs) are responsible for the regulation of this exchange. It has been
shown that endothelial cells in the heart are responsible for the uptake of up to 65% of
free adenosine (12). Therefore, changes in the ability of MVECs to transport or
metabolize adenosine can have profound effects on the cardiovasculature and
surrounding tissues.
Here, we describe the nucleoside and nucleobase transport capabilities of primary
human cardiac MVECs.

3.2 MATERIALS AND METHODS
3.2.1 Materials.
2-[8-3H]chloroadenosine (4-7 Ci/mmol), [2,8-3H]hypoxanthine (24-35 Ci/mmol), [2,83

H]adenine (50 Ci/mmol), [3H] NBMPR (5.5 Ci/mmol), and [3H]water (1 mCi/g) were
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purchased from Moravek Biochemicals (Brea, CA). Nonradiolabeled 2-chloroadenosine,
hypoxanthine,

NBMPR,

nitrobenzylthioguanine

bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]

riboside,

dipyridamole

pyrimidine},

and

all

{2,6other

nucleosides and nucleobases were obtained from Sigma-Aldrich (St. Louis, MO). Dilazep
{N,N'-bis[3-(3,4,5-trimethoxybenzoyloxy)propyl] homopiperazine} was from Asta Werke
(Frankfurt, Germany), and draflazine {2-(aminocarbonyl)-4-amino-2,6-dichlorophenyl-4[5,5-bis(4-fluorophenyl)-pentyl]-1-piperazineacetamide 2HCl} was provided by Janssen
Research Foundation (Beerse, Belgium).
3.2.2 Cell culture.
Culture of primary human cardiac MVECs is described in Chapter Two. HMEC-1 cells
were obtained from the Center for Disease Control (Atlanta, GA) and cultured in MCDB131 medium supplemented with 10 % fetal bovine serum (FBS), 100 U/ml penicillin G,
100 µg/ml streptomycin sulfate, 10 ng/ml epidermal growth factor, and 1 µg/ml
hydrocortisone. HMEC-1 cells were used between passage 15-40. Some studies required
the use of additional cell types, and all media and culture reagents were from Invitrogen
(Burlington, ON). All cells were cultured and harvested as described in Chapter Two.
Primary rat MVECs were isolated as previously described (3) and cultured in M199
medium containing 10% FBS, 100 U/ml penicillin G, 100 µg/ml streptomycin sulfate, 0.25
µg/ml amphotericin B, 2 mM L-glutamine, 0.025 U/ml heparin, and 75 µg/ml endothelial
cell growth supplement. Nucleoside transporter-deficient PK15 cell line (PK15NTD) and
PK15NTD-human ENT2 (hENT2) cells were a generous gift from Dr. Ming Tse (Johns
Hopkins University) and were cultured in MEM containing 10% bovine growth serum
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with penicillin G (100 U/ml), streptomycin sulfate (100 mg/ml), nonessential amino acids
(0.1 mM), and sodium pyruvate (1 mM). G418 (300 µg/ml) was added to the culture
medium of the PK15NTD-human ENT2 cells to maintain a selection pressure on the
stable transfection. UMR-108 and HEK-293 cells were a gift from Dr. Peter Chidiac
(Department of Physiology and Pharmacology, University of Western Ontario). UMR-108
cells were cultured in α-MEM with 10% FBS, penicillin G (100 U/ml), and streptomycin
sulfate (100 mg/ml). HEK-293 cells were cultured in MEM with 10% FBS and 10 µg/ml
gentamicin. Madin-Darby canine kidney cells were cultured in MEM with 10% FBS and
penicillin G (100 U/ml) and streptomycin sulfate (100 µg/ml). Cells were collected by
centrifugation, and pellets were washed in either PBS or a Na +-free buffer [NMG (in
mM): 140 N-methyl-D-glucamine, 5 KCl, 4.2 KH2PO4, 0.36 K2HPO4, 10 HEPES, 1.3
CaCl2·2H2O, and 0.5 MgCl2·6H2O; pH 7.4] and resuspended in the same buffer as
required for immediate use. In some cases, cells were depleted of ATP by sequential
incubation at 37°C with rotenone and 2-deoxyglucose as described previously (3).
3.2.3 Substrate efflux assay.
ATP-depleted cells were loaded with 100 µM [3H]hypoxanthine for 10 min. Cells were
collected by brief centrifugation and resuspended in buffer ± 1 mM adenine. One ml
aliquots were taken at desired time points and centrifuged through a mixture of silicone
and light mineral oil (21:4 v/v) to terminate efflux. Remaining [ 3H] activity in the pellet
was determined and expressed as pmol/106 cells.
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3.2.4 Data analysis and statistics.
Data are presented as means ± SEM. Curves were fitted with the use of Graphpad Prism
4.03 software. Where appropriate, statistical analysis was performed using a two-tailed
Student's t-test with P < 0.05 considered significant. Ki values were determined with the
Cheng-Prusoff relationship (10).

3.3RESULTS
3.3.1 [3H]NBMPR binding.
Specific [3H]NBMPR binding to human cardiac MVECs revealed 53,000 ± 6,000 ENT1
sites/cell with a Kd of 0.031 ± 0.003 nM (Figure 3.1). A second population of low-affinity
(Kd > 5 nM) binding sites was also present.
3.3.2 2-[3H]Chloroadenosine uptake.
A time course profile showed that human cardiac MVECs accumulated 10 µM 2[3H]chloroadenosine with an initial rate of 1.6 ± 0.5 pmol/µl/s. Incubation of cells with
50 nM NBMPR to block ENT1-mediated uptake resulted in a rate of uptake that was not
significantly different from that seen in the presence of 10 µM dipyridamole and NBMPR
(Figure 3.2A). Furthermore, when uptake buffer was changed from NMG (–Na+) to PBS
(+Na+), there was no change in initial rate of uptake or maximal intracellular
accumulation

(Figure

3.2B).

Uptake

of

increasing

concentrations

of

2-

[3H]chloroadenosine demonstrated a Km of 42 ± 19 µM and a Vmax of 3.4 ± 1.0 pmol/µl/s
(Figure 3.2C). Inhibition of 10 µM 2-[3H]chloroadenosine was examined with the classical
ENT inhibitors NBMPR, dipyridamole, draflazine, and dilazep. All four compounds (Figure
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3.3) displayed high-affinity inhibition with no indication of an inhibitor-insensitive (ENT2)
component to the uptake. The lack of ENT2 was especially evident from the monophasic
NBMPR inhibition curve. Ki values derived from these data are listed in Table 3.1.
3.3.3 [3H]hypoxanthine uptake.
Human cardiac MVECs were able to accumulate [3H]hypoxanthine under Na+-free
conditions despite an apparent lack of ENT2 activity. Uptake was insensitive to
dipyridamole; however, the addition of 1 mM adenine was able to block uptake (Figure
3.4A). As with 2-[3H]chloroadenosine, Na+ had no effect on the uptake of
[3H]hypoxanthine (Figure 3.4B). ATP depletion of the cells before exposure to 5 µM
[3H]hypoxanthine reduced the extrapolated maximum intracellular accumulation from
39 ± 18 to 4.1 ± 0.2 pmol/µl (Figure 3.4C). Consequently, subsequent experiments were
performed under ATP-depleted conditions to minimize the effects of intracellular
metabolism. With the use of a 15-s time point to estimate initial rate, the Vmax of
[3H]hypoxanthine influx was determined as 1.6 ± 0.3 pmol/µl/s with a Km of 96 ± 37 µM
(Figure 3.4D). Additional nucleobases were tested for the ability to inhibit 5 µM
[3H]hypoxanthine uptake. Adenine was the most effective, with a Ki of 19 ± 7 µM.
Guanine produced significant inhibition of 17 ± 4% at a concentration of 1 µM (Figure
3.5A). Higher concentrations of guanine could not be achieved because of low solubility
in assay buffers at physiological pH. Pyrimidines were much less effective, with thymine
producing inhibition only at 1 mM (59 ± 6%) and cytosine and uracil had no effect at 1
mM concentrations.
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The chemotherapeutic thiopurine analogs 6-mercaptopurine (6-MP) and 6-thioguanine
(6-TG) and the pyrimidine analog 5-fluorouracil (5-FU) were also examined. Both 6-MP
and 6-TG were able to inhibit 5 µM [3H]hypoxanthine uptake with an IC50 of 37 ± 11 µM
and 20 ± 2 µM, respectively (Figure 3.5B). As with other pyrimidines, 5-FU had no effect
on [3H]hypoxanthine uptake (data not shown).
To confirm that the dipyridamole-insensitive hypoxanthine uptake mechanism was
nucleobase selective, the nucleosides adenosine and uridine were tested. Adenosine
had an extrapolated IC50 value of 1.3 ± 0.9 mM (Figure 3.5A), and uridine had no effect.
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Figure 3.1. 3H-labeled nitrobenzylmercaptopurine riboside (NBMPR) binding to human
cardiac microvascular endothelial cells (MVECs).
Human cardiac MVECs were incubated with increasing concentrations of [3H]NBMPR in
the presence (nonspecific) or absence (total) of 10 µM nitrobenzylthioguanine riboside
(NBTGR) for 45 min. Cells were collected on glass fiber filters, and cell-associated 3H
content was determined. Specific binding was determined as total bound minus
nonspecific bound (n = 5).
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Figure 3.2. 2-[3H]chloroadenosine uptake characteristics of human cardiac MVECs.
A: time course of 2-[3H]chloroadenosine uptake. Human cardiac MVECs were incubated
with 10 µM 2-[3H]chloroadenosine for the times indicated. Some cell lots were
preincubated with 50 nM NBMPR to inhibit only equilibrative nucleoside transporter 1
(ENT1). Total uptake (no inhibitors) minus ENT1 inhibited uptake represents ENT2mediated uptake. Nonmediated uptake was determined with cells preincubated with 10
µM NBMPR and 10 µM dipyridamole (n = 5). B: Effect of sodium (Na+) on 2[3H]chloroadenosine uptake. Uptake was performed as in A) in either sodium free (-Na+)
or sodium replete (+Na+) conditions (n = 5). C: concentration-dependent uptake of 2[3H]chloroadenosine. Cells were incubated with increasing concentrations of 2[3H]chloroadenosine for 7 s. Transporter-mediated uptake is presented as pmol/µl/s and
was defined as total uptake minus nonmediated uptake (n = 4).
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Figure 3.3. Inhibition of 2-[3H]chloroadenosine uptake.
Cells were incubated with increasing concentrations of inhibitor for 15 min before
uptake of 10 µM 2-[3H]chloroadenosine for 15 s. Uptake in the absence of any inhibitor
was defined as 100%, and totally inhibited cells (10 µM NBMPR + 10 µM dipyridamole)
was defined as 0% (n = 4). Ki values are reported in Table 1. DY, dipyridamole.
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Figure 3.4. [3H]hypoxanthine uptake characteristics of human cardiac MVECs (hMVECs).
A: [3H]hypoxanthine time course. Cells were incubated with 5 µM [3H]hypoxanthine for
the times indicated. Some cells were preincubated with 10 µM DY to inhibit any ENT2
that may be present in the cells. To completely block uptake, cells were coincubated
with 1 mM adenine (n = 5). B: Effect of sodium on [3H]hypoxanthine uptake. Uptake was
performed as in A) in the absence (-Na+) or presence (+Na+) of sodium (n = 5). C: ATPdepleted [3H]hypoxanthine time course. Uptake was performed identical to A, except
that cells were depleted of ATP before assay (n = 6). D: concentration-dependent
[3H]hypoxanthine uptake. ATP-depleted cells were incubated with increasing
concentrations of [3H]hypoxanthine for 15 s. Transporter-mediated uptake is presented
and was defined as uptake in the absence of any inhibitor minus uptake in the presence
of 1 mM adenine (n = 4).
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Figure 3.5. Inhibition of [3H]hypoxanthine uptake.
A: Inhibition of [3H]hypoxanthine uptake by nucleobases and nucleosides. Cells were
coincubated with 5 µM [3H]hypoxanthine and indicated purine for 60 s. Uptake in the
absence of inhibitor was defined as 100%, and totally inhibited uptake (1 mM adenine)
was defined as 0% (n = 3). B: Inhibition of [3H]hypoxanthine uptake by pyrimidine
nucleobases. Assays were conducted in the same manner as A (n = 3). C: Inhibition of
[3H]hypoxanthine uptake by purine and pyrimidine nucleobase analogs. 6-MP, 6mercaptopurine; 6-TG, 6-thioguanine; 5-FU, 5-flurouracil. Assays were conducted in the
same manner as A (n = 3). Ki values are reported in Table 1.
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Table 3.1 Ki values for inhibition of uptake by hMVECs 2-chloroadenosine and
hypoxanthine
Ki
2-chloroadenosine uptake
NBMPR
0.5 ± 0.2 nM
Dipyridamole
14 ± 8 nM
Dilazep
0.4 ± 0.1 nM
Draflazine
0.9 ± 0.2 nM
Hypoxanthine uptake
Adenine
19 ± 7 µM
Guanine
>1 µM
Cytosine
No effect
Thymine
>1 mM
Uracil
No effect
6-MP
37 ± 11 µM
6-TG
20 ± 2 µM
5-FU
No effect
Adenosine
1.2 ± 0.8 mM
Uridine
No effect
Ki values were determined with the Cheng-Prusoff relationship from IC50 values obtained from
data presented in Figs. 3 and 5. (n ≥ 3). NBMPR, nitrobenzylmercaptopurine riboside; 6-MP, 6mercaptopurine; 6-TG, 6-thioguanine; 5-FU, 5-fluorouracil.
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3.3.4 Nucleobase transport in other cell types.
The identification of Na+-independent [3H]hypoxanthine transport in human cardiac
MVECs, by a mechanism other than ENT2, led to the examination of other cell types for
evidence of a similar dipyridamole-insensitive nucleobase transport system. Established
cell lines from human (U2OS and HEK-293), rat (UMR-108), pig (PK15NTD), and dog
(Madin-Darby canine kidney) were examined along with primary rat skeletal muscle
MVECs. Figure 3.6 shows the time course profiles for dipyridamole-insensitive
hypoxanthine uptake by these cells. All cells tested displayed evidence of dipyridamoleinsensitive nucleobase transport with the exception of HEK-293 cells.
PK15NTD cells were chosen for further characterization of this nucleobase transporter.
These cells do not have ENT1 or ENT2 (10; 32), thereby eliminating any contribution
from

other

nucleoside/nucleobase

transporters

to

the

results

obtained.

[3H]hypoxanthine uptake by PK15NTD cells was concentration dependent with a similar
Km (122 ± 31 pmol/µl) to the human cardiac MVEC in ATP-depleted conditions and a Vmax
of 7.0 ± 0.6 pmol/µl/s (Figure 3.7A). There was no effect of pH on [3H]hypoxanthine
uptake, and the thiopurines 6-MP and 6-TG displayed Ki values (21 ± 5 and 19 ± 1 µM,
respectively) similar to those for human cardiac MVECs (data not shown). [ 3H]adenine
was tested as a transport substrate with unlabeled hypoxanthine as the inhibitor (Figure
3.7B). Hypoxanthine at 150 µM was able to produce ~20% inhibition of 500 nM
[3H]adenine uptake under ATP-depleted conditions. The use of unlabeled 1 mM adenine
was required for total inhibition.
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Figure 3.6. Dipyridamole-insensitive [3H]hypoxanthine uptake in various cell types. Cells
were incubated with 5 µM [3H]hypoxanthine for the times indicated. Cell lots were
preincubated with 10 µM DY to inhibit any ENT2. To completely block uptake, cells were
coincubated with 1 mM adenine (n = 2). UMR, UMR-108 cells; NTD, nucleoside
transporter deficient PK15 cells (PK15NTD); MDCK, Madin-Darby canine kidney cells;
rMVEC, rat skeletal muscle MVECs; HEK, HEK-293 cells.
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Figure 3.7. PK15NTD cells as a model for nucleobase transport.
A: concentration dependent uptake of [3H]hypoxanthine under ATP-depleted
conditions. Cells were incubated with increasing concentrations of [ 3H]hypoxanthine for
15 s. Transporter-mediated uptake is presented and was defined as uptake in the
absence of any inhibitor minus uptake in the presence of 1 mM unlabeled adenine (n =
3). B: Initial rate of 5 µM [3H]hypoxanthine was determined in NMG at varying pH. (n =
4). C: Inhibition of [3H]hypoxanthine uptake by 6-MP and 6-TG (n = 3) D: [3H]adenine
uptake time course. ATP-depleted cells were incubated with 500 nM [3H]adenine in the
presence or absence of 150 µM hypoxanthine or 1 mM adenine (n = 2).
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[3H]hypoxanthine uptake in the presence or absence of dipyridamole was also examined
in PK15NTD cells that had been previously transfected with human ENT2. Accumulation
of 5 µM [3H]hypoxanthine in ATP-depleted conditions reached a maximum intracellular
concentration of 3.8 ± 0.03 pmol/µl; however, in the presence of dipyridamole, the
amount of [3H]hypoxanthine that accumulated in the cell rose to 18 ± 4 pmol/µl.
Blocking ENT1 with NBMPR in the human cardiac MVECs (no ENT2) did not have an
effect on [3H]hypoxanthine accumulation (Figure 3.8).
3.3.5 Characterization of HMEC-1 Cells
In the interest of having a MVEC cell model that was more economical than the primary
human cells, HMEC-1 cells were tested as a suitable replacement. HMEC-1 cells bound
[3H]NBMPR with two apparent populations, similar to the primary human cardiac
MVECs. The high affinity binding had 76,000 ± 14,000 sites with a K d of 0.03 ± 0.01 nM
(Figure 3.9A). The low affinity binding was not always rational, and thus was probably an
artifact of the binding assay.
The time course of 10 µM 2-[3H]chloroadenosine uptake in the presence or absence of
50 nM NBMPR showed a lack of NBMPR-insensitive uptake much like the primary
human cardiac MVECs (Figure 3.9B). Inhibition of 10 µM 2-[3H]chloroadenosine by
NBMPR was also monophasic and had a Ki of 0.098 ± 0.011 nM (Figure 3.9C)
Finally, the time course of 5 µM [3H]hypoxanthine uptake was also similar to the primary
human MVECs with uptake being insensitive to dipyridamole but could be inhibited by 1
mM adenine (Figure 3.9D).
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3.3.6 Decynium-22 and [3H]Adenine Km/Vmax
A report by Hoque and colleagues (18) suggested that the compound decynium-22 (D22) was capable of inhibiting purine nucleobase uptake. Indeed, in PK15NTD cells, D-22
inhibited hypoxanthine uptake with a Ki of 202 ± 156 nM. Similarly, D-22 inhibited 5 µM
adenine uptake with an IC50 of 1.01  0.59 M (Figure 3.10A). Using D-22 to define nonmediated uptake, concentration-dependent uptake of [3H]adenine was observed for
concentrations of [3H]adenine up to 150 µM. Higher concentrations of [3H]adenine
appeared to actually inhibit the transport mechanism. A curve was fit to the data up to
150 µM to generate a Km of 36  10 M and a Vmax of 8.2  0.8 pmol/µl/s (Figure 3.10B).
3.3.7 [3H]Hypoxanthine Efflux
ATP-depleted PK15NTD cells were preloaded with 100 µM [3H]hypoxanthine for 10
minutes, then transferred to buffer with or without 1 mM adenine. [ 3H]hypoxanthine
was released from cells by an adenine sensitive mechanism as illustrated by a significant
increase in efflux half-time from 0.9 ± 0.3 min in the absence of 1 mM adenine to 4.8 ±
0.9 min in the presence of 1 mM adenine (Figure 3.11).
3.3.8 Candidates for the identity of ENBT1
The purine selective dipyridamole-insensitive nucleobase transporter ENBT1 identified
in this chapter was done so through functional and pharmacological analyses only. The
molecular identity of the transporter is still unresolved. Some potential candidates were
identified and tested.

72

3.3.8.1 The unnamed human protein product hUPP1
Through collaboration with Dr. Imogen Coe at York University (Toronto, Canada), a gene
product for a potential new transporter was identified. Known only as unnamed protein
product (Genbank Accession: BAC86869), this protein was predicted to be a member of
the Major Facilitator Superfamily (MFS) which contains all transporters that rely on the
concentration gradient of their substrate for transport. Stable expression of GFP-hUPP1
in HEK cells was confirmed by fluorescent microscopy, however there was no gain of
dipyridamole-insensitive [3H]hypoxanthine uptake (Figure 3.12).
3.3.8.2 Organic Cation Transporter as a possible candidate for ENBT1
The compound D-22 used in section 3.3.6 as an inhibitor of ENBT1 is a known organic
cation transporter (OCT) inhibitor (31). OCTs have been shown to transport nucleobase
analogues, therefore we tested one nucleobase analogue substrate, acyclovir, and one
non-nucleobase substrate, metformin (11; 35). At a concentration of 1 mM, acyclovir
inhibited the uptake of 5 µM [3H]hypoxanthine by 36 ± 7 %, however 1 mM metformin
had no effect (Figure 3.13).
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Figure 3.8. Complex effects of nucleoside and nucleobase transporter coexpression and
inhibition.
A: PK15NTD [3H]hypoxanthine uptake ± dipyridamole (DY). ATP-depleted PK15NTD cells
were incubated with 5 µM [3H]hypoxanthine for the times indicated in the presence or
absence of 5 µM DY (n = 3). B: PK15NTD-human ENT2 (hENT2) [3H]hypoxanthine uptake
± DY. ATP-depleted PK15NTD-human ENT2 cells were incubated with 5 µM
[3H]hypoxanthine for the times indicated in the presence or absence of 5 µM DY (n = 2).
C: hMVEC [3H]hypoxanthine uptake ± NBMPR. Cells were incubated in 100 µM
[3H]hypoxanthine in the presence or absence of 50 nM NBMPR (n = 4).

74

75

76

Figure 3.9. Characterization of HMEC-1 cells.
A) Cells were harvested, resuspendend in PBS and subjected to [ 3H]NBMPR binding as
described in the methods. ENT1 sites per cell was determined by subtracting [3H]NBMPR
binding in the presence of NBTGR (non-specific binding) from total binding. Data are
means ± SEM of four independent experiments performed in duplicate. B) Cells were
harvested, resuspended in NMG buffer and subjected to 2-[3H]chloroadenosine uptake
as described in the methods. Solid squares represent uptake of 10 µM 2[3H]chloroadenosine in the absence of inhibitors (total uptake). Half-solid circles with
dashed line represent uptake in the presence of 50 nM NBMPR (+NBMPR), or the
contribution of NBMPR-insensitive ENT2 mediated uptake. Open circles with the dotted
line represent uptake in the presence of both 5 µM NBMPR and 5 µM dipyridamole
(non-mediated uptake). ENT1 mediated uptake is the difference between ENT2
mediated uptake (+NBMPR minus non-mediated) and total mediated uptake (total
minus non-mediated). Only ENT1 mediated 2-chloroadenosine transport was present in
these cells. Data are means ± SEM of seven independent experiments. C) Cells were
incubated with increasing concentrations of NBMPR for 15 min before analysis of the
uptake of 10 µM 2-[3H]chloroadenosine for 15 s. Uptake in the absence of any inhibitor
was defined as 100%, and totally inhibited cells (10 µM NBMPR + 10 µM dipyridamole)
was defined as 0% (n = 3).D) Cells were harvested, resuspended in NMG, ATP-depleted,
and subjected to [3H]hypoxanthine uptake as described in the methods. Solid squares
represent uptake of 5 µM [3H]hypoxanthine in the absence of any inhibitors (total
uptake). Half-solid circles with dashed line represent uptake in the presence of 5 µM
dipyridamole (+DY), or the contribution of the dipyridamole-insensitive nucleobase
transporter. Open circles with the dotted line represent uptake in the presence of both
5 µM dipyridamole and 1 mM adenine (+DY and adenine; non-mediated uptake). Data
are means ± SEM of three independent experiments.
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Figure 3.10. Decynium-22 and [3H]adenine Km/Vmax.
A) PK15NTD cells were preincubated with increasing concentrations of decynium-22 (D22) for 15 min followed by exposure to 5 µM [3H]adenine (solid squares) or 50 µM
[3H]hypoxanthine (open squares) for 20 s (n = 4). B) PK-15 NTD cells were ATP-depleted
as described and preincubated with 10 µM D-22 (non-mediated) or DMSO (total) for 15
minutes before exposure to increasing concentrations of [3H]adenine for 15 s (n = 5).
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Figure 3.11. [3H]hypoxanthine efflux. PK15NTD cells were ATP-depleted and loaded with
100 µM [3H]hypoxanthine for 10 min. Cells were collected by brief centrifugation and
resuspended in buffer ± 1 mM adenine. Aliquots of cells were taken at the indicated
time points and centrifuged through oil as described in the methods section 3.2.3 (n =
3).
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Figure 3.12. GFP-hUPP1 does not increase hypoxanthine uptake in HEK cells.
HEK cells (A) or HEK cells stably transfected with GFP-hUPP1 (B) were depleted of ATP
and subjected to uptake of 5 µM [3H]hypoxanthine over time. C) Total uptake of 5 µM
[3H]hypoxanthine of HEK cells (solid squares) and GFP-hUPP1 cells (open squares, dotted
line). D) Uptake of 5 µM [3H]hypoxanthine in the presence of 10 µM dipyridamole,
representing any uptake that is mediated by ENBT1. No significant uptake was observed
in HEK cells or GFP-hUPP1 cells. E) ENT2 mediated [3H]hypoxanthine uptake as
determined by subtracting uptake in the presence of dipyridamole from total uptake.
Uptake data is mean ± SEM of 4 independent experiments.
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Figure 3.13. OCT substrate acyclovir but not metformin can inhibit hypoxanthine uptake.
A) 1 mM acyclovir (solid bar) or metformin (open bar) was co-incubated with 5 µM
[3H]hypoxanthine for 60 s. Control (or 100%) was defined as accumulation of 5 µM
[3H]hypoxanthine after 60 s incubation in the absence of any inhibitor. *P<0.05
compared to 100%. Data are mean ± SEM of 4 independent experiments performed in
duplicate.
B) Chemical structures of acyclovir (nucleobase analogue) and metformin (nonnucleobase).
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3.4 DISCUSSION
The microvasculature forms a barrier between the circulation and peripheral tissues and
is responsible for mediating nutrient exchange between these two compartments.
MVEC regulation of nucleosides via NTs can have profound effects on the cardiovascular
actions of adenosine, warranting further investigation of NTs as potential therapeutic
targets (23).
3.4.1 Characterization of Nucleoside Transport in Human Cardiac Microvascular
Endothelial Cells.
Human cardiac MVECs have both high- and low-affinity binding sites for the ENT1selective probe NBMPR. The Kd of the high-affinity site is consistent with reported values
for ENT1 (19). Our group, in rat skeletal muscle MVECs (3), and others (7) have reported
the presence of the low-affinity population of NBMPR binding sites, which may be a
result of [3H]NBMPR binding to intracellular ENT1 proteins. The high-affinity maximum
binding capacity of ∼53,000 ENT1 sites/cell likely represents the transporters associated
with the plasma membrane.
2-Chloroadenosine is an established substrate of NTs and was chosen to limit the effects
of intracellular metabolism on the measurement of transport kinetics (6; 20). Na+independent uptake of 2-chloroadenosine in the presence or absence of a low
concentration of NBMPR (50 nM) to inhibit ENT1 revealed no significant contribution of
the NBMPR-insensitive ENT2 to the overall uptake. In addition, NBMPR, dilazep,
draflazine, and dipyridamole all produced monophasic inhibition curves for inhibiting 2chloroadenosine uptake (pseudo Hill coefficients were approximately –1) with Ki values
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typical of ENT1 inhibition (36). Numerous endothelial cell models express a combination
of ENT1 and ENT2, including primary rat MVECs (3), human umbilical vein endothelial
cells (2), primary mouse MVECs (see Chapter 5), and EVC 304 cells (26). In this regard,
human MVECs, which demonstrate only ENT1 function, appear to be an exception.
3.4.2 Identification of a Novel Nucleobase Transporter in Human Cardiac Microvascular
Endothelial Cells.
Although human cardiac MVECs had no functional ENT2, they were still able to
accumulate hypoxanthine under Na+-free conditions. Uptake was insensitive to
dipyridamole; however, other purine nucleobases were capable of blocking influx. There
was no significant change in uptake in the presence of Na+, thus ruling out the ascorbic
acid transport system. An increase in H+ had no effect, and uptake was not inhibited by
monoamines; thus this hypoxanthine transporter is not the recently identified ENT4
(14). The apparent Km of hypoxanthine uptake (96 ± 37 µM) was threefold lower, and
the Ki of adenine inhibition of hypoxanthine uptake (19 ± 7 µM) reported in this study
was ∼140 times lower than previously reported for human ENT2 (26). Together, these
data support that hypoxanthine uptake in human cardiac MVECs was mediated by a
transport system distinct from ENT2. Further characterization showed that the transport
system as purine nucleobase selective. The only pyrimidine tested that could inhibit
hypoxanthine uptake was thymidine at nonphysiological concentrations (>1 mM). The
nucleoside adenosine also inhibited uptake at high concentrations (IC50 > 1 mM), but this
may be the result of adenosine metabolism releasing adenine.
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The chemotherapeutic purine nucleobase analogs 6-MP and 6-TG demonstrated an
affinity for the nucleobase transport system, whereas the pyrimidine analog 5-FU did
not. The Ki determined for 6-MP and 6-TG inhibition of hypoxanthine uptake (∼20–30
µM) were similar to reported values of therapeutic concentrations found within cells
(13). This has relevance in the role that the vasculature plays in delivering
chemotherapeutic agents to the intended target such that if this nucleobase transport
system is blocked or down-regulated the chemotherapeutic purine nucleobase analogs
would be less able to gain access to their intracellular site of cytotoxic action.
3.4.3 Physiological Importance of Nucleobase Transport
The ability of a cell to mediate the transmembrane flux of nucleobases is important, as
evidenced by the existence of at least two distinct transport systems for nucleobases in
many cell types. Regulation of intracellular levels of nucleobases, such as hypoxanthine,
may be critical during periods of physiological stress, including hypoxia or ischemia.
During hypoxia or ischemia in the heart, the breakdown of ATP in cardiomyocytes results
in an increase in adenosine, which is released to the interstitial space via NTs (16). The
surrounding endothelium then accumulates this extracellular adenosine. Adenosine
kinase becomes saturated with the excess adenosine therefore shifting the metabolism
to inosine via adenosine deaminase. Subsequent metabolism by purine nucleoside
phosphorylase produces hypoxanthine as an intermediate to the final product of uric
acid (33). It is in the production of hypoxanthine that the role of MVEC nucleobase
transporters may hold importance. Because hypoxanthine is metabolized to xanthine by
xanthine oxidase, reactive oxygen species (ROS) are produced (25). Links have been
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established between xanthine oxidase-derived ROS and endothelial dysfunction (5; 29).
Therefore, having a system capable of regulating hypoxanthine levels, before xanthine
oxidase-mediated metabolism of hypoxanthine were to occur, may prevent or reduce
ROS-induced endothelial dysfunction.
The molecular identity of this distinctive dipyridamole-insensitive, purine-selective
nucleobase transporter is presently not known. Despite this lack of identity, we have
named the transporter equilibrative nucleobase transporter 1 (ENBT1). There is some
evidence in the literature that similar transporters may exist (28; 32), and we have been
able to identify its presence through function in several cell types from various species.
Preliminary data from our laboratory have suggested that mouse MVECs are more
similar to human cardiac MVECs than rat MVECs with respect to their nucleoside and
nucleobase transport properties. However, rat MVECs appear to have less of the
dipyridamole-insensitive [3H]hypoxanthine transporter and instead use ENT2 as the
primary nucleobase transport system. This needs to be considered when using rat as a
model for human extrapolation studies.
Of the cells tested, only HEK-293 cells appeared to be deficient in ENBT1. Thus HEK-293
cells may prove useful to the heterologous expression of candidate genes for ENBT1. In
contrast, PK15NTD cells, which lack ENTs, have very high levels of ENBT1. Thus PK15NTD
cells may provide a useful model to study dipyridamole-insensitive hypoxanthine
transport. The lack of ENTs in these cells allows for the transfection of a NT of interest
for the study of interactions between nucleoside and nucleobase transporters, as we
have shown with the PK15NTD-human ENT2 cell line. HMEC-1 are an immortalized cell

87

line created from human dermal microvascular endothelial cells that were transfected
with the simian virus 40 large T antigen, that are generally accepted to be a suitable
model for the study of microvascular endothelial cells (1). Given that HMEC-1 cells
appear to have identical transport characteristics as the primary human MVECs, we
conclude that at the general level of nucleoside and nucleobase transport that these
cells are a suitable substitute for primary human cells. However, it remains to be seen if
HMEC-1 cells will respond in a similar manner when exposed to stimuli that elicit
physiological responses.
The 4.5-fold enhancement of hypoxanthine accumulation in the presence of
dipyridamole in PK15NTD-human ENT2 cells (see Fig. 3.8) may be the result of
intracellular trapping of hypoxanthine metabolites, or perhaps hypoxanthine itself, that
normally are substrates for ENT2. It is possible for ENT2-preferring nucleosides, like
inosine (36), to be formed from hypoxanthine by purine nucleoside phosphorylase when
normal physiological conditions are changed to allow the enzyme to catalyze the
preferred reaction of nucleoside synthesis (8). Thus nucleobases can be used to
replenish depleted nucleoside and nucleotide stores, using ENBT1 as a salvage pathway.
Cells that lack ENT2, like human MVECs, or ones that have their existing ENT2
transporters blocked will see an enhancement of this salvage pathway, possibly leading
to improved cellular function during periods of physiological stress.
Decynium-22 is a known inhibitor of organic cation transporters and has been shown to
inhibit the purine nucleobase uptake in PK15NTD cells by others (18; 31). We too have
shown that D-22 works as an inhibitor in our hands. Before this discovery, the only
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inhibitor of ENBT1 was adenine, which was not suitable for determining the uptake
kinetics of adenine itself. The use of D-22 allowed a Km/Vmax profile for adenine to be
generated, however the reason that transport rates returned to zero at high
concentrations remains unresolved (Figure 3.10B). Since PK15NTD cells lack nucleoside
transporters, it was unlikely that a nucleoside metabolite was being transported out of
the cells. A more likely explanation would be an inability of D-22 to completely inhibit
the transporter at very high concentrations of substrate.
Despite the overlap of D-22 and nucleobase analogues with ENBT1 and OCTs, the nonnucleobase OCT substrate metformin was unable to inhibit hypoxanthine mediated
uptake. Like the ENT family, there are multiple OCTs and metformin is transported by
OCT1 and OCT3 (9; 24; 34; 37). The lack of inhibition in this study lowers the likelihood
that ENBT1 is actually an OCT, however there is still the possibility that ENBT1 resembles
an OCT in some genetic or structural manner.
The ability to move substrates bi-directionally across the plasma membrane is a defining
feature of equilibrative transporters. ENBT1 is truly equilibrative, as hypoxanthine was
transported out of PK15NTD cells in an adenine sensitive manner (Figure 3.11). This
evidence supports the hypothesis that ENBT1 is capable of regulating intracellular
nucleobase concentrations that may impact on ROS production. In an ischemic event, as
hypoxanthine accumulates in the endothelial cell as a result of adenosine metabolism
through the deaminase pathway, the concentration gradient of hypoxanthine would be
from the intracellular compartment out. Transport of hypoxanthine out of the cell
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through ENBT1 would reduce the amount of substrate available for xanthine oxidase
and ROS production when oxygen returns.
In summary, we have characterized the nucleoside and nucleobase transporters of
primary human cardiac MVECs. Human cardiac MVECs rely solely on ENT1 for nucleoside
transport, and we have identified a novel nucleobase transport system, which we have
named ENBT1. ENBT1 is present in a variety of different cell types in combination with
ENT2; however, this combination varies between species and cell types. We recommend
that

future

studies

involving

nucleoside

or

nucleobase

regulation

in

the

microvasculature be conducted in mouse models if human models are unavailable. The
role of nucleoside and nucleobase transporters in the vasculature is important and
complex. Regulation of extracellular adenosine levels, either through ENT expression or
pharmacological intervention, will impact cardiovascular function. Considering the
vasodilatory effects of adenosine, ENT regulation of purine levels can impact perfusion
and thus nutrient exchange between the microvasculature and surrounding tissues (23).
Control of nucleobase levels by ENT2 or ENBT1 will have implications in nutrient salvage,
chemotherapy, and ROS production during hypoxia or ischemia.
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CHAPTER FOUR
REGULATION OF HUMAN MICROVASCULAR ENDOTHELIAL CELL PURINE TRANSPORTERS.
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4.1 Introduction
In human microvascular endothelial cells, transmembrane flux of nucleosides and
nucleobases is controlled by equilibrative nucleoside transporter 1 (ENT1) and
equilibrative nucleobase transporter 1 (ENBT1) respectively (4). In mice, there is an
additional small, but measurable, contribution to both nucleoside and nucleobase
transport by equilibrative nucleoside transporter 2 (ENT2) (4). These transporters act as
important regulators of intracellular concentrations of their substrates, and influence
the interaction of these compounds with receptors on the plasma membrane. Thus,
alteration of the expression and/or function of purine transporters can have far reaching
consequences for the microvascular endothelium.
Regulation of nucleoside and nucleobase transporters in the context of hypoxia and
ischemia is an under-appreciated field. As described in Chapter One, hypoxia/ischemia
results in increased extracellular adenosine, a substrate of ENT1 (and ENT2).
Extracellular adenosine is known to promote protection of surrounding tissue during
hypoxia/ischemia. Intracellular adenosine metabolism produces hypoxanthine, a
substrate of ENBT1 (and ENT2), and reactive oxygen species (ROS). Therefore,
understanding the function of transporters during hypoxia/ischemia may contribute to
the understanding of pathologies such as ischemia-reperfusion injury.
It has been shown previously that ENT1 can be transcriptionally regulated by hypoxia
inducible factor 1 alpha (HIF-1α) in human, mouse, and rat cell lines representing
epithelial, endothelial, cardiomyocyte, and carcinoma cells (9; 15; 25), but not in
primary microvascular endothelial cells (MVECs). One gene target of HIF-1α is vascular
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endothelial growth factor (VEGF). Interestingly, adenosine is also capable of promoting
VEGF

production.

However,

the

potential

interaction

between

VEGF

and

nucleoside/nucleobase transporters has not yet been investigated.
Surprisingly, the effect of adenosine receptor activation/inhibition on nucleoside
transport is poorly understood. Some attempts have been made to study the
interaction, however the results are not readily interpretable (16; 33). Instead, there has
been more success on studying downstream effector proteins including protein kinase A
(PKA) (13; 27) and protein kinase C (PKC) (10; 12; 14; 18; 21). An additional kinase,
protein kinase CKII (CKII), has also been implicated in nucleoside transport regulation
(Figure 4.1) (6; 14; 41). The factors linking these studies together are 1) most are in
immortalized cell lines, 2) several are from rodent cell lines, and 3) nucleobase transport
was not addressed.
The effects of ROS on nucleoside and nucleobase transport function have not been
directly addressed. Endothelial cells produce nitric oxide (NO), which can react with the
free radical superoxide to produce the reactive nitrogen species (RNS) peroxynitrite
(ONOO-). Peroxynitrite, a very powerful oxidant, has been shown to reduce the function
of other transport proteins, as well as prevent adenosine accumulation in rat astrocytes
(42). However, ENT1 mediated transport of adenosine following peroxynitrite exposure
was not properly addressed in that study.
While the effect of ROS and RNS on transporter function is not well studied, there have
been efforts to understand the effects of hypoxia on ENT1. It has been previously shown
that ENT1 was transcriptionally regulated by HIF-1α in a number of cell lines following
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chronic hypoxia (9; 15; 25). Short term hypoxia (2 hr or less) had no effect on ENT1
expression. The impact of ischemia, however, has not been addressed, nor has the
model of primary MVECs been reported.

4.2 Materials and Methods
4.2.1 Materials
2-[3H]Chloroadenosine, [2,8-3H]hypoxanthine (28.7 Ci/mmol), [3H]NBMPR (23.8
Ci/mmol), and [3H]water (1mCi/ml) were purchased from Moravek Biochemicals (Brea,
CA).

Non-radiolabeled,

2-chloroadenosine,

hypoxanthine,

NBMPR,

nitrobenzylthioguanine riboside (NBTGR), and adenine were from Sigma-Aldrich. Human
recombinant VEGF-165 was purchased from Cell Signaling Technology (Danvers, MA).
Sunitinib malate (N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
salt),

ZM323881

(2S)-2-hydroxybutanedioate

(5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol

hydrochloride), CGS21680 (4-[2-[[6-Amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9Hpurin-2-yl]amino]ethyl]benzene propanoic acid hydrochloride), NECA (1-(6-Amino-9Hpurin-9-yl)-1-deoxy-N-ethyl-β-D-ribofuranuronamide),

forskolin,

sp-cAMP,

KT5270

((9R,10S,12S)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1Hdiindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-][1,6]benzodiazocine-10-carboxylic acid, hexyl
ester),

8-CPT-2Me-cAMP(8-(4-Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic

monophosphate sodium salt), PMA (phorbol 12-myristate 13-acetate), Gö6983 (3-[1-[3(Dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-
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dione), Gö6976 ( 5,6,7,13-Tetrahydro-13- methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile),

and

TBB

(4,5,6,7-tetrabromobenzotriazole)

were

obtained from Tocris Bioscience (Ellisville, MO).4α-PMA and BFA (γ,4-Dihydroxy-2-(6hydroxy-1-heptenyl)-4-cyclopentanecrotonic acid λ-lactone) were from Sigma. Tertbutyl hydroperoxide (TBHP), menadione, and cobalt chloride (CoCl2) were from SigmaAldrich. 3-Morpholinosydnonimine hydrochloride (SIN-1) was from BIOMOL Research
Laboratories (Plymouth Meeting, PA)

and manganese(III) tetrakis(1-methyl-4-

pyridyl)porphyrin (MnTMPyP) was from Calbiochem (Mississauga, ON). One percent
oxygen gas was from Praxair (London, ON).
4.2.2 Vascular Endothelial Growth Factor Treatment
Confluent cells were washed with PBS and fed with EBM-2 medium or MCDB 131
medium for MVECs and HMEC-1 cells respectively, without serum or other growth
factors plus the indicated concentration of human recombinant VEGF or PBS and
cultured for 24 hr. In cases where treatment time was less than 24 hr, cells were
cultured in basal medium without serum until VEGF was added. The total time in serum
free medium was always 24 hr. When required, cells were pretreated with 1 µM
sunitinib (non-selective VEGF receptor inhibitor) or 1 µM ZM323881 (VEGFR2 selective
inhibitor) for 1 hr before the addition of VEGF.
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Figure 4.1. Putative intracellular phosphorylation sites on human ENT1.
Amino acid sequence and predicted topology of human ENT1 with highlighted residues
predicted to be phosphorylated by receptor tyrosine kinases (RTK), protein kinase C
(PKC), protein kinase CKII (CKII), or protein kinase A (PKA). Residues were predicted
using NetPhos 2.0 web based software (http://www.cbs.dtu.dk/services/NetPhos/) (3).
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4.2.3 Protein Kinase Modulation
Serum starved cells were harvested and resuspended in HBSS. Cells were then treated
with 100 µM forskolin or 1 µM of the direct PKA activator sp-cAMP and incubated at
37°C for 15 min. When used, inhibitors were added to the cells 15 min at 37°C before
the addition of forskolin or sp-cAMP. Treated cells were then used for substrate uptake
assays as described in Chapter 2. Alternatively, cells were then treated with the PKC
activator PMA for 15 min at 37°C. Inhibitors were added to the cells 15 min at 37°C
before the addition of PMA.
To test the contribution of CKII to transporter regulation, cells were washed and fed
with medium containing 10 µM TBB or DMSO and incubated at 37°C for 24 to 48 hr prior
to uptake assays.
4.2.4 Adenosine Receptor Agonists
For uptake assays, cells were harvested, resuspended in buffer and treated with the
indicated concentration of agonist or antagonist for the time mentioned at 37°C.
Following incubation, cells were harvested and subjected to substrate uptake assays.
4.2.5 Treatment with a Reactive Oxygen Species Generator
Menadione, an intracellular superoxide generator, was dissolved in 100% ethanol and
prepared fresh each day. Cells were washed with warm HBSS and fed with warmed
HBSS containing vehicle (control) or 100 µM menadione. In some cases, 100 µM
MnTMPyP, a superoxide dismutase mimetic dissolved in ddH2O, was also added to cells
at the same time as menadione, or to cells alone. Cells were incubated at 37°C for 30
min before harvesting and subsequent uptake studies (as described in Chapter 2).
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4.2.6 Simulated Hypoxia and Ischemia
4.2.6.1 Cobalt Chloride Treatment
Cobalt chloride (CoCl2) is an established stabilizer of HIF-1α (35). Confluent cells were
washed with PBS and fed with medium containing 100 µM CoCl2 and incubated at 37°C
for the time indicated before harvesting for substrate uptake assays.
4.2.6.2 Simulated Ischemia
Based on a method developed by Meldrum and colleagues(29), primary mouse cells
were harvested and resuspended in fresh complete medium. Cell suspensions were
placed in a 37°C 5%CO2-95% air humidified atmosphere for 1 hr to equilibrate. Following
equilibration, a cell lot was centrifuged briefly and all medium was aspirated off with the
exception of enough to keep the pellet covered. The pellet was resuspended by flicking
the tube. Simulated ischemia was initiated by the layering of mineral oil over the
concentrated cell suspension, creating a gas exchange barrier. Mineral oil overlayed
cells were placed back in the atmosphere described above for 2 hr. Control cells were
left in the complete medium with no overlay. Cells were gently mixed every 30 min.
Following treatment, cells were washed with PBS, centrifuged, and supernatant was
aspirated. This procedure was repeated three times to ensure no mineral oil was
remaining. Cells were then resuspended in a final volume appropriate for substrate
uptake assays.
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4.3 RESULTS
4.3.1 Regulation of transport by VEGF
4.3.1.1 VEGF protects against serum starvation cell death in primary but not
immortalized microvascular endothelial cells.
Primary human cardiac microvascular endothelial cells (MVEC) and immortalized cell
line HMEC-1 were treated with human recombinant VEGF165 for 24 hr at
concentrations ranging from 0.1 to 25 ng/ml. A dose-dependent increase in cell
concentration, as determined by cell counting, was observed with MVECs cells but not
HMEC-1 cells (Figure 4.2).
4.3.1.2 VEGF reduces [3H]NBMPR binding sites in microvascular endothelial cells.
Treatment with VEGF for 24 hr in serum free medium resulted in a dose-dependent
decrease in the number of [3H]NBMPR binding sites, representative of ENT1 protein, to
a maximum of 66 ± 4 % of control at a concentration of 25 ng/ml in MVECs (Figure
4.3A). HMEC-1 cells also had reduced [3H]NBMPR binding sites after VEGF treatment,
however this effect was achieved at a lower concentration of 1 ng/ml. The magnitude of
drop was similar to MVECs at 65 ± 9 % of control (Figure 4.3B).
4.3.1.3 The reduction in [3H]NBMPR binding is temporally different between MVEC and
HMEC-1 cells.
Primary MVECs and immortalized HMEC-1 cells were treated with 25 ng/ml and 1 ng/ml
VEGF, respectively, over a range of different times. The number of [3H]NBMPR binding
sites in MVECs was unaffected up to 2 hr of treatment. However, after 4 hr of
treatment, [3H]NBMPR binding was reduced to 69 ± 9 % of control and remained
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depressed at the same level at both 6 and 24 hr (Figure 4.4A). In contrast, the number of
[3H]NBMPR sites in HMEC-1 remained at control levels until 24 hr (Figure 4.4B).
4.3.1.4 VEGF reduction in [3H]NBMPR binding sites in MVECs may be mediated by
VEGFR2.
Primary MVECs were pretreated with the non-selective VEGF receptor antagonist
sunitinib malate or the VEGFR2 selective antagonist ZM323881 at a concentration 1 µM
for 15 min. Following pretreatment, 25 ng/ml VEGF was added to culture medium and
cells were incubated for an additional 24 hr. The VEGFR2 inhibitor ZM332881 was able
to prevent a VEGF mediated reduction in [3H]NBMPR Bmax. Sunitinib malate failed to
prevent a VEGF induced reduction in [3H]NBMPR binding sites, however sunitinib alone
also significantly reduced [3H]NBMPR Bmax (Figure 4.5). Both ZM323881 and sunitinib
were able to directly inhibit [3H]NBMPR binding at high concentrations (10µM), however
there was no significant inhibition of [3H]NBMPR binding at the 1µM concentration used
for both compounds in the [3H]NBMPR binding assay (Figure 4.6).
4.3.1.5 Nucleobase, but not nucleoside transport is increased by VEGF.
In contrast to the findings that VEGF was capable of reducing the number of [3H]NBMPR
binding sites in both primary MVECs and HMEC-1 cells, the transport of 2[3H]chloroadenosine by ENT1 was not affected by 24 hr VEGF treatment of either cell
type. Interestingly, the Vmax of [3H]hypoxanthine uptake indicating an increase in the
activity of the purine selective nucleobase transporter ENBT1 was significantly increased
in HMEC-1 cells to from 4.3 ± 0.3 to 6.0 ± 0.6 pmol/µl/s (n = 4). The primary MVEC
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[3H]hypoxanthine uptake Vmax was also increased from, 7.8 ± 1.7 to 11.8 ± 2.5 pmol/µl/s,
however this did not reach statistical significance in this data set (Figure 4.7).
4.3.2 Regulation by PKC
Treatment of serum starved hMVECs with 100 nM PMA for 15 min resulted in a 35 ± 6 %
decrease in ENT1 mediated uptake of 10 µM 2-[3H]chloroadenosine compared to
control. In contrast PMA had no effect on ENBT1 mediated uptake of 50 µM
[3H]hypoxanthine (Figure 4.8A). The effect of PMA on ENT1 was inhibited by the
compound Go6983 which is a non- specific PKC inhibitor, but was not affected by
Go6976 which is selective for the alpha and beta isoforms of PKC. The inactive PMA
analogue 4α-PMA had no effect on ENT1 mediated transport (Figure 4.8B)
Kinetic analysis of ENT1 transport of 2-[3H]chloroadenosine after 100 nM PMA
treatment revealed a 74 ± 11 % decrease in Vmax and an 81 ± 9 % decrease in Km
compared to control (Figure 4.8C).
Treatment with 100 nM PMA in serum free medium for 24 hr was also performed.
Uptake of 10 µM 2-[3H]chloroadenosine by ENT1 was increased to 180 ± 33 % of control
(n=4). Additionally, uptake of 50 µM [3H]hypoxanthine by ENBT1 dramatically increased
to 279 ± 39 % of control (Figure 4.8D).
4.3.3 Regulation by CKII
Treatment with 10 µM TBB in serum free medium for 24 hr, resulted in a substantial
decrease in 10 µM 2-[3H]chloroadenosine uptake to 21 ± 6 % of control. Additionally,
there was a significant decrease in 50 µM [3H]hypoxanthine uptake to 52 ± 11 % of
control (Figure 4.9).
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Figure 4.2 VEGF enhances cell concentration in primary MVECs but not immortalized
HMEC-1 cells.
Primary hMVECs or immortalized HMEC-1 cells were washed with PBS and then cultured
with serum free medium containing vehicle or the indicated concentration of VEGF for
24 h (shaded boxes). Cells were harvested and resuspended in buffer and counted by
using either a hemocyotmeter or TC-10 automated cell counter. Cell concentration in
cells/ml of VEGF treated cells was taken as a percentage of control cells. *P<0.05 one
sample t-test compared to 100%, n ≥ 3. Data are means ± SEM.
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Figure 4.3. VEGF decreased [3H]NBMPR binding Bmax in both hMVECs and HMEC-1 cells.
Confluent primary hMVECs or immortalized HMEC-1 cells were washed with PBS and
then fed with serum free medium containing vehicle or the indicated concentration of
VEGF for 24 h. Cells were harvested and resuspended in PBS and subjected to
[3H]NBMPR binding as described in the methods. A) Primary MVECs had a significant
decrease in [3H]NBMPR binding Bmax compared to 66 ± 4 % of control at 25 ng/ml
(*P<0.05, one sample t-test vs 100%, n = 3). B) HMEC-1 cells had a significant decrease
in [3H]NBMPR binding sites to 65 ± 9 % of control at 1 ng/ml VEGF (n ≥ 4).
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Figure 4.4. The reduction in [3H]NBMPR binding was temporally different between
MVEC and HMEC-1 cells.
A) Primary MVECs were incubated with 25 ng/ml VEGF for the times indicated and
[3H]NBMPR binding was measured. A significant decrease to 69 ± 9 % of control was
obtained after 4 hr and did not change at 6 or 24 hr of treatment (*P<0.05 one sample,
two-tailed t-test vs 100%, n ≥ 3).
B) HMEC-1 cells were incubated with 1 ng/ml VEGF for the times indicated and
[3H]NBMPR binding was measured. A significant decrease to 65 % of control was seen at
24 hr of treatment (*P<0.05 one sample, two-tailed t-test vs 100%, n ≥ 3).
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Figure 4.5. VEGF reduction in [3H]NBMPR Bmax was mediated by VEGF receptor VEGFR2.
Primary MVECs were pretreated with or without 1 µM of the non-selective VEGFR
inhibitor sunitinib (A) or the VEGFR2 selective inhibitor ZM323881 (B) for 15 min prior to
the addition of 25 ng/ml VEGF in serum free medium. In parallel, cells were treated with
inhibitors only (C). Cells were incubated for 24 hr followed by the determination of
[3H]NBMPR Bmax. Changes in Bmax were compared to serum free control in the absence
of VEGF or inhibitors. Data is mean ± SEM of 9 experiments performed in duplicate.
*P<0.05 two-tailed, one sample t-test vs 100%. #P<0.05 two-tailed t-test.
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Figure 4.6. Sunitinib inhibition of [3H]NBMPR binding does not correspond to Bmax
decreases.
Primary hMVECs were co-incubated with 0.15 nM [3H]NBMPR and increasing
concentrations of sunitinib (closed squares) or ZM323881 (open squares) for 45 min at
room temperature. Specific bound [3H]NBMPR in the presence of a VEGFR inhibitor was
taken as a percentage of specific bound [3H]NBMPR in the absence of any inhibitor.
The vertical dotted line represents the concentration of sunitinib and ZM323881 that
were used to inhibit the effects of 24 hr treatment with 25 ng/ml VEGF as described by
Figure 4.5.
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Figure 4.7. Nucleobase transport, but not nucleoside transport, is increased by VEGF.
Primary MVECs and immortalized HMEC-1 cells were treated with 25 ng/ml VEGF for 24
hr. ENT1 mediated transport of 2-[3H]chloroadenosine was unchanged in MVECs (A) or
HMEC-1 cells (B). The Vmax of ENBT1 mediated transport of [3H]hypoxanthine was
increased in both MVECs (C) and HMEC-1 cells (D) The increase in Vmax in HMEC-1 cells
reached statistical significance. (P<0.05 two-tailed t-test, n = 4).
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Figure 4.8. Nucleoside and nucleobase transport are differentially regulated by PKC.
A) Serum starved cells were harvested and treated with PMA for 15 min at 37°C in HBSS
prior to analysis of 10 µM 2-[3H]chloroadenosine(ENT1) and 50 µM [3H]hypoxanthine
(ENBT1) uptake. *P<0.05 two-tailed, one sample t-test vs 100%. #P<0.05 two-tailed ttest. Data are means ± SEM of four independent experiments performed in duplicate.
B) Serum starved cells were harvested and pretreated with the broad spectrum PKC
inhibitor Go6983 or the PKC-α/β selective inhibitor Go6976 for 15 min prior to the
addition of PMA. Some cells were treated with 100 nM 4α-PMA, an inactive analogue of
PMA. Mediated uptake of 10µM 2-[3H]chloroadenosine after 5 sec was then
determined. *P<0.05 two-tailed, one sample t-test vs 100%. #P<0.05 two-tailed t-test.
Data are means ± SEM of at least 4 independent experiments performed in duplicate. C)
Serum starved cells were treated with 100 nM PMA (open squares, dotted line) for 15
min prior to 2-[3H]chloroadenosine uptake. PKC activation resulted in a 74 ± 11 %
decrease in Vmax and an 81 ± 9 % decrease in Km compared to control (P<0.05 two-tailed,
one sample t-test vs 100%, n = 3). D) Cells were treated with 100 nM PMA for 24 hr in
serum free medium. Cells were then harvested and subjected to 10 µM 2[3H]chloroadenosine uptake (ENT1) and 50 µM [3H]hypoxanthine uptake (ENBT1). Data
are means ± SEM of three independent experiments performed in duplicate. *P<0.05
two-tailed, one sample t-test vs 100%.

117

118

Figure 4.9. Inhibition of CKII decreases nucleoside and nucleobase uptake.
Primary hMVECs were treated with or without 10 µM TBB in serum free medium for 24
hrs. Treated cells were then harvested and subjected to uptake assay of 10 µM 2[3H]chloradenosine (ENT1) or 50 µM [3H]hypoxanthine. Data is mean ± SEM of three
independent experiments performed in duplicate. *P<0.05 two-tailed, one sample t-test
vs 100%.
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4.3.4 Regulation by PKA
ENT1 mediated transport of 10 µM 2-[3H]chloroadenosine was decreased by both
forskolin and sp-cAMP, whereas ENBT1 mediated transport of [3H]hypoxanthine was
unaffected. The adenylate cyclase activator forskolin decreased ENT1 function by 40 ±
11 % of control, and the cAMP analogue sp-cAMP reduced ENT1 by 56 ± 13 % of control
(Figure 4.10A)
The PKA inhibitor KT5720 was unable to inhibit the decrease in ENT1 function caused by
forskolin or sp-cAMP. In fact, KT5720 caused a concentration-dependent enhancement
of the effects of both forskolin and sp-cAMP (Figure 4.10B). When tested against
[3H]NBMPR binding, KT5720 inhibited specific binding with a K i of 70 ± 17 nM (Figure
4.10C).
Both adenosine A2A and A2B receptors are known to couple to Gs proteins which
stimulate the production of cAMP through the activation of adenylate cyclase. However,
treatment with the A2A selective agonist CGS21680 or the non selective agonist NECA
did not have any effect on ENT1 (Figure 4.11)
4.3.5 Effect of ROS on nucleoside and nucleobase transporter function.
HMEC-1 cells were treated with the intracellular superoxide generator menadione as
described in section 4.2.5. Both ENT1 and ENBT1 Vmax was significantly reduced by
menadione to 46 ± 3 and 28 ± 9 percent of control respectively. The superoxide
dismutase mimetic MnTMPyP could not prevent the reduction in ENT1 V max, however
MnTMPyP significantly diminished the effect of menadione on the reduced Vmax of
[3H]hypoxanthine uptake by ENBT1 (Figure 4.12).
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Figure 4.10. Effect of cAMP on nucleoside and nucleobase transporter function.
A) Cells were serum starved for 24 hrs, harvested and treated with 100 µM forskolin, 1
µM sp-cAMP, or 10 mM 8CPT-2Me-cAMP for 15 min at 37°C in HBSS followed by
analysis uptake of 10 µM 2-[3H]chloroadenosine(ENT1) and 50 µM [3H]hypoxanthine
(ENBT1). Data are mean ± SEM of at least 3 experiments performed in duplicate.
*P<0.05 two-tailed, one sample t-test vs 100%, n ≥ 3. #P<0.05 two-tailed t-test
compared to ENT1.
B) Cells were pretreated with the PKA inhibitor KT5720 for 15 min at 37°C in HBSS prior
to the addition of 100 µM forskolin (solid bars) or 1 µM sp-cAMP (open bars) for an
additional 15 min at 37°C. Data are mean ± SEM of three experiments performed in
duplicate. *P<0.05 two-tailed, one sample t-test vs 100%.
C) Primary human MVECs were harvested and incubated with 0.15 nM [ 3H]NBMPR and
increasing concentrations of KT5720 for 45 min at room temperature. Using the ChengPrusoff equation, KT5720 was found to have a Ki of 70 ± 17 nM. Data are means ± SEM
of three independent experiments performed in duplicate.
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Figure 4.11. Adenosine A2 receptor agonism does not alter ENT1 function.
Primary MEVCs were treated with 300 nM of the A2A selective agonist CGS21680 or 10
µM of the non-selective A2 agonist NECA for 2 hrs in HBSS at 37°C. Cells were then
harvested and subjected to analysis of 2-[3H]chloroadenosine uptake. Data are mean ±
SEM of six independent experiments.
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Figure 4.12. Intracellular superoxide production by menadione reduced ENBT1 but not
ENT1 function.
HMEC-1 cells were treated with 100 µM menadione in HBSS at 37°C for 30 min ± 100
µM MnTMPyP. A) The Vmax of 2-[3H]chloroadenosine uptake by ENT1 was significantly
reduced to 45 ± 2 % of control. MnTMPyP had no effect on menadione treated cells or
on its own.
B) The Vmax of [3H]hypoxanthine uptake by ENBT1 was significantly reduced to 25 ± 7 %
of control. Co-treatment with MnTMPyP was able to limit the reduction in Vmax to 68 ± 6
% of control. As with ENT1, MnTMPyP had no effect on ENBT1 transport alone.
Panels C) and D) show the effects of menadione ± MnTMPyP on V max and Km parameters
as percent of control. Effects of MnTMPyP alone are excluded for clarity. *P<0.05, twotailed one sample t-test vs 100%, n ≥ 3. #P<0.05 one way ANOVA with a Tukey-Kramer
post hoc test, n ≥ 4.
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4.3.6. Simulated Ischemia
Treatment with the HIF-1α stabilizer CoCl2 had no effect on ENT1 or ENBT1 in primary
hMVECs (Figure 4.13 A-B). The mineral oil overlay to simulate ischemia had no
significant effect on 2-[3H]chloroadenosine transport with Vmax of 2.0 ± 0.4 pmol/µl/s
and 2.0 ± 0.2 pmol/µl/s for control and ischemia respectively. However, mineral oil
overlay dramatically reduced [3H]hypoxanthine uptake by ENBT1 to levels that
resembled non-mediated uptake (Figure 4.13 C-D).
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Figure 4.13 Effects of hypoxia and ischemia on nucleoside and nucleobase transport.
A & B) Primary MVECs were treated with 100 µM CoCl2 for 2 hrs at 37°C in complete
medium. 2-[3H]chloroadenosine (A) and [3H]hypoxanthine (B) uptake assays were
performed. Data are mean ± SEM of four experiments.
C&D) Cells were subjected to mineral oil overlay as described in Section 4.2.3.2.
2-[3H]chloroadenosine uptake by ENT1 was not significantly affected (C) however,
[3H]hypoxanthine uptake by ENBT1 (D) was abolished following 2 hrs of mineral-oil
overlay ischemia. Data are mean ± SEM of four experiments.

127

128
4.4 Discussion
This chapter addressed the regulation of purine transporters in the context of
hypoxia/ischemia. This included the generation and effects of ROS as well as
physiological molecules, receptors, and kinases that have been shown to be important
in both the normal vasculature, as well as during times of vascular stress.
4.4.1 Regulation of Transport by VEGF
This is the first study to demonstrate that VEGF is a regulator of purine transporters in
microvascular endothelial cells. VEGF acts through a family of transmembrane receptor
tyrosine kinases (RTKs). A recent study by Vega et al., demonstrated that transforming
growth factor beta 1, another molecule that signals through a family of RTKs, limits the
expression of ENT1 in human umbilical vein endothelial cells (44). While the model is
different, the overlap in signaling pathways between TGF-β and VEGF receptors
supports our finding that VEGF has the potential to regulate ENT1. In silico analysis of
the ENT1 protein revealed a potential RTK phosphorylation consensus sequence at Tyr-2
of intracellular N-terminal, suggesting a possible direct link between RTK activation and
ENT1 post-translational regulation.
It is widely accepted that changes in [3H]NBMPR binding are mirrored by similar changes
in substrate transport, i.e. a decrease in [3H]NBMPR binding would result in decreased
transport. However, in the current study, we found that there was no decrease in
nucleoside transport despite a decrease in [3H]NBMPR binding of about 35%. The
decrease in [3H]NBMPR binding could be a result of a conformational change elicited by
phosphorylation of the transporter by VEGFR2 that alters the [3H]NBMPR binding site
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that does not impact the substrate translocation site. The physiological relevance of this
effect remains to be elucidated.
We observed a difference between the primary hMVECs and the immortalized HMEC-1
cells in the response to VEGF-165 treatment. This was despite the fact that HMEC-1 cells
have a comparable number of ENT1 sites per cell to hMVECs and show a complete lack
of functional ENT2 (5). The HMEC-1 cell line is a well established endothelial cell model
created from human dermal microvascular endothelial cells that were transfected with
the simian virus 40 large T antigen (1). This cell line is reported to maintain many of the
characteristics of the original microvascular endothelial cells, and is capable of
producing VEGF (17).
The observation that the nucleoside transporter ENT1, as measured by [ 3H]NBMPR
binding, is reduced by VEGF while cell numbers increased is counter-intuitive. In fact,
ENT1 expression has been shown to increase during cell proliferation (7). This finding
suggests that the VEGF cell proliferation and ENT1 regulation pathways are divergent.
This also suggests, therefore, that ENT1 regulation by VEGF signaling is of greater
importance than regulation via normal cell cycle progression. The VEGFR2 selective
antagonist ZM323881 was able to prevent a VEGF-mediated decrease in ENT1,
suggesting that it is the VEGFR2 receptor responsible for this effect. These data are
consistent with VEGF pharmacology as the VEGF-165 used in this study is the most
common form of the protein produced and the VEGFR2 receptor is believed to be the
receptor subtype that mediates the biological effect of VEGF-165 (49). However,
VEGFR2 may not be the only RTK capable of regulating ENT1 expression. The drug
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sunitinib is capable of inhibiting a wide variety of RTKs including platelet derived growth
factor receptor (PDGFR), stem cell grown factor receptor (KIT), and fms-like tyrosine
kinase receptor-3 (FLT3) (30; 31). Given that inhibition [3H]NBMPR binding and
reduction of [3H]NBMPR binding sites after 24 hr treatment of sunitinib do not co-relate
(Figures 4.5,4.6), it is possible that the sunitinib effect is receptor mediated.
When viewed in a physiological context, VEGF release and signaling is most likely to
occur during periods of hypoxia/ischemia. During hypoxia, adenosine levels increase as a
result of increased ATP breakdown. Adenosine is a known stimulator of VEGF
production (11). Additionally, the VEGF gene contains a hypoxia response element, and
therefore is directly regulated by oxygen tension (19). Thus, a VEGF signal in endothelial
cells causing a decrease in ENT1 protein may be acting to potentiate the protective
actions of adenosine by reducing the amount taken up into the endothelium. Reduced
intracellular adenosine accumulation in the endothelium could also be a protective
mechanism against ischemia-reperfusion injury. Adenosine metabolism to hypoxanthine
provides substrate for xanthine oxidase to produce reactive oxygen species upon reoxygenation. Less adenosine in the cell means less hypoxanthine and therefore less ROS.
The other main observation of this study is the VEGF mediated increase in the function
of the hypoxanthine transporter ENBT1 in HMEC-1 cells, with a trending towards a
similar increase in MVECs. This increase would compliment an endothelial protective
function for VEGF, as more ENBT1 would result in enhanced removal of hypoxanthine
from the cells and thus another way to limit ROS production.
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There is also potential application of the presented results to cancer treatment. It is well
known that solid tumours are hypoxic and rely on VEGF to generate new blood vessels
to supply the tumour with blood (22; 26; 48). Given that VEGF increases ENBT1 function,
therapies involving nucleobase analogues that are potential substrates for ENBT1, like 6mercaptopurine or 6-thioguanine (5), may more effectively cross the endothelial barrier
and reach the tumour cells.
4.4.2 Regulation by Protein Kinase C
Regulation of ENT1 by PKC is a widely studied phenomenon. However, the effect on
ENT1 function, and by which PKC isoform, is still disputed. In human MCF7 and HeLa
cancer cell lines, short term PMA treatment (10 min) caused an increase in uptake that
was mediated through PKC-δ or -ε, whereas chronic treatment (24 hr) caused a
decrease in uptake (12). In mouse HL-1 cardiomyocytes acute PMA (10 min) also caused
an increase in ENT1 mediated transport (10). However, in human umbilical vein
endothelial cells, PMA treatment (30 min) resulted in decreased ENT1 activity (34). In
rat cardiac fibroblasts, PKC-ζ has been implicated in the down-regulation of ENT1 in
response to elevated glucose (21), and PKC-ε down-regulation by chronic hypoxia (18
hr) has also been linked to decreased ENT1 activity (9). In Figure 4.8, activation and
inhibition of PKC with PMA and Go6983, respectively, supports a role for PKC-δ/ε,
however the effects on ENT1 are the opposite of that observed in MCF7 and HeLa cells
as well as the mouse HL-1 cardiomyocyte cell line.
The role of PKC in the regulation of ENBT1 is much more complex. Acute PMA treatment
of serum starved cells had no effect on ENBT1 function; however chronic PMA exposure
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resulted in a significant increase in the uptake of 50 µM hypoxanthine. These data
suggest that PKC has no direct effect on ENBT1 function, rather that ENBT1 is regulated
by another protein that is the target of PKC phosphorylation. Alternatively, ENBT1 may
be constitutively phosphorylated and the decrease in PKC activity caused by chronic
PMA treatment leads to a decreased ENBT1 phosphorylation state. Recent evidence in
human umbilical vein endothelial cells showed that PKC inhibition led to increased nitric
oxide (NO) production (40), perhaps a similar mechanism occurs in MVECs and is
responsible for the [3H]hypoxanthine uptake increase. However, since the uptake assay
was performed in ATP-replete conditions to allow cellular regulation events to function
properly, the increase in [3H]hypoxanthine uptake could be an artifact of altered
metabolism. That is, with ATP present, nucleobase scavaging enzymes, such as
hypoxanthine-guanine phosphoribotransferase are capable of producing [3H]nucleotides
from [3H]hypoxanthine, trapping the [3H]label inside the cell, and thus artificially
increasing the apparent rate of [3H]hypoxanthine uptake.
4.4.3 Regulation by CKII
In agreement with the study by Bone et al.,(6) CKII inhibition by TBB resulted in
decreased ENT1 transport activity. However, this was not achieved under the same
conditions as that study, instead, the decrease was observed after 24 hr in serum free
medium, compared to 48 hr in complete medium as described by Bone (6). Differences
in cell model and culture medium could contribute to the temporal differences observed
between the two studies. The cells used by Bone were nucleoside transporter deficient
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cells stably expressing recombinant human ENT1 (6) compared to the primary MVECs
used presently.
4.4.4 Regulation by Protein Kinase A
The in silico analysis of ENT1 predicted potential PKA phosphorylation sites (Figure 4.1),
therefore the effects of PKA activators were investigated on nucleoside and nucleobase
transport. Forskolin, an adenylate cyclase activator and therefore an indirect PKA
activator, and the cAMP analogue sp-cAMP, a direct PKA activator, both led to a
decrease in ENT1 mediated uptake but had no effect on ENBT1 mediated nucleobase
uptake. The decrease in ENT1 mediated uptake is in agreement with a study by Sen et
al., who showed that forskolin was able to decrease ENT1 uptake by 30% in mouse
Neuro-2a cells (39). It has also been shown that active PKA is required for ethanol
mediated inhibition of adenosine uptake in neuronal cells (13). However a difficulty
arose when trying to confirm PKA as the protein responsible for the ENT1 downregulation. The cAMP analogue 8-CPT-2Me-cAMP, a direct activator of another cAMP
binding protein Epac-1, is a direct inhibitor of ENT1 (46). Additionally, the commonly
used PKA inhibitor H89 is a direct ENT1 inhibitor as well (23). Thus a different PKA
inhibitor, KT5720 was used, however it also turned out to be a direct, high affinity
inhibitor of ENT1 as shown by the ability to inhibit [ 3H]NBMPR binding with a Ki of 70
nM.
Adenosine A2 receptors stimulate adenylate cyclase activity and thus activate PKA when
presented with an agonist. Therefore, it was expected that the adenosine A2A agonist
CGS21680 or the non-selective A2 agonist NECA would produce the same effect as
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forskolin and sp-cAMP. However, this was not the case as adenosine receptor agonism
had no effect on 2-[3H]chloroadenosine uptake (Figure 4.11). Primary human MVECs are
expected to express the adenosine A2A receptor (38) therefore the lack of response
could be a lack of sufficient cAMP production to effectively activate PKA. Another
possibility could be that cAMP, forskolin, or sp-cAMP directly interact with ENT1 to
prevent [3H]NBMPR binding. The presence of potential PKA phosphorylation sites on
ENT1 suggests that PKA is responsible for the decrease in ENT1 function, but without a
PKA inhibitor that does not directly interfere with ENT1 function this phenomenon could
not be properly addressed.
4.4.5 Effects of ROS on Purine Transporters
The superoxide generator menadione had differential effects on ENT1 and ENBT1
transport of nucleosides and nucleobases, respectively. Menadione reduced the Vmax of
both ENT1 and ENBT1 mediated uptake (Figure 4.12). The superoxide dismutase
mimetic, MnTMPyP reduced the effect of menadione on ENBT1 uptake but not ENT1.
Therefore, ENBT1 transport function is sensitive to the presence of superoxide, and thus
most likely selectively oxidized on a residue important to transport function. Oxidation
of sulphydryl groups, especially those found on cysteine residues, is typically the cause
of modifications that lead to protein dysfunction (2; 8; 36). Modification of cysteine
residues has been shown to inhibit function of a number of different transporter types
(24; 43; 45).
Unfortunately, it cannot be determined using menadione if ENT1 is also sensitive to
superoxide modification. Since MnTMPyP could not reverse the effects of menadione,
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direct inhibition of ENT1 by menadione is the probable outcome. Direct inhibition of
ENT1 by menadione is supported by the fact that antibiotics containing quinone, the
same class of chemical as menadione, reduced nucleoside uptake via ENT1 (32).
4.4.6 Effects of Simulated Hypoxia and Ischemia on Purine Transporters
CoCl2 stabilizes HIF-1α in the presence of normal oxygen concentrations, thus making it
an easier tool to study the impact of HIF-1α (and by extension hypoxia) on your gene of
interest (35). The mineral-oil overlay model has been shown to reduce oxygen
concentrations to which the cells are exposed (28; 29). The lack of effect of CoCl2 after 2
hr indicates that stabilization of HIF-1α does not impact ENT1 or ENBT1 in the short
term (Figure 4.13). It was previously shown that ENT1 responds to actual hypoxia after 8
hr in HUVEC cells (15), and thus these data are not totally unexpected. The loss of
ENBT1 function, with no effect on ENT1 after 2 hr of ischemia, suggests that another
mechanism other than low oxygen is mediating this effect. In vivo, ischemia-reperfusion
is known to produce ROS (20; 37; 47), and may be produced in culture leading to
oxidation of ENBT1. However, another possibility could be an increase in intracellular
hypoxanthine, as a result of increase adenosine metabolism, that establishes a
concentration gradient favouring efflux. However, in this model of ischemia, it could be
argued that the resuspension of cells in buffer and washing away of the mineral oil is the
reperfusion step. This would allow both efflux and metabolism of any endogenous
hypoxanthine, generating superoxide and establishing the proper conditions for uptake.
Thus, taken with the data generated with menadione treatment, these data suggest that
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ENBT1 is indeed sensitive to the presence of ROS, to the point of complete loss of
function.
4.4.7 Conclusions
Primary human MVECs were used to study the roles of VEGF, intracellular kinases,
adenosine receptors, reactive oxygen species, and ischemia on purine transport. These
studies were successful in identifying VEGF as a novel regulator of purine transporters
through VEGFR2. Additionally, intracellular kinases PKC and CKII are capable of altering
transport function. The intracellular kinase PKA may also play a role in the regulation of
ENT1, however more work is needed to confirm a PKA interaction and rule out a direct
cAMP interaction with the transporter.
These data suggest that the microvascular purine transporters ENT1 and ENBT1 may be
altered in the pathophysiology of hypoxia/ischemia and oxidative stress. Intracellular
superoxide, generated by menadione, produced dramatic decreases in transporter Vmax.
ROS may also be a contributing factor to the down-regulation of ENBT1 during ischemia,
with ENT1 being less sensitive to oxidative insult. Further ROS dose response studies are
needed to clarify the mechanism of regulation.
These alterations may contribute to endothelial dysfunction, especially the downregulation of ENBT1, which would trap the superoxide producing hypoxanthine inside
endothelial cells. Fortunately, these transporters are also regulated by proteins that are
targets of pharmacological manipulation and thus interventions could be devised to
prevent or reduce the impact they have on endothelial cell oxidative stress.
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CHAPTER FIVE
MICROVASCULAR ENDOTHELIAL CELLS ISOLATED FROM MICE: TRANSPORTER
CHARACTERIZATION AND REGULATION, SUBSTRATE METABOLISM, AND
CONSEQUENCES OF ENT1 KNOCKOUT1
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5.1 INTRODUCTION
All mammalian cells express at least one form of equilibrative transporter responsible
for the cellular uptake and release of endogenous nucleosides such as adenosine. The
predominant transporters are equilibrative nucleoside transporter subtypes 1 (ENT1;
SLC29A1) and 2 (ENT2; SLC29A2) (4). The inhibition of ENTs has been shown to enhance
the cardioprotective (28) and neuroprotective (17) actions of adenosine. These
transporters are also responsible for the cellular uptake of cytotoxic nucleoside analogs
used to treat cancer and viral infections (35).
An ENT1-null (ENT1−/−) mouse model has been generated by Choi and colleagues (12).
The ENT1−/− mice are phenotypically normal with the only difference from wild-type
(WT) littermates being a slight (<10%) decrease in body weight and some differences in
their behavioral characteristics. The ENT1-null mice are less sensitive to the intoxicating
effects of ethanol compared with their WT littermates (12), and they also display less
anxiety-like behavior (11). It has been noted that there is less tonic A 1 adenosine
receptor signaling in the brains of ENT1−/− mice (12), reflecting either reduced
extracellular adenosine levels or a decreased sensitivity of the receptor to adenosine,
suggesting that ENT1 plays an important role in modulating the interaction of adenosine
with its concomitant receptors in the central nervous system.
In addition to its regulatory activities in the nervous system, adenosine is well
established as an endogenous cardioprotective agent via interactions with
cardiomyocytes and is also a potent vasodilator through actions on vascular smooth
muscle and endothelial cells (23). The availability of ENT1−/− mice will now allow an in-
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depth examination of the role of ENT1 (and the effects of its absence) in adenosine
metabolism and bioactivity in the various cell types that constitute the cardiovascular
system under both normal and pathophysiological conditions. We have recently
published the results of a study based on cardiomyocytes isolated from WT and ENT1−/−
mice (31). The present study extends this work to an examination of the impact of ENT1
loss on the nucleoside flux and metabolism in microvascular endothelial cells (MVECs).
Previous studies from our laboratory have established that rat MVECs express high
levels of both ENT1 and ENT2 (3), whereas human MVECs express predominantly the
ENT1 subtype of nucleoside transporter (7). MVECs are considered to be the major site
of accumulation and metabolism of the adenosine released into the interstitial space by
myocytes during periods of high energy demand in heart and skeletal muscle (15);
therefore, in the absence of biological compensation, one might expect the loss of ENT1
to have dramatic effects on the vascular actions of adenosine.
In this communication, we describe the nucleoside and nucleobase transport profile of
MVECs derived from skeletal muscle of ENT1−/− mice and their WT littermate controls.

5.2 MATERIALS AND METHODS
5.2.1 Materials
8-2-[3H]chloroadenosine(4–7

Ci/mmol),

2,8-[3H]hypoxanthine

(24–35

Ci/mmol),

[3H]nitrobenzylmercaptopurine riboside (NBMPR) (5.5 Ci/mmol), and [ 3H]water (1
mCi/g) were purchased from Moravek Biochemicals (Brea, CA). Nonradiolabeled 2chloroadenosine, hypoxanthine, NBMPR, nitrobenzylthioguanine riboside, dipyridamole
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{2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]pyrimidine},

collagenase,

trypsin, BSA, tert-butyl hydroperoxide (TBHP), menadione, and cobalt chloride (CoCl2)
were obtained from Sigma-Aldrich (St. Louis, MO). All cell culture media, fetal bovine
serum (FBS), culture grade Dulbecco's PBS, trypsin-EDTA, antibiotic/antimycotic
(penicillin, streptomycin, and amphotericin B), and heparin were purchased from
GIBCO/BRL (Burlington, ON, Canada). Endothelial cell growth supplement (ECGS) was
supplied by Beckton Dickinson (Oakville, ON, Canada). Rabbit polyclonal anti-adenosine
deaminase (ADA), goat polyclonal anti-ENT3, rabbit polyclonal anti-adenosine receptor
A3, and donkey anti-goat horseradish peroxidase conjugated antibodies were all from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-adenosine receptor
A2a and rabbit-anti mouse horseradish peroxidase-conjugated and mouse anti-rabbit
horseradish peroxidase-conjugated antibodies were from Abcam (Cambridge, MA).
5.2.2 ENT1−/− mouse model
ENT1−/− mice were generated in the laboratory of Dr. Doo-Sup Choi as described
previously (12); ENT1−/− mice were backcrossed with outbred WT C57BL/6 mice to
generate ENT1−/+ mice. Only ENT1−/+ mice were crossed (producing ENT1+/+, ENT1+/−, and
ENT1−/− offspring) to establish a breeding colony at the University of Western Ontario.
Genotyping was done using isolated genomic DNA and standard PCR as previously
described (11). All aspects of this study were conducted in accordance with the policies
and guidelines set forth by the Canadian Council on Animal Care and were approved by
the Animal Use Committee of the University of Western Ontario.
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5.2.3 MVEC isolation/culture
MVECs were isolated as described previously for rats (3), based on the affinity of their αd-(+)galactosyl residues for isolectin B4 from Bandeiraea simplicifolia (BSI-B4; Sigma)
bound to magnetic microbeads (Dynabeads, M-450 Epoxy, Dynal, Lake Success, NY). The
extensor digitorum longus muscles of female mice were removed from the hindlimbs
under anesthesia by pentobarbital sodium (42 mg/kg ip). After careful removal and
disposal of tissue containing larger blood vessels, the isolated muscle was sliced into
∼0.5-mm pieces and digested for 30–45 min in 0.84 mg/ml collagenase, 0.12 mg/ml
trypsin and dispase, and 1.62 mg/ml BSA in 50 ml Krebs-Ringer solution containing (in
mM) 127 NaCl, 4.6 KCl, 1.1 MgSO4, 1.2 KH2PO4, 8.3 d-glucose, 24.8 NaHCO3, 2 pyruvate,
11.4 creatinine, 20 taurine, 5 d-ribose, 2 l-asparginine, 2 l-glutamine, 1 l-arginine, and
0.5 uric acid in a 37°C water-jacketed organ bath bubbled with 95% O2-5% CO2. The
enzymatic digest was filtered through 100-μm nylon mesh to remove undigested
fragments, and the dissociated cells were collected by centrifugation and washed in
37°C DMEM-F12 media. Cells were then resuspended with ∼1 × 106 BSI-B4 coated
Dynabeads (in DMEM-F12 media) and rotated on a spindle for 10–15 min. Endothelial
cells bound to the magnetic beads were collected using a magnetic particle collector
(MPC-1, Dynal), washed twice, and transferred to six-well plates in DMEM-F12 media
supplemented with 20% FBS, 100 U/ml penicillin G, 100 μg/ml streptomycin sulfate,
0.25 μg/ml amphotericin B, 2 mM l-glutamine, 0.025 IU/ml heparin, and 125 μg/ml ECGS
and cultured at 37°C in a 5% CO2-95% room air humidified atmosphere. The media was
changed routinely every 3 to 4 days, and the cells were passaged using 0.05% trypsin in
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0.53 mM EDTA upon reaching confluence. After passage 3, the FBS and ECGS levels
were reduced to 10% and 75 μg/ml, respectively. The endothelial cell phenotype was
confirmed by the presence of von Willebrand factor VIII and BSI-B4 antigens as
described previously (3). The cultures were typically found to contain >95% endothelial
cells. In general, five passages were required to obtain sufficient cells to undertake the
transport assays described herein.
In preparation for experimental assays, MVECs (passage 5–15) were trypsinized for 5
min at 37°C and then diluted with DMEM-F12 media + 10% FBS and collected by
centrifugation. The cells were washed once by resuspension/centrifugation in PBS
containing (in mM) 137 NaCl, 6.3 Na2HPO4, 2.7 KCl, 1.5 KH2PO4, 0.9 CaCl2·2H2O, and 0.5
MgCl2·6H2O (pH 7.4) or a modified Na+-free PBS containing N-methyl-d-glucamine
(NMG) buffer consisting of (in mM) 140 NMG, 10 HEPES, 5 KCl, 4.2 KHCO 3, 0.44 KH2PO4,
0.36 K2HPO4, 1.3 CaCl2·2H2O, and 0.5 MgCl2·6H2O (pH 7.4) as appropriate to the assay
and then resuspended in the same buffer for immediate use as described in [3H]NBMPR
binding and [3H]substrate uptake. In some cases, the cells were depleted of ATP by
sequential incubation at 37°C with rotenone and 2-deoxyglucose as described previously
(3).
5.2.4 Analysis of [3H]hypoxanthine metabolites in MVECs
[3H]Hypoxanthine

can

be

phosphorylated

to

inosine

5′-monophosphate

by

hypoxanthine-guanine phosphoribosyltransferase (HGPRT) or oxidized to xanthine via
xanthine oxidase. To determine whether the ENT1−/− MVECs metabolized hypoxanthine
differently than WT cells, we assessed the [3H]metabolites arising from incubating cells
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for 20 min with 100 μM *3H]hypoxanthine. The cells were harvested as described in
MVEC isolation/culture, ATP depleted, and then incubated for 15 min in the presence
and absence of 5 μM dipyridamole before exposure to *3H]hypoxanthine for 20 min at
room temperature. After incubation with [3H]hypoxanthine, the cells were centrifuged
through oil as described in [3H]substrate uptake, and the cell pellet was digested with
7% perchloric acid for ∼16 h. The acid soluble extract was removed and neutralized with
an equal volume of 1 M potassium hydroxide and then centrifuged (10,000 g for 10 min)
to remove insoluble precipitate. Extracts were stored at −20°C until required.
The separation of purine nucleobases, nucleosides, and nucleotides was performed
using two one-dimensional thin-layer chromatography methods modified from Metz et
al. (25) (6 min 0.5 M LiCl, 10 min 1.0 M LiCl, and remainder in 1.5 M LiCl, all at pH 4.0
and included 0.1 M EDTA; condition 1) and Shimizu et al. (33) (n-butanol:ethyl
acetate:methanol:ammonium hydroxide; 7:4:3:4, vol:vol; condition 2). Plastic-backed
PEI-cellulose F TLC plates (EMD Chemicals or Merck) were loaded with 10-μl aliquots of
neutralized extract and developed using the two solvent conditions in parallel. Purine
metabolite locations were determined under UV light, and the Rf values were calculated
and compared with standards for identification. The plates were then cut into 5-mm
strips for liquid scintillation analysis of [3H] content using Beckman Ready Protein+
scintillation fluid.
Neither solvent system on its own was capable of separating all the purine metabolites
of interest. The organic solvent (condition 2) was able to retard all nucleotides at the
loading point on the plate and could clearly isolate adenosine and xanthine. However,
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the hypoxanthine and inosine spots overlapped. The LiCl gradient (condition 1), on the
other hand, could isolate inosine effectively but produced a blended hypoxanthineadenosine spot. Thus the amount of hypoxanthine was determined from the equation:
dpm hypoxanthine = dpm hypoxanthine/adenosine (condition 1) − dpm adenosine
(condition 2). Since xanthine oxidase removes the tritium at the two position of 2,8[3H]hypoxanthine to give 8-[3H]xanthine, the dpm values associated with xanthine were
doubled to compensate for this.
5.2.5 Reverse-transcriptase polymerase chain reaction
Total RNA was isolated from the WT and ENT1−/− MVECs using the phenol-chloroform
extraction. First-strand DNA template was generated using 5 μg (MVECs) of DNaseI
(Invitrogen, Carlsbad, CA)-treated total RNA and the Superscript First Strand Synthesis
System for RT-PCR using oligo d(T) primers (Invitrogen).
RT-PCR amplifications were performed using Platinum Taq DNA polymerase (Invitrogen)
in a Thermocycler PE 480 (Perkin Elmer, Norwalk, CT) using an oil-overlaid 50-μl reaction
mixture in 500-μl thin-walled reaction tubes. Reaction conditions included a 2-min 94°C
initial activation, followed by 25, 30, or 35 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at
72°C. Preliminary experiments determined the number of cycles of PCR that were
required to obtain a visible product on agarose gels for each of the transcripts while
remaining on the log-linear portion of the cycle number versus product formation
curves. PCR products were resolved by electrophoresis on 2% agarose gels against the
O'GeneRuler 50-bp DNA ladder mix (Fermentas, Burlington, ON, Canada). Based on
qualitative PCR, ENT1, ENT3, ADA, and the adenosine receptor A 2a and A3 genes were
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chosen for quantitative real-time PCR analysis using a Roche LightCycler (Roche Applied
Sciences, Mississauga, ON, Canada). β-Actin was chosen as a reference control. All
primers used were the same as those for qualitative PCR. Standard curves for all
transcripts were generated using the same cDNA preparation at concentrations ranging
from 10−7 to 10−12 M. The PCR was conducted using 1 μl of WT or knockout (KO) cDNA
and SYBR Green Jumpstart Taq ReadyMix capillary formulation (Sigma). PCR conditions
were as follows: initial denaturing at 94°C for 30 s, followed by 40 cycles of 94°C for 0 s,
55°C for 5 s, 72°C for 17 s, and 78°C for 1 s. The melting curve analysis of products at the
end of the reaction revealed single products from each primer pair. At least three
individual reactions were performed using two different cDNA preparations.
Primer sequences and expected sizes are summarized in Table 5.1 for ENT1; ENT2;
ENT3; ENT4; concentrative nucleoside transporter subtypes 1 (CNT1), 2 (CNT2), and 3
(CNT3); adenosine kinase; ADA; adenine phosphoribotransferase; hypoxanthine-guanine
phosphoribotransferase; purine nucleoside phosphorylase; xanthine oxidase; A1, A2a,
A2b, and A3 adenosine receptors; and β-actin.
5.2.6 Immunoblots
Extensor digitorum longus muscles were isolated from age- and sex-matched mice and
quickly placed in ice-cold lysis buffer containing 20 mM Tris·HCl, 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM βglycerophosphate, 1 mM Na3VO4, and 1 μg/ml leupeptin (pH 7.5), supplemented with 1
mM phenylmethylsulfonyl fluoride just before use (Cell Signaling Technology, Pickering,
ON, Canada). Total protein from tissue lysates (100 μg for ADA and ENT3; and 200 μg for
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adenosine receptor A2a and A3) was subjected to SDS-PAGE and transferred to
polyvinylidene difluoride membranes. Membranes were incubated overnight (≥12 h) at
4°C with one of the following primary antibody dilutions: ADA, 1:1,000; ENT3, 1:400;
adenosine receptor A2a, 1:1,000; or adenosine receptor A3, 1:200. Secondary antibodies
were used at dilutions of 1:10,000, 1:1,000, 1:4,000, and 1:1,000 for ADA, ENT3, A 2a, and
A3, respectively, and incubated with membranes for 1 h at room temperature. Detection
was performed using LumiGLO chemiluminescent substrate (Cell Signaling Technology)
and the VersaDoc Imaging System (Bio-Rad). After exposure, the membranes were
stripped (200 mM glycine, 1% Tween-20, and 0.1% SDS; pH 2.2) and then probed for
GAPDH using a 1:1,000 dilution of primary antibody for 2 h at room temperature. The
secondary antibody was used at dilutions of 1:2,000 for ADA and ENT3 and 1:4,000 for
adenosine receptor A2a to account for the double amount of protein used. Densitometry
was performed using ImageJ software (http://rsbweb.nih.gov/ij/index.html). In all cases,
the major protein detected by each antibody reflected the expected size of the product
based on manufacturers' specifications and previously published data using these
antibodies (10; 27).
5.2.7 Treatment with Reactive Oxygen Species Generators
Reactive oxygen species (ROS) generators were made fresh each day. TBHP was diluted
in ddH2O from a concentrated stock. Menadione was dissolved in 100% ethanol. In all
cases, confluent cells were washed with warm PBS and fed with warmed complete
medium containing vehicle (control) or the indicated concentration of ROS generator.
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Cells were placed back into the 37°C CO2 incubator for the desired time before
harvesting and subsequent uptake studies (as described in Chapter 2).
5.2.8 Simulated Ischemia and Hypoxia
5.2.8.1 Cobalt Chloride Treatment
Cobalt chloride (CoCl2) is an established stabilizer of HIF-1α (30). Confluent cells were
washed with PBS and covered with medium containing 100 µM CoCl2 and incubated at
37°C for the time indicated before harvesting for uptake.
5.2.8.2 Simulated Ischemia
Based on a method developed by Meldrum and colleagues (24), primary mouse cells
were harvested and resuspened in fresh complete medium. Cell suspensions were
placed in a 37°C 5%CO2-95% air humidified atmosphere for 1 hour to equilibrate.
Following equilibration, a cell lot was centrifuged briefly and all medium was aspirated
off with the exception of enough to keep the pellet covered. The pellet was
resuspended by flicking the tube. Simulated ischemia was initiated by the layering of
mineral oil over the medium, creating a gas exchange barrier. Mineral oil overlayed cells
were placed back in the atmosphere described above for 2 hr. Control cells were left in
the complete medium with no overlay. Cells were gently mixed every 30 minutes.
Following treatment, cells were washed with PBS, centrifuged, and supernatant was
aspirated. This procedure was repeated three times to ensure no mineral oil was
remaining. Cells were then resuspended in a final volume appropriate for substrate
uptake assay.
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5.2.8.3 Hypoxia
For true low oxygen exposure, culture flasks were place in Hypoxia Chambers (BillipsRothenberg, Del Mar, CA). Chambers were flushed with 1% O2 for 5 min and expelled air
was measured with an O2 detector to confirm low oxygen levels. Chambers were then
sealed and placed in a 37°C incubator for the desired time. Following hypoxia, flasks
were removed from the chambers and harvested for uptake.

5.3 RESULTS
5.3.1 MVECs from ENT1-/- Lack [3H]NBMPR Binding
The gross phenotype of the ENT1−/− mice was similar to that reported previously by Choi
and colleagues (12). The ENT1−/− mice had a consistently lower body weight. They were
also notably easier to handle than WT mice (less distress because of handling), likely
reflecting the anxiolytic phenotype reported previously (11). Quantitative RT-PCR
confirmed the loss of the full-length ENT1 transcript in the ENT1−/− mice (Figure 5.2).
MVECs from the ENT1−/− mice had no detectable high-affinity binding sites for the ENT1selective radioligand probe [3H]NBMPR (Figure 5.1), confirming the specificity of this
radioligand for the ENT1 protein. WT mouse MVECs had 150,000 ± 27,000 [3H]NBMPR
sites/cell with an affinity of 0.09 ± 0.02 nM, which is typical of NBMPR binding to ENT1.
5.3.2 Compensatory Changes in Purinergic Genes in ENT1-/- MVECs
We found no evidence for Na+-dependent CNT1, CNT2, and CNT3, and we confirmed
that MVECs do not express the A1 adenosine receptor subtype (19). No changes were
observed in the expression of the ENT2 subtype of plasma membrane-located
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nucleoside transporters in ENT1−/− mice compared with littermate controls (Figure 5.2A),
nor was the ENT4 transcript detected in either the WT or ENT1 −/− cells. Furthermore, no
significant differences were noted in the expression of adenosine kinase, xanthine
oxidase, HGPRT, adenine phosphoribotransferase, purine nucleoside phosphorylase, or
A2B adenosine receptors in the ENT1−/− MVECs compared with WT controls (Figure 5.2A).
However, MVECs from ENT1−/− mice showed significant increases of 15 ± 3- and 11 ± 2fold, respectively, in the expression of mRNA transcripts for ADA and A 2a adenosine
receptors, relative to WT littermate controls (Figure 5.2B). There was a trend toward a
decrease in adenosine A3 receptor transcript in the ENT1−/− mice, but this did not reach
statistical significance and there was no corresponding change in A 3 receptor protein
levels (Figure 5.3). Likewise, there was a small but significant increase in ENT3 transcript
(Figure 5.2B), which was also not paralleled by an increase in ENT3 protein in skeletal
muscle (Figure 5.3). Attempts to measure ADA and A2a adenosine receptor protein levels
in the MVECs proved to be problematic. However, significant increases in ADA (2.1-fold)
and adenosine A2a receptor (2.4-fold) protein was evident by immunoblotting using the
skeletal muscle tissue of ENT1−/− mice from which the MVECs were derived, relative to
WT mice (Figure 5.3).
5.3.3 Nucleoside and Nucleobase Transport Function in WT and ENT1-/- MVECs
In terms of the ability to accumulate [3H]substrates associated with ENT activity, the WT
MVECs accumulated both [3H]formycin B (Figure 5.4) and 2-[3H]chloroadenosine (Figure
5.5) via two distinct Na+-independent dipyridamole-sensitive processes (Table 5.2). The
majority (∼90%) of the substrate uptake in WT MVECs was inhibited by 50 nM NBMPR

156

and hence was mediated by ENT1. The remainder of the uptake was inhibited by
dipyridamole, but not NBMPR, and hence was mediated by ENT2. The uptake of
[3H]formycin B (Figure 5.4) and 2-[3H]chloroadenosine (Figure 5.5) by MVECs was
reduced dramatically in the cells derived from the ENT1 −/− mice (Table 5.2). The initial
rate of uptake of 10 μM *3H]formycin B in the ENT1−/− MVECs was 0.07 ± 0.01 pmol/μl/s,
which is not significantly different from the rate of ENT2-mediated formycin B uptake by
WT mMVECs (0.06 ± 0.01 pmol/μl/s) (Figure 5.4). When 2-[3H]chloroadenosine was used
as a substrate, it was evident that in WT MVECs, ENT1 accounted for the majority of
nucleoside transport, with ENT2 providing a very small component of the total. In
ENT1-/- MVECs, only ENT2 mediated transport was present. Interestingly, the Vmax of 2chloroadenosine uptake in the ENT1−/− mice (0.19 ± 0.07 pmol/μl/s) was actually
significantly lower than the Vmax of ENT2-mediated 2-chloroadenosine uptake in the WT
mice (1.2 ± 0.5 pmol/μl/s) (Figure 5.5).
To further assess the ENT2-mediated component in the MVECs, the uptake of
[3H]hypoxanthine was examined after depleting the cells of ATP to reduce trapping of
[3H]hypoxanthine metabolites. ENT2 differs from ENT1 in that it accepts nucleobases,
such as hypoxanthine, as substrates in addition to purine and pyrimidine nucleosides. It
was apparent from the initial time course studies using 10 μM hypoxanthine that mouse
MVECs readily accumulated hypoxanthine via a saturable system that was relatively
insensitive to dipyridamole but that was inhibited by adenine (Figure 5.6). These data
suggest that hypoxanthine was being accumulated via an ENT-independent transport
process. When adenine (1 mM) is used to define the nonmediated uptake component,
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the WT mouse MVECs accumulated hypoxanthine with Km and Vmax estimates of 125 ±
29 μM and 16.5 ± 3.8 pmol/μl/s, respectively, while ENT1−/− cells had similar Km and Vmax
values of 123 ± 28 μM and 11.6 ± 2.1 pmolμl/s, respectively (Figure 5.7).
Interestingly, the apparent rate of [3H]hypoxanthine influx tended to increase when cells
from WT mice were incubated with the ENT blocker dipyridamole before the uptake
measurements, particularly at higher (>100 μM) concentrations of hypoxanthine (Figure
5.7). In contrast, dipyridamole had no effect on hypoxanthine uptake by ENT1 −/− MVECs.
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Figure 5.1. MVECs from ENT1-/- lack [3H]NBMPR binding.
MVECs isolated from either wild-type (WT) or equilibrative nucleoside transporter
subtype-1 (ENT1) knockout (KO) (ENT1-/-) littermates were exposed to a range of
concentrations of [3H]nitrobenzylmercaptopurine riboside (NBMPR) (abscissa) in the
absence

(total

binding)

or

presence

(nonspecific

binding)

of

10

µM

nitrobenzylthioguanine riboside. Specific binding (ordinate) was calculated as the
difference between total and nonspecific binding. Each point is the mean ± SEM of 5
experiments performed in duplicate.
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Gene

ENT1
ENT2
ENT3
ENT4
CNT1
CNT2
CNT3
Adenosine Kinase
Adenosine Deaminase
Adenine Phosphoribosyltransferase
Hypoxanthine-Guanine
Phosphoribosyltransferase
Purine nucleoside phosphorylase
Xanthine Oxidase
A1 adenosine receptor
A2A adenosine receptor
A2B adenosine receptor
A3 adenosine receptor
β-actin

Primer 5’-3’

CAAGTATTTCACAAACCGCCTGGAC
GAAACGAGTTGAGGCAGGTGAAGAC
GACCTCTGCTCTTGGATACTTCAT
GACAACAAAGACTGAAGGTTTTCC
CCCTCCCTGCTGTTCCTGGT
CATGGGGAAGGAGCCTGTGA
ATTGGCGGCTGTGCTCCTAAA
TGCCGTGCTCTCTCCAGTCAT
GCAGCTGTTTGAGTGGATCA
ACCACACAGGTGATGACGAA
ATTTGTGGCCTACCAGCAAC
GCCTCCCAGTGTGATTCCTA
TGTGCGATAAGCTTCCACAG
CAAGTTTTGTTGGCCCAGTT
TGGAGCGGAACTGGGTGTTGG
GGAAGAGCCTGCGCCTTTTTGG
GAAGGCAAAGGAGGGCGTGGTCTA
GATGTCCACAGCCTCACGCACAAC
CAAGATCGACTACATCGCAGGTCT
GCTCACACACTCCACCACTTCAG
CATTGTGGCCCTCTGTGTGCTCAA
CGAGAGGTCCTTTTCACCAGCAAGC
GCCGACTGGTGTTTGGATTGCTG
TCGTTGCTCCCCCATTTGTTTCC
TGCCTGCTTGACCCCCATCTG
CCTCCACAGCACCCACCATCC
ATCCCTCTCCGGTACAAGACAGT
ACTCAGGTTGTTCCAGCCAAAC
CCGAATTCCACTCCGGTACA
CAGTTGTTCCAGCCCAGCAT
TCTTCCTCGCCTGCTTCGT
CCAGTGACCAAACCTTTATACCTGA
ACTTCTATGCCTGCCTTTTCATGT
AACCGTTCTATATCTGACTGTCAGCTT
GTGACGTTGACATCCGTAAA
CTCAGGAGGAGCAATGATCT

Product Size
(bp)

# of cycles

196

25

288

35

245

30

279

35

120

35

169

35

243

35

300

30

423

25

297

25

326

25

358

25

299

30

119

35

119

35

120

35

128

35

148

25

Table 5.1 RT-PCR primers
Primers used for the amplification of each of the indicated genes are shown along with
the expected product size and the number of cycles used in the PCR reactions. The cycle
number was selected based on the lowest number that revealed a product up to a
maximum of 35 cycles in the qualitative reverse-transcriptase PCR reactions. ENT,
equilibrative nucleoside transporter; CNT, concentrative nucleoside transporter.
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Figure 5.2. Analysis of purine transporter/metabolic enzyme gene expression in MVECs.
A: qualitative reverse-transcriptase PCR: PCR reactions were conducted using the
primers shown in Table 5.1, and the products were resolved on 2% agarose gels. The
same PCR conditions were used for each primer pair in both the WT and ENT1 -/samples, and all amplifications shown on each gel set were done in parallel using the
same WT and KO cDNA preparations. The first lane on each gel set represents the DNA
ladder (bp sizes as labeled). Set 1: ENT1, ENT2, ENT3, and β-actin (the vertical bar
indicates where a blank section of the gel image was removed between the ENT3 and βactin lanes); set 2: adenosine A2A receptor, adenosine A2B receptor, A3 receptor, and βactin; and set 3: adenosine kinase (ADK), adenosine deaminase (ADA), adenine
phosphoribosyltransferase (APRT), hypoxanthine-guanine phosphoribosyltransferase
(HGPRT), purine nucleoside phosphorylase (PNP), xanthine oxidase (XO), and β-actin. All
products were of the expected size. B: quantitative real-time PCR: apparent differences
in gene expression between the WT and ENT1-/- MVECs, as noted in the studies shown in
A, were confirmed by real-time PCR. Crossing point (CP) values, obtained from SYBR
green I fluorescence signals, were used to compute the concentrations of ENT3, ADA,
and adenosine A2A and A3 receptor transcripts, relative to β-actin. β-Actin CP values
were 19.3 ± 0.6 and 18.8 ± 0.7 for the WT and ENT1-/- samples, respectively. The geneto-β-actin ratios derived from each independent experiment were then averaged to
obtain the data shown. Each bar is the mean ± SEM of 3 separate amplification runs
from 2 independent mRNA isolations (n = 6). *P<0.05, significant difference in
expression between the WT and ENT1-/- cells (Student’s t-test). C: data from B plotted as
the relative change between the WT and ENT1-/- mice.
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Figure 5.3. ADA and A2A are upregulated at the protein level.
Proteins extracted from the extensor digitorum longus muscles of WT and ENT1 -/- mice
were separated by electrophoresis and immunoblotted, in parallel, with antibodies to
GAPDH (37 kDa), ADA (50 kDa), adenosine A2A receptor (45 kDa), adenosine A3 receptor
(43 kDa), and ENT3 (52 kDa).Representative immunoblots are shown in A. The results
(mean ± SEM) of densitometry analysis of 3 independent experiments with adenosine
receptor A2A and ADA are shown in B as a ratio relative to GAPDH. *P<0.05, significant
difference in expression between the WT and ENT1-/- muscle (Student’s t-test).
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Figure 5.4. Formycin B uptake by ENT2 is unchanged in MVECs from ENT1-/- mice.
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated with 10 µM
[3H]formycin B (FB) in the absence (Total, ▪) or presence of 50 nM NBMPR (+NBMPR;
selective inhibition of ENT1-mediated uptake, □) or 10 µM dipyridamole/NBMPR (+DY;
complete inhibition of transporter-mediated uptake, ●) for the times indicated. Uptake
is represented as picomoles of [3H]FB accumulated per microliters of intracellular water.
Each point is the mean ± SEM from 4 experiments.
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Figure 5.5. Uptake of 2-[3H]chloroadenosine by ENT2 is reduced in MVECS from ENT1-/mice.
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated for 5 or 15 s,
respectively, with the indicated concentrations of 2-[3H]chloroadenosine. Parallel assays
were conducted in the absence (total influx) and presence of either 50 nM NBMPR
(NBMPR-resistant influx) or 10 µM DY/NBMPR (nonmediated uptake) as described in
Figure 5.4 for [3H]FB uptake. The total transporter-mediated uptake of substrate was
calculated as the total influx minus the nonmediated component. The ENT2-mediated
uptake was calculated as the NBMPR-resistant uptake minus the nonmediated
component, and the ENT1-mediated uptake was estimated as the difference between
the total uptake and that seen in the presence of NBMPR. Results are plotted as
picomoles of 2-[3H]chloroadenosine accumulated per microliter of cell water per second
(Vi, ordinate) against the concentration of 2-[3H]chloroadenosine used (abcissa). Each
point is the mean ± SEM from 5 experiments. The transporter kinetic constants derived
from these data are shown in Table 5.2.
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Figure 5.6. Uptake of [3H]hypoxanthine was mediated by a dipyridamole-insensitive
transporter.
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated with 5 µM
[3H]hypoxanthine in the absence (Total) or presence of 10 µM DY (inhibition of ENT2mediated uptake) or 1 mM adenine for the times indicated. Uptake is represented as
picomoles of [3H]hypoxanthine accumulated per microliter of intracellular water (in
µM). Each point is the mean ± SEM from 4 experiments.
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Figure 5.7. Dipyridamole enchanced [3H]hypoxanthine uptake in WT, but not ENT1-/MVECS.
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated for 10 s with the
indicated concentrations of [3H]hypoxanthine (abcissa). Parallel assays were conducted
in the absence and presence of 1 mM adenine with or without the inclusion of 10 µM DY
as described in Figure 5.6. Results are plotted as the transporter-mediated uptake of
substrate (in pmol per µl of cell water accumulated per s; Vi, ordinate) after subtraction
of the adenine-insensitive component. Each point is the mean ± SEM from 5
experiments. The transporter kinetic constants derived from these data are shown in
Table 5.2.
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5.3.4 Purine Metabolism in ENT1-/- MVECs
We examined the [3H]metabolite profile of WT and ENT1−/− MVECs after exposure to
[3H]hypoxanthine under the conditions that we used for the uptake assays (Figure 5.8).
ENT1−/− MVECs had significantly higher intracellular levels of [3H]hypoxanthine than did
the WT MVECs after exposure to 100 μM *3H]hypoxanthine for 20 min. [3H]inosine levels
showed a trend toward being increased in ENT1−/− MVECs; however, this difference was
not significant unless dipyridamole was present to block the remaining ENT2-mediated
efflux. The difference between the WT and ENT1 −/− MVECs was also attenuated in the
presence of the ENT blocker dipyridamole.
5.3.5 Effects of Free Radical Generators on Purine Transport in Mouse MVECs
The hydroxy radical producing TBHP had no effect on ENT1, ENT2 or ENBT1 in primary
mouse MVECs following 100 µM treatment for 30 minutes (Figure 5.9). Following
treatment with the intracellular ROS generator menadione, the Vmax of ENT1 mediated
2-[3H]choloroadenosine uptake dropped significantly from 15.6 ± 2.7 pmol/µl/s to 4.9 ±
2.1 pmol/µl/s. The Vmax of ENT2 also appeared to drop, however the small amount of
ENT2 present in mMVECs resulted in high background that prevented statistical analysis.
[3H]Hypoxanthine mediated uptake via ENBT1 was not affected by menadione
treatment, however the small amount of ENT2 mediated [3H]hypoxanthine uptake that
was present in control cells appeared to be abolished in menadione treated cells (Figure
5.10).
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Table 5.2 Kinetic parameters for the transporter-mediated uptake of 2-chloroadenosine
and hypoxanthine by MVECs isolated from WT and ENT1-/- mice.

Total

WT
ENT1

ENT1 -/ENT1

ENT2

Total

Vmax (pmol/μl/s)

18 ± 3

24 ± 5

1.2 ± 0.5

-

nd *

0.19 ± 0.06 *

Km (μM)

84 ± 17

147 ± 44

9±3

-

nd *

13 ± 6

Total

DY
-insensitive

ENT2

Total

DY
-insensitive

ENT2

Hypoxanthine
Vmax (pmol/μl/s)

12 ± 2

17 ± 4

nd

10 ± 2

12 ± 2

nd

Km (μM)

84 ± 20

126 ± 29

nd

96 ± 29

131 ± 32

nd

ENT2

2-Chloroadenosine

Values are means ± SEM; n = 5 WT and 5 ENT1-/- mice. MVECs, microvascular
endothelial cells; WT, wild-type; ENT1-/-, ENT knockout; DY, dipyridamole; ND, no
transport activity detected. *P<0.05, significant difference between WT and ENT1-/(Student’s

t-test).
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Figure 5.8. [3H]Metabolite profile in WT and ENT1-/- MVECs.
MVECs isolated from WT and ENT1-/- mice were depleted of ATP and incubated with 100
µM [3H]hypoxanthine in the absence and presence of 10 µM DY for 20 min. Acid extracts
of cell pellets were neutralized with 1 M KOH, and aliquots were subjected to thin-layer
chromatography as described in section 5.2.4. A repeated-measures ANOVA was
performed within each metabolite group. *P<0.05 compared with WT -ATP condition;
†P <0.05 compared with WT -ATP +DY condition.
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5.3.6 Effects of Ischemia and Hypoxia on Purine Transporters
Treatment with the HIF-1α stabilizer CoCl2 resulted in a significant decrease in mENBT1
Vmax of [3H]hypoxanthine uptake to 21 ± 10% of control. 2-[3H]Chloroadenosine uptake
by mENT1 was not affected (Figure 5.11A-B). Exposure of cells to a simulated ischemic
environment by mineral oil overlay caused significant reduction in ENBT1 V max in
primary mouse MVECs. (Figure 5.11C). When cells were exposed to true hypoxia of 1%
O2 ENBT1 Vmax of [3H]hypoxanthine uptake increased significantly from 9.5 ± 2.2
pmol/µl/s to 31.4 ± 5.1 pmol/µl/s in MVECs (Figure 5.11D).
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Figure 5.9. TBHP had no effect on purine transport.
Primary mouse MVECs were treated with 100 µM TBHP for 30 minutes at 37°C. Uptake
of 2-[3H]chloroadenosine(A and B) and [3H]hypoxanthine (C and D) was determined as
described in Chapter 2. Data are means ± SEM of 6 (A and B) or 5 independent
experiments (C and D).
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Figure 5.10. Menadione reduced the Vmax of ENT1 mediated 2-chloroadenosine uptake.
Primary mouse MVECs were treated with 100 µM menadione for 30 minutes at 37°C
prior to uptake of 2-[3H]chloroadenosine (A and B) and [3H]hypoxanthine (C and D). A)
Uptake of 2-[3H]chloroadenosine by ENT1 following menadione treatment (open
squares, dotted line) had a Vmax of 4.9 ± 2.1 pmol/µl/s compared to the Vmax of control
cells (solid squares, solid line) of 15.6 ± 2.7 pmol/µl/s. Data are mean ± SEM of three
independent experiments, P<0.05 by two-tailed t-test. B) ENT2 mediated uptake of
2-[3H]chloroadenosine also appeared to decrease following menadione treatment but
high variability prevented statistical analysis (n=3). C) ENBT1 mediated uptake of
[3H]hypoxanthine was not affected by menadione treatment (n=3). D) ENT2 mediated
uptake of [3H]hypoxanthine was abolished (n=3).

179

180

Figure 5.11. Hypoxanthine uptake can be altered by both ischemia and hypoxia in
mouse MVECs.
Primary mouse MVECs were treated with 100 µM CoCl2 for 2 hr at 37°C. ENT1 and
ENBT1 uptake of 2-[3H]chloroadenosine and [3H]hypoxanthine, respectively, (A and B)
was determined. Only ENBT1 function was altered. The Vmax of CoCl2 treated cells (open
squares, dotted line) decreased to 21 ± 10% of control (solid squares, solid line). Data
are means ± SEM of 4 independent experiments for each substrate. C) MVECs were
subjected to simulated ischemia by mineral oil overlay. The Vmax of ENBT1 mediated
uptake of [3H]hypoxanthine dropped from 23 ± 6 pmol/µl/s to 5 ± 1 pmol/µl/s after 2 hr
of simulated ischemia. P<0.05 two-tailed t-test, n = 4. D) Following exposure to 1% O2
for 2 hr, uptake of [3H]hypoxanthine increased in primary mouse MVECs following
hypoxia, with ENBT1 Vmax increasing from 9.5 ± 2.2 pmol/µl/s to 31.4 ± 5.1 pmol/µl/s,
P<0.05 two-tailed t-test, n = 3.
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5.4. DISCUSSION
5.4.1 Compensatory Changes in ENT1-/- MVECs
We performed both semi-quantitative and quantitative real-time PCR to determine
which purinergic genes, if any, had altered transcript expression as a result of the
genetic loss of ENT1. Statistical differences in PCR were followed up by western blotting.
While there were significant changes in adenosine receptor A3 and ENT3 at the
transcript level, the lack of correlation between changes in mRNA versus protein levels
for these relatively low abundance transcripts may reflect posttranscriptional regulation
of translation efficiency and protein processing. The significant increases in ADA and A2a
transcripts were confirmed at the protein level as well. These adaptive changes can be
rationalized, from a cell homeostasis perspective, if one assumes that the loss of ENT1 is
leading to a reduced efflux of adenosine (arising from ATP metabolism) from the MVECs.
This would result in an increased cytoplasmic adenosine and a decreased extracellular
adenosine in the ENT1−/− compared with WT mice. The increase in ADA would lead to
more adenosine metabolism to inosine, which may then be converted to either
hypoxanthine or inosine monophosphate (2), thereby reducing intracellular adenosine.
Adenosine has well-established vasodilatory (5) and anti-inflammatory activities (21),
mediated in part via extracellular adenosine A2A receptors on vascular endothelial cells.
Thus the increase in adenosine A2A receptor expression may be compensating for the
lower levels of adenosine-mediated signaling in the ENT1−/− mice as a consequence of
reduced extracellular adenosine concentrations. A previous study has also invoked
lower extracellular adenosine levels as an explanation for the reduced A 1 adenosine
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receptor signaling observed in the brains of ENT1−/− mice (12). In contrast to our findings
in MVECs, there does not appear to be a compensatory upregulation of adenosine A 2a
receptors in cardiomyocytes isolated from the ENT1−/− mice (31), suggesting that
different cell types respond differently to changes in adenosine bioavailability. With the
consideration that adenosine receptor expression varies between different tissues and
therefore adenosine has differing physiological effects in each tissue, the compensatory
changes that would result from altered adenosine levels might be expected to differ in
different tissues and cell types.
5.4.2 Alterations in Purine Transport Capacity
The

WT

MVECs

accumulated

both

[3H]formycin

B

(Figure

5.4)

and

2-

[3H]chloroadenosine(Figure 5.5) via two distinct Na+-independent dipyridamolesensitive processes (Table 5.2). The majority (∼90%) of the substrate uptake in WT
MVECs was inhibited by 50 nM NBMPR and hence was mediated by ENT1. The
remainder of the uptake was inhibited by dipyridamole, but not NBMPR, and hence was
mediated by ENT2. It is noteworthy that mouse MVECs are very different from rat
MVECs where ENT2 mediates ∼50% of the total nucleoside uptake (3). Thus one would
expect an ENT1-selective inhibitor such as NBMPR to have a much greater effect on
nucleoside levels in the cardiovasculature of mouse compared with its effects in rat. The
lack of change in ENT2 mediated [3H]formycin B uptake corresponds to the lack of
change in ENT2 transcript levels. The interesting observation that the 2[3H]chloroadenosine Vmax for ENT2 was significantly decreased in ENT1-/- knockout cells
may be an artifact of the uptake procedure, as ENT2 mediated uptake is defined as
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2-[3H]chloroadenosine uptake in the presence of 50 nM NBMPR, to inhibit ENT1
transport function.
Mouse MVECs appear to have a dipyridamole-insensitive nucleobase transporter very
similar to the ENBT1 transporter described in detail in Chapter 3, and therefore quite
possibly was the mouse ortholog of the human transporter. As such, ENBT1 was used to
refer to the dipyridamole-insensitive hypoxanthine transporter in mMVECs.
Hypoxanthine is a metabolite of adenosine metabolism and would be produced in the
endothelial cells under conditions of high adenosine release from surrounding cells,
such as would occur during tissue ischemia (2; 15; 16). This hypoxanthine is metabolized
intracellularly by xanthine oxidase with the consequent production of reactive oxygen
species. Reactive oxygen species are believed to play a role in mediating the endothelial
dysfunction observed in various pathological conditions including diabetes and
ischemia-reperfusion injury (6; 20; 32). Therefore, understanding how MVECs handle
hypoxanthine is important in the overall evaluation of purine metabolism in the
vasculature. It appears that both mouse and human MVECs, which have low or no ENT2,
respectively, rely heavily on this nucleobase transporter for the transfer of nucleobases
across the cell membrane. Rat MVECs, on the other hand, which express high levels of
ENT2 (which can transport nucleobases), do not appear to express functional ENBT1.
Further studies on this novel nucleobase transport system are needed.
When studying ENBT1 transport kinetics in mouse MVECs, it was found that the ENT2
blocker dipyridamole caused an apparent increase in Vmax in WT cells but had no effect
in ENT1-/- cells (Figure 5.7). Given that part of the hypoxanthine uptake in the MVECs
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would be due to the activity of ENT2, one should actually expect to see a small decrease
in hypoxanthine uptake in the presence of dipyridamole. One interpretation of these
data is that dipyridamole was blocking the efflux of a metabolite of hypoxanthine via
ENT1. In normal cell metabolism, hypoxanthine is typically formed as a metabolite of
inosine and is efficiently metabolized by xanthine oxidase to xanthine or by HGPRT to
inosine monophosphate such that there is little free hypoxanthine in cells. However,
under the experimental conditions used in this study, where cells are exposed to high
concentrations of hypoxanthine, it is possible that the [3H]hypoxanthine is being
metabolized to [3H]inosine via purine nucleoside phosphorylase (9). As noted above,
inosine is a substrate for ENT2 and ENT1, both of which are blocked by dipyridamole.
The WT MVECs, with their high level of expression of ENT1, would release the
[3H]inosine formed in this way much more rapidly than would the ENT1-deficient cells
and would thus be more sensitive to the effects of dipyridamole. To test this hypothesis,
a [3H]metabolite profile was produced using a 1-D TLC method. The profile generated
(Figure 5.8) supported the idea that [3H]hypoxanthine is being metabolized to
[3H]inosine by nucleoside phosphorylase under these assay conditions and that this
[3H]inosine is not released from ENT1−/− cells as effectively as it is from WT MVECs.
These data also show that the ATP-depletion protocol used led to the expected
reduction in the conversion of hypoxanthine to its phosphorylated metabolites.
5.4.3 Impact of Ischemia and Hypoxia on Purine Transport in WT MVECs
The oxidation of proteins is known to result in altered function. To determine how
nucleoside and nucleobase transporters respond to the presence of increased ROS,
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cultured primary cells were treated with extracellular (TBHP) or intracellular
(menadione) ROS generators. Only menadione affected transport, and resulted in
decreased transport capacity. This effect was similar to that observed in primary human
MVECs in Chapter 4. Menadione (2-methyl-1,4-naphthoquinone) produces ROS
intracellularly via metabolism by NAD(P)H:quinone oxidoreductase 1 in a redox cycling
manner, directly generating superoxide anions(14). This is in contrast to TBHP, a
peroxide, which forms hydroxyl radicals in the presence of iron via the Fenton reaction,
or in the presence of superoxide anions by the Haber-Wells reaction. Peroxides are also
detoxified to water and oxygen enzymatically by glutathione peroxidase (26). Thus, it is
possible that the lack of effect of TBHP on purine transport could be at least three fold:
1) the conditions were not suitable for hydroxyl radicals to be formed, 2) glutathione
peroxidase removed all TBHP prior to radical formation, or 3) ENT1 and ENBT1
transporters are not sensitive to oxidation by hydroxyl radicals.
The superoxide anions produced by menadione are usually short lived and are
converted into hydrogen peroxide by superoxide dismutase. However, in the presence
of nitric oxide (NO) which is produced by endothelial nitric oxide synthase, the two
radicals combine to form peroxynitrite (ONOO-), a much more potent oxidizing agent
(34). Peroxynitrite has been shown to decrease the function of other transport proteins
including the high affinity choline transporter, the human serotonin transporter(8), and
the human dopamine transporter (29). Therefore it is possible that that the decrease in
ENT1 and ENT2 function observed following mMVEC exposure to menadione was the
result of peroxynitrite formation.
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It has been previously established that ENT1 is a target of the HIF-1α transcription
factor(1; 18). However the time required for a down-regulation was upwards of 8 hr
(18). It was unknown if the nucleobase transporter ENBT1 was also a target. Initial
experiments were conducted with the known HIF-1α stabilizer, CoCl2 (30). Treatment
with 100 µM CoCl2 for 2 hr was only capable of reducing transport function of ENBT1,
not ENT1. The treatment time used was much less than that known to cause HIF
mediated ENT1 down-regulation but was chosen to reflect an acute ischemic event in
the vasculature. In Chapter 4, it was shown that CoCl2 has no effect on human
transporters. CoCl2 has also been shown to generate ROS in addition to HIF-1α
stabilization, and the effects of CoCl2 are selectively blocked by the antioxidant ascorbic
acid (vitamin C)(13). A major difference between the mouse and human MVEC medium
was that the CoCl2 added to the human medium contained an additional
supplementation of ascorbic acid (concentration unknown; proprietary information).
Therefore, the lack of similar ENBT1 down-regulation in hMVECs may have been due to
the protective presence of ascorbic acid.
The nucleobase transporter ENBT1 was extremely sensitive to 2 hr of simulated
ischemia with hypoxanthine uptake function being reduced by approximately 80%,
similar to that of the human ENBT1 as shown in Chapter 4. The increase in V max of ENBT1
mediated [3H]hypoxathine uptake after 2 hr of hypoxia (1% O2) suggests that ischemia
and hypoxia cause differential effects in mouse MVECs. Since these assays were
conducted in ATP-replete conditions as not to interfere with any regulatory processes,
the most likely explanation for the apparent increased Vmax is due to increases in
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[3H]hypoxanthine metabolism. Hypoxia is known to convert xanthine dehydrogenase to
the hypoxanthine metabolizing xanthine oxidase.
5.4.4 Conclusions
The loss of ENT1 in the ENT1−/− mice leads to a dramatic reduction in the ability of
MVECs to accumulate and release nucleosides such as adenosine. Despite this loss of
nucleoside transport capacity, the ENT1−/− mice appear phenotypically normal under
baseline conditions. There did not appear to be any compensatory upregulation of the
other major plasma membrane nucleoside transporter ENT2 in the ENT1 −/− mice, but
there were increases in both ADA and A2A adenosine receptor expression in MVECs and
the skeletal muscle tissue from which the cells were isolated. The consequent changes
in adenosine metabolism and adenosine-mediated signaling via the A2A receptor likely
compensate for decreased extracellular adenosine levels in the ENT1−/− mice and allow
them to function normally under baseline conditions. However, given the widely
acknowledged role of adenosine as a cardioprotectant in conditions of cardiovascular
stress, it might be anticipated that the ENT1−/− mice will be less able to respond to
cardiovascular stresses associated with conditions such as diabetes and ischemiareperfusion injury. Alternatively, a reduced uptake of extracellular adenosine might
potentiate adenosine-receptor activation and subsequent cardioprotection, suggesting
that ENT1−/− mice might be permanently preconditioned (22; 23) and thus protected
from ischemic or hypoxic challenge.
The studies in this chapter have provided the ground work for studying the role of
purine transporters in oxidative stress in the microvasculature. Observations that the
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hypoxanthine transporter, ENBT1 is affected by both intracellular ROS and ischemia
point to ENBT1 being a contributing factor to endothelial dysfunction following an
ischemic insult. Using the ENT1-/- MVECs will establish how ENT1 and thus adenosine
transport contribute to the generation of ROS and the impact on ENBT1 function.
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CHAPTER SIX
ADDITIONAL PHENOTYPES OF THE ENT1-/- MOUSE: FROM HYPOTENSION TO
SPINAL HYPEROSTOSIS.
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6.1 Introduction
The equilibrative nucleoside transporter 1 (ENT1; SLC29A1) is the predominant
nucleoside transporter expressed in mammalian cells. ENT1 is a sodium-independent,
facilitative diffusion transporter that is responsible for the movement of hydrophilic
nucleosides, like the purine adenosine, across biological membranes in a concentration
dependent manner. Pharmacological inhibition of ENT1 has been shown to increase
local adenosine levels and promote the cardio- and neuro-protective actions of the
nucleoside.
An ENT1-/- mouse has been generated by Choi and his collaborators (4). ENT1-/- mice
were viable but had a slightly lower body weight upon reaching maturity. The behaviour
of the ENT1-/- mice is altered compared to their wild-type (WT) counterparts, especially
in respect to increased ethanol consumption (4) and decreased anxiety (3).
Work in our lab has explored changes at the cellular level in the microvascular
endothelium (MVEC) and in cardiomyocytes. In MVECs, ENT1 loss results in an increase
in both adenosine receptor A2A and adenosine deaminase transcript and protein(1).
Cardiomyocytes from ENT1-/- mice are more resistant to ischemic insult(23).
Despite the work that has already been done, a complete phenotype of the ENT1-/mouse has not been described. In particular it is unknown what phenotypes manifest as
the mouse ages. Here we report for the first time novel cardiovascular and skeletal
phenotypes of the ENT1-/- mouse.
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6.2 Materials and Methods
6.2.1 Animals
ENT1−/− mice were generated in the laboratory of Dr. Doo-Sup Choi as described
previously(4); ENT1−/− mice were backcrossed with outbred WT C57BL/6 mice to
generate ENT1−/+ mice. ENT1-/- had reduced reproductive viability, therefore only
ENT1−/+ mice were crossed (producing ENT1+/+, ENT1+/−, and ENT1−/− offspring) to
establish a breeding colony at the University of Western Ontario. Genotyping was done
using isolated genomic DNA and standard PCR as previously described(1). All aspects of
this study were conducted in accordance with the policies and guidelines set forth by
the Canadian Council on Animal Care and were approved by the Animal Use Committee
of the University of Western Ontario.
6.2.2 Quantitative Real-Time PCR
Female ENT1-/- and wild type mice were sacrificed simultaneously at 4 to 6 weeks of age.
Whole heart, brain and kidney samples were extracted and placed in 10 ml guanidine
thiocyanate (GTC) buffer (4.2M GTC, 25mM sodium citrate, 1mM EDTA, 0.7% (v/v) 2mercapto-ethanol, in distilled water; pH adjusted to 7.0) per gram of tissue. Tissue was
homogenized using a Polytron® benchtop homogenizer. First-strand DNA template was
generated using 5 μg (MVECs) of DNaseI (Invitrogen, Carlsbad, CA)-treated total RNA
and the Superscript First Strand Synthesis System for RT-PCR using oligo d(T) primers
(Invitrogen). Quantitative real-time PCR analysis was performed using a Roche
LightCycler (Roche Applied Sciences, Mississauga, ON, Canada) as described in Chapter
5, section 5.2.5.
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6.2.3 Haemodynamics
Heart rate and blood pressure were determined using the CODA-6 non-invasive tail-cuff
machine (Kent Scientific) (8). Where needed, anaesthesia was induced using
ketamine/xylazine at 80% of a 100/10 mg/kg dose. Anaesthetized animals were kept on
a heated pad to prevent loss of body temperature. Animals were subjected to five
acclimatization rounds (no data collection) followed by two separate acquisition cycles
of 15 measurements each. There was a 60 second rest between acquisition cycles. The
tail cuff deflated over a period of 20 seconds during data acquisition.
6.2.4 High Performance Liquid Chromatography
Three month old mice were anaesthetized with pentobarbital and blood was collected
by cardiac puncture into a syringe containing 118 mM NaCl, 5mM KCl, 13.2mM EDTA,
10µM 5-iodotubercidin, 100µM erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride
(EHNA), and 10µM dilazep (21). Serum was isolated by centrifugation at 3000 x g for 10
minutes at 4°C. Serum was applied to a 10 kDa cutoff ultra-filtration column and
centrifuged at 14 000 x g for 15 minutes at 4°C. Filtrate was used for HPLC analysis(5).
Filtered serum was analyzed on an Onxy monolithic C18 column with a slightly modified
protocol established by Farthing D et al (5) in which adenosine was detected with a UVdetector at 260nm and adenosine metabolites were detected at 250nm, instead of all
compounds being detected at 250nm.
6.2.5 Micro Computed Tomography (µCT) Imaging
Formalin fixed or snap frozen whole mice and spines were imaged in collaboration with
Dr. David Holdsworth at the Preclinical Imaging Research Centre at Robarts Research
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Institute (London, ON) using the explore speCZT scanner (GE Healthcare Biosciences,
London, Ontario, Canada). Data were acquired with an x-ray tube voltage of 90 kV and a
current of 40 mA. In one continuous rotation, 900 views were obtained at an angular
increment of 0.4o. The scan time was 5 minutes. A calibrating phantom, consisting of a
vial of water, air and a synthetic bone (SB3), was imaged together with the specimens.
Images were acquired at isotropic voxel size of 50 m and reconstructed into 3D images,
at the same voxel size, using a modified conebeam algorithm (6). The reconstructed
data were expressed in Hounsfield units by calibrating the grey level values against
those of water and air.
6.2.6 Histology
Spines and joints were dissected from WT and ENT1-/- mice of various ages and fixed in
10% neutral buffered formalin. Samples were processed by The Molecular Pathology
Laboratory at Robarts Research Institute (London, ON) and were decalcified before
being embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).
6.2.7 Scanning Electron Microscopy
A small section of spine isolated from an ENT1-/- mouse that included two verterbrae
and their corresponding intervertebral space was sent to The Nanofabrication Facility at
the University of Western Ontario. The sample was analyzed with a Leo (Zeiss) 1540XB
scanning electron microscope (SEM).
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6.3 Results

6.3.1 Changes in Purinergic Genes in Organs
Organs were chosen with respect to known adenosine physiology. ENT2 transcript levels
were found to be significantly increased in the kidney and significantly decreased in the
heart of ENT1-/- mice as compared to their wild type litter mates. CNT2 expression was
found to be significantly elevated in both kidney and brain tissue from ENT1 -/- mice.
Adenosine receptor A2A transcript levels were significantly higher in brain tissue of
ENT1-/- mice and significantly lower in the heart as compared to the wild type. There
was no difference in A2A expression between wild type and ENT1-/- kidney samples.
Expression of adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and
xanthine oxidase (XO) was compared between wild type and ENT1-/- kidney, brain and
heart samples. ADA transcript was present at a significantly higher level in kidney
samples of ENT1-/- mice as compared to the wild type. No significant differences in ADA
expression were observed in brain or heart. PNP expression was also significantly
elevated in ENT1-/- kidneys compared to the wild type with no differences in expression
of this gene in the brain or heart. XO expression was shown to be significantly lower in
ENT1-/- mouse brain tissue than in wild type brain tissue. No significant differences in
XO expression were found in kidney or heart samples (Figure 6.1).
6.3.2 Haemodynamics
The heart rate of awake WT mice was 680 ± 20 beats/minute and was significantly
higher than the 590 ± 20 beats/minute heart rate of ENT1-/- mice (n=7; P<0.05 Student’s
t-test) (Figure 6.2). There was no strain-related difference in blood pressure between
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awake animals. However, when the animals were anaesthetized, the heart rate for both
WT and ENT1-/- mice was the same, 440 ± 20 and 430 ± 20 beats/minute respectively. To
ensure animals were on an equal baseline, all subsequent measurements were
performed on anaesthetized mice. In mice aged 2-3 months, WT mice had significantly
higher blood pressure than their ENT1-/- counterparts, systolic: 131 ± 12 mm/Hg, 115 ± 5
mm/Hg; diastolic: 99 ± 9 mm/Hg, 80 ± 6 mm/Hg; mean arterial pressure: 110 ± 10
mm/Hg, 91 ± 5 mm/Hg respectively. Interestingly, mice aged >6 months did not. In fact
there was a trend towards the reverse with older ENT1-/- mice having elevated blood
pressure compared to their WT counterparts (Figure 6.2).
6.3.3 Plasma Purines
Free plasma adenosine in WT animals was 600 ± 100 ng/ml where as ENT1-/- animals
had 2.75 fold higher levels at 1650 ± 370 ng/ml (Figure 6.3).
6.3.4 Unexpected Paresis and Paralysis
During the studies leading to the publication by Bone et al. (2), a number of ENT1-/mice were left to age without any intervention, simply for the sake of not wanting to
sacrifice the poorly breeding genotype. When ENT1-/- mice reached an age of around 8
months it was noted that they had decreased mobility in their hind limbs. Mice would
live from anywhere between 12 and 16 months of age before their condition required
euthanasia. Some mice requiring euthanasia had complete paralysis of their hind limbs.
All mice had abnormal curved spines that were extremely rigid; freshly euthanized ENT1 /-

mice were unable to be laid out flat on their backs. Any ENT1-/- mouse to reach this

age
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Figure 6.1. Purinergic gene changes in other organs.
Purinergic genes of interest were examined by quantitative real-time PCR. Solid bars
represent wild-type (WT) mRNA levels while open bars represent ENT1-/- (KO) mRNA
levels, normalized to β-actin. Statistical comparisons were made between WT and KO
per gene per organ. No comparisons were made between genes or between organs.
ENT2, equilibrative nucleoside transporter 2; CNT2, concentrative nucleoside
transporter 2; ADA, adenosine deaminase; PNP, purine nucleoside phosphorylase; XO,
xanthine oxidase; A2a, adenosine receptor 2A. *P<0.05 two-tailed t-test, n ≥ 3.
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Figure 6.2. ENT1-/- mice have lower blood pressure than WT mice.
Aged matched male mice were analyzed with a CODA-6 non-invasive tail-cuff machine
as described in the methods. A) Heart rates of awake WT and ENT1 -/- mice were
determined. WT mice had an elevated mean heart rate of 680 ± 20 beats/minute
compared to 590 ± 20 beats/minute heart rate of ENT1-/- mice (n=7; P<0.05 Student’s ttest). There was no difference between the heart rate of anaesthetized animals at 440 ±
20 and 430 ± 20 beats/minute for WT and ENT1-/- animals respectively. B) Blood
pressure of anaesthetized 2-3 month old male mice was determined. C) Blood pressure
was determined in anaesthetized WT and ENT1-/- mice older than 6 months. No
statistical differences were observed however there was a trend towards increased
pressure in the ENT1-/- mice.
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Figure 6.3. Circulating plasma adenosine is elevated in ENT1-/- mice.
Blood was obtained from age matched WT and ENT1-/- mice via cardiac puncture and
processed for HPLC analysis as described in the methods. Adenosine levels were
significantly elevated in ENT1-/- mice at 1650 ± 370 ng/ml compared to 600 ± 100 ng/ml
in WT mice. There were no differences in xanthine or uric acid concentrations.

206

developed these symptoms. A post-mortem analysis conducted on one male ENT1-/mouse revealed the presence of hard, white deposits on the ventral side of the spine.
These deposits were most numerous in the thoracic region however, they did extend
into the lumbar spine. In the lumbar region, the lesions were much more organized and
appeared to be localized in the intervertebral space (Figure 6.4).
6.3.5 Histology
Histological examination of formalin-fixed, decalcified, paraffin-embedded sections of
spine confirmed the lesions were associated with the intervertebral spaces and were
large, irregular accumulations of eosinophilic, amorphous material. In fact, the lesions
appeared to have replaced the intervertebral discs in their entirety in the thoracic
region. Some lesions were so large they would protrude into the spinal column and
impinge on the spinal cord, leading to compression that most likely was the source of
the paresis and paralysis observed. Lesions appeared to be specific to the ventral spine
(Figure 6.5)
Joints, including knees and shoulders were examined histologically for evidence of
abnormal mineralization or mineral deposits between opposing bones. Interestingly,
there was no indication of abnormal mineral being present in these areas (Appendix 4).
6.3.6 µCT Scanning
Since the lesions forming on the spine contained minerals similar to bone, µCT scanning
was used to examine both whole mice and isolated spines preserved at fixed ages. Scans
of a one year old ENT1-/- mouse confirmed the extensive mineral deposits were
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Figure 6.4. ENT1-/- mice develop mineralized lesions on the spine.
Spines from WT and ENT1-/- mice (KO) were removed and examined with a Nikon
SMZ1500 microscope with digital camera. A) WT and KO thoracic spinal sections (as
labelled) were compared side by side ventrally. Abnormal mineralization is highlighted
by arrows. 1: vertebrae, 2: intervertebral disc, 3: rib. B) Ventral view of lumbar spines
from WT and KO mice. Abnormal mineral is highlighted by arrow. 4: vertebrae, 5:
intervertebral disc.

208

209

Figure 6.5. Histology of ENT1-/- spines reveals spinal cord impingement.
Formalin fixed, decalcified spines were sectioned longitudinally and stained with H&E.
Images were captured at 4x magnification, with dorsal orientation at the top of the
image. Top images are sections of thoracic spine, bottom images are sections of lumbar
spine. Images on the left are from a wild-type (WT) mouse and images on the right are
from an ENT1-/- (KO) mouse. Yellow arrow identifies abnormal mineralization protruding
into spinal column and resultant spinal cord compression. a: normal intervertebral disc,
b: normal spinal cord, c: normal vertebra, 1: compressed spinal cord, 2: dorsal
intervertebral disc, 4: ventral intervertebral disc, 5: vertebra.
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localized to the spine and confined to the intervertebral spaces in a ventral specific
manner (Figures 6.6A&C). A rostral to caudal view through the spinal column showed
that some lesions did indeed intrude into the spinal column as first seen in histological
sections (Figures 6.6B&D). A time course of lesion development and progression was
also developed using µCT scanning. Spines from 2, 4, 5, and 6 month old WT and ENT1 -/mice were scanned and compared. Mineralized lesions could be seen in the 2 month old
ENT1-/- mice (Figure 6.7A). A very distinct pattern of lesion development was observed,
with the cervical spine being affected first. At the age of five months, lesions can be
observed in the thoracic spine (Figure 6.7C). Very specific lesion formation was also
observed at the first false rib (Figures 6.7C&D).
In contrast to the histology and µCT performed on spines of 12 month old mice, these
time course data suggest the abnormal mineralization begins to form on the outside of
the spine and slowly progresses into the intervertebral space.
6.3.7 Scanning Electron Microscopy
High resolution, high magnification images of the mineral deposit found in the
intervertebral space supported descriptions of the lesion from histological sections. The
lesion appeared devoid of any biological material. Organization resembled that of
angular crystals (Figure 6.8).
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Figure 6.6. Micro computed tomography of ENT1-/- spines.
Micro CT scans were performed and maximum intensity projections (MIP) images were
made. A) Spine from a WT mouse age 12 months. a: anterior, d: dorsal, p: posterior,
v:ventral. B) Rostral to caudal view showing individual vertebra and spinal column. C)
Spine from age matched ENT1-/- mouse. Arrows highlight areas of abnormal
mineralization. Orientation is the same as A). D) Rostral to caudal view of ENT1 -/- spine.
Arrow highlights mineral protrusion into spinal column.
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Figure 6.7. Time course of lesion development in ENT1-/- mice.
Spines from age matched WT and ENT1-/- mice (KO) were isolated and fixed in formalin.
Micro CT scans were performed and MIP images were rendered at 100 µm resolution.
A) WT (left) and KO (right) spines from 2 month old mice. B) 4 months old. C) 5 months
old. D) 6 months old. In all cases arrows highlight areas of abnormal mineralization.
These images are representative of µCT scans performed on at least three mice at each
age point.
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Figure 6.8 Scanning electron microscopy (SEM) images of mineral deposits in ENT1-/intervertebral spaces.
A sample of ENT1-/- spine that had a mineralized lesion in the intervertebral space was
imaged by SEM. A representative area was chosen and images were captured at 4
different magnifications: A) 500x, B) 758x, C) 1000x, D) 8660x.
Note the lack of any cellular or other biological presence. Since the mineral deposits do
not occur in WT mice, there are no images for comparison between the two strains.
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6.4 Discussion
We have characterized previously unreported age-related phenotypes of the ENT1-/mouse. This study furthers our understanding of the physiological roles of ENT1 and
adenosine, with particular focus on the local control of mineralization of paraspinal
tissue.
6.4.1 Altered gene expression
Changes in gene expression in microvascular endothelial cells isolated from mouse
skeletal muscle of ENT1-/- were presented in Chapter 5. Organs were chosen based on
the overall cardiovascular aspect of this thesis (heart) and organs in which adenosine
plays key physiological roles (brain, kidney, and heart). Of particular note are genes that
differentially change depending on the organ. ENT2 drops significantly in KO hearts but
rises significantly in KO kidneys. Adenosine receptor A2A rises significantly in the KO
brain but drops significantly in the KO heart. Rose and colleagues also examined gene
expression changes in the heart of ENT1-/- mice and found no statistical differences,
however there was a trend towards decreased A2A mRNA as well (23). The only other
reported gene change in the ENT1-/- mouse is an increase in adenosine receptor A1
protein in the striatum (4). In other model, where human ENT1 was over-expressed in
mouse neurons, there were no reported changes in gene expression (19). Clinically
based work examining the lack of human ENT1 expression in cancer, have linked ENT1
to response to nucleoside analogue chemotherapy (18; 25). Given that there are known
polymorphisms in the ENT1 gene (14; 17), and that the lack of ENT1 affects the
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expression of other genes that regulate adenosine bioactivity, more research is needed
to study the role of ENT1 in human diseases of the heart, brain, and kidney.
6.4.2 Altered cardiovascular function
ENT1-/- mice had a lower awake heart rate than their WT counterparts. The CODA-6
system has holding tubes for awake mice that limits mobility to obtain accurate
readings. This environment would lead to stress and anxiety in the WT mouse, where as
the ENT1-/- mouse is known to be less anxious in stressful situations(3). The normal
heart rate for C57BL/6 mice that are trained for the tail-cuff apparatus ranges between
600 and 620 bpm (11; 24), which is lower than the 680 bpm reported for the WT mice in
this study and higher than the 590 bpm of the ENT1-/- mice (Figure 6.2). Therefore, it is
proposed that anxiety in the WT mouse translated into a higher heart rate. This was
supported by the equal heart rates in anaesthetized mice, and evidence that anxiety in
mice results in elevated heart rates (7).
To avoid the differences in anxiety between WT and ENT1-/- mice, blood pressure was
measured in anaesthetized animals. ENT1-/- male mice aged 2-3 months had lower blood
pressure than aged matched WT mice (Figure 6.2). Our group has previously reported
that ENT1-/- mice have elevated adenosine receptor A2A protein expression in
microvascular endothelial cells isolated from skeletal muscle(1). A2A receptor signaling is
known to mediate vasodilation. In fact, the A2A-/- mouse is hypertensive (16). Adding to
the increased A2A expression previously reported, the current study showed that ENT1 -/had an elevated adenosine concentration in plasma from whole blood collected by
cardiac puncture (Figure 6.3). An increase in both the vasodilatory receptor and the
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ligand could result in consistently decreased peripheral resistance, resulting in lower
blood pressure in young mice. However, as these mice age, additional unknown factors
contribute to a normalization of blood pressure. While it is known that blood pressure in
mice increases as they age (8), the differential change between WT and ENT1-/- suggests
an altered condition in the ENT1-/- animal. It could be possible that there is a progressive
hardening of vessel walls, due to ectopic mineralization as seen with the soft tissue
found around the intervertebral spaces of the ENT1-/- mice. There are links between
adenosine, adenine nucleotides, and the calcification of arteries (12; 26). However, since
there is no µCT evidence, either the calcification is extremely diffuse to be undetectable,
or alternatively perhaps there is a gradual overcompensation of vasoconstrictor
production that eventually takes over the initial vasodilatory signal.
6.4.3 Abnormal mineral deposits in the spine
The role of adenosine in the formation of abnormal mineral deposits is poorly
understood. Abnormal calcification of vascular smooth muscle cells isolated from rat
aorta is enhanced by a cAMP dependent mechanism that aids in the reduction of
extracellular inorganic pyrophosphate (PPi) accumulation (20). Adenosine is capable of
increasing cAMP levels via the adenosine A2A and A2B receptor subtypes. However, a
very recent report by St. Hilarie et al., (26) suggests that adenosine is an inhibitor of
calcification. In that study, human patients with a non-function mutation in the CD73
enzyme that forms adenosine from AMP presented with abnormal vascular
mineralization. Fibroblasts isolated from one patient spontaneously formed calcium
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deposits in culture that was reversed by the addition of adenosine to the culture
medium (26).
A similar phenotype to our identified hypermineralization has been reported in mice
lacking nucleotide pyrophosphatase phosphodiesterase-1 (NPP1; Enpp1-/-). NPP1 is
responsible for the production of PPi via the metabolism of triphosphate nucleotides,
like ATP, to monophosphate nucleotides. These Enpp1-/- mice, also known as tip-toe
walking mice, spontaneously develop progressive ankylosing intervertebral and
peripheral joint hyperostosis and articular cartilage calcification (10). However, our
ENT1-/- mice do not appear to have any abnormal mineralization in other joints,
suggesting a different mechanism.
Interestingly, our spinal mineralization phenotype most closely resembles the human
condition diffuse idiopathic skeletal hyperostosis (DISH). DISH affects about 25% of the
male population over the age of 65, with a slightly lower occurrence in women (27).
Resnick and Niwayama state that a diagnosis of DISH must meet the following criteria:
1) the involvement of at least 4 contiguous vertebrae of the thoracic spine, 2)
preservation of the intervertebral disc space (distinct from akylosing spondylitis), and 3)
absence of apophyseal joints or sacroiliac inflammatory changes (22). Our phenotype
clearly agrees with conditions 1 and 3. If examined solely on 12 months of age or older
mice, then it would appear that condition 2 is not met. However, the µCT images of
younger mice (Figure 6) would suggest that as the mineralization develops the
intervertebral disc is intact. In reality, the severity of the mineral deposits in older mice
is much more likely an extreme that would not be found in human patients because
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humans will report their discomfort much sooner and more effectively than mice. Much
like the phenotype of our ENT1-/- mice, DISH is asymptomatic until there is compression
of surrounding tissues including the glottis resulting in dysphagia, or compression of the
spinal cord producing neurological complications (28). The etiology of DISH is unknown.
However in attempts to aid in the understanding of DISH, the Boxer dog has been
identified as having an unusually high prevalence (41% compared to an average of 4% in
other breeds) of DISH (15). Our lab had previously cloned the dog ENT1 gene (9), and
given the DISH like phenotype in the ENT1-/- mouse there was interest in the ENT1 gene
of the Boxer dog. In silico analysis of the ENT1 gene from mouse, human, Boxer dog, and
Alsatian dog, revealed that the Boxer dog has an altered ENT1 gene resulting in a
mutated protein missing 7 amino acids in a highly conserved region (Figure 6.9A). When
mapped to the proposed structure of ENT1, this deletion is predicted to be in the
second extracellular loop (Figure 6.9B), a region identified to be important in transport
function (13). Given the similarities between this condition and the hypermineralization
phenotype of our ENT1-/- mice, we are currently pursuing the hypothesis that alterations
in local adenosine concentrations as a result of the loss of ENT1 function contributes to
the development of DISH.
6.4.4 Conclusions
In conclusion, the ENT1-/- mouse is a valuable model for the study of adenosine
mediated regulation of vascular tone and is a possible novel model for the study of a
common but poorly understood human disease.
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Figure 6.9. Alterations in Boxer dog ENT1 protein.
A) Alignment of ENT1 sequences (from Genbank). Letters are single character amino
acid codes. Green colour indicates conserved, yellow indicated a unique residue, dashed
line represents missing residues.
B) Schematic of the proposed topology of dog ENT1 with missing amino acids identified
in red and unique amino acids in yellow. Additional species specific differences are not
shown.
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CHAPTER SEVEN
GENERAL DISCUSSION
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7.1 Review of Research Questions
In Chapter 2 research questions were identified that would be addressed in this thesis.
Study of nucleoside transporters in the microvasculature had been neglected, with the
majority of studies using the macrovascular HUVECs as a model. The understanding of
nucleobase transport was even sparser.
Choosing primary human MVECs as a model, questions regarding the expression and
function of nucleoside and nucleobase transporters were addressed. This work included
identifying what transporters existed in this cell type to mediated nucleoside and
nucleobase transport, as well as the molecular mechanisms in place that regulated the
function of these transporters.
An ENT1-/- mouse was also studied to understand how ENT1 contributes to purine
handling in the microvasculature. Through culturing primary mouse MVECs, it was
possible to address questions about compensatory mechanisms that exist to respond to
the missing nucleoside transporter ENT1. The whole animal was also studied to
determine the impact of the loss of ENT1 on cardiovascular physiology.

7.2 Picking an Appropriate Model: Differences in species and cell type
The idea that differences exist between species and cell types is not new. In fact there
are already several examples in the nucleoside transporter field that highlight this. It has
long been known that the pharmacology of ENT1 is species-dependent with inhibitor
affinities displaying a rank order of human being the most sensitive, rat being least
sensitive, and mouse falling in the middle (8). Additionally, the mouse ENT1 gene has
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multiple splice variants that affect transporter regulation and expression that do not
appear to exist in humans (9; 17).
7.2.1 Differences in expression of nucleoside and nucleobase between species.
It has been previously shown that primary MVECs isolated from rat skeletal muscle
express ENT1 and ENT2 in approximately equal amounts (1). In these cells ENT2 was the
nucleobase transporter of note and mediated both the uptake and release of
hypoxanthine (16). However, as shown in Chapter 3, primary human cardiac MVECs did
not display any functional ENT2. Additionally, it was discovered that a novel purineselective nucleobase transporter, ENBT1, was the transporter responsible for the uptake
and release of hypoxanthine. In Chapter 5, primary mouse skeletal muscle MVECs were
found to be different from both human cardiac and rat skeletal muscle. Mouse MVECs
expressed both ENT1 and ENT2, however the contribution of ENT2 to nucleoside uptake
was minimal. A mouse orthologue of ENBT1 was also discovered and was the
predominant nucleobase transporter. The relative expression of ENT1, ENT2, and ENBT1
with respect to species is highlighted in Table 7.1.
7.2.2 Impact of cell type.
In Chapter 4 regulation of ENT1 and ENBT1 was examined in primary human MVECs and
in some cases the immortalized endothelial cell line HMEC-1.
The effect of PKC activation and down-regulation in MVECs on ENT1 (Figure 4.8) was the
opposite of reported effects in cancer cells (4), but similar to HUVECs (13). The effect of
the CKII inhibitor TBB was similar to a recombinant expression model (3), but different
from a dominant negative model (18). Adenosine A2 receptor agonists had no effect on
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ENT1 in MVECs whereas it has been shown previously that both receptors can affect
ENT1 and ENT2 in HUVECs (6). There was even temporal and concentration differences
in the response to VEGF between MVECs and HMEC-1 cells within this work (Figures 4.3
and 4.4).
7.2.3 Species differences and cell types: conclusions.
It is clear that the choice of species and cell type is critical to the proper interpretation
of data. Based on rat MVECs it was predicted that human MVECs would express ENT2 as
both a nucleoside and nucleobase transporter. If human or mouse MVECs were not
actually studied, then the discovery of ENBT1 would not have occurred and the
realization that rat is not an appropriate model of nucleoside/nucleobase transport
would not have been made. Mouse, although closer to human MVECs than rat, is still
not an ideal model; however, mice have the advantage of providing genetically modified
models to study gene function.
The variation seen in response in different cell types when studying transporter
regulation reinforces the importance of proper model selection and highlights the need
to be careful when extrapolating results to another model.
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Table 7.1. Relative expression of nucleoside and nucleobase transporters in primary
MVECs from different species

Species
Human
Mouse
Rat

Tissue
Cardiac
Skeletal muscle
Skeletal muscle

ENT1
+
+++
+

ENT2
+
+

ENBT1
*
***
n.d.

In human primary MVECs only ENT1 and ENBT1 are expressed for nucleoside and
nucleobase transport respectively. In mouse, there is some detectable ENT2 expression,
however the contribution to either nucleoside or nucleobase transport is minimal,
hence the 3:1 ratio of symbols (this ratio is representative and not meant to be an
absolute measure of expression levels). In rat MVECs there is approximately equal ENT1
and ENT2 distribution.
-: no expression
n.d.: not determined (1; 16)
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7.3 Physiological Relevance
7.3.1 Discovery of a novel purine nucleobase transporter: A change in dogma.
Following the cloning and molecular characterization of ENT1 and ENT2, it was generally
accepted that ENT1 was the primary sodium-independent nucleoside transporter and
ENT2 was the sole sodium-independent nucleobase transporter (23). However, it is clear
from the data presented in this thesis that this dogma is in need of revision.
The existence of ENBT1, the dipyridamole-insensitive purine selective nucleobase
transporter changes the understanding of purine transport in mammalian cells.
Understanding that ENT2 most likely is not the transporter mediating uptake or release
of nucleobases and nucleobase analogues will change our views on cardiovascular
physiology, chemotherapy in cancer and other conditions, and possibly other areas of
physiology and pharmacology that are not yet appreciated. Figure 7.1 contrasts the old
and new understanding of nucleoside and nucleobase transport in mammalian cells.
7.3.1.1 Future Directions: The Genetic Identity of ENBT1
Characterization of ENBT1, as presented in Chapter 3, has laid the ground work for
understanding how the transporter functions. However, without knowing the genetic,
and therefore, molecular identity of ENBT1, these studies are limited in progression.
Expression studies using PCR and western blotting techniques are impossible without
this knowledge. Additionally, structure-function studies that would provide better
understanding of substrate recognition and inhibitor sensitivities, and even allow for the
rational design of nucleobase analogues that could be used in chemotherapies, are not
possible without knowing the genetic identity of ENBT1.
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With the sequencing of the human genome complete, the gene that encodes ENBT1 is
known, it just needs to be found. A group in Japan has ruled out that ENBT1 is a member
of the SLC23 family, or sodium-dependent ascorbate transporters (see Chapter 1). Since
ENT2 has a similar substrate profile to ENBT1, and the amino acids in ENT2 that help
confer the ability to transport nucleobases is known, genome searches for similar
regions may prove to be a good starting point.
In an alternative approach, further examination of the OCT family of transporters can be
performed. Chapter 3 tested a potential candidate, hUPP1, without success. As well,
substrates of OCT1 and OCT3 were tested as potential inhibitors of [ 3H]hypoxanthine
uptake, with mixed results. Despite these outcomes, there is still enough potential in an
OCT to justify a different approach. Expression of recombinant OCTs in HEK cells (which
lack functional ENBT1) can be used in gain of function experiments to better test the
possibility that an OCT is ENBT1.
7.3.2 ENBT1 and Ischemia-Reperfusion injury of MVECs
The generation of ROS from purine metabolism in endothelial cells during reperfusion
after ischemia is an established phenomenon (12). There is also evidence that ROS
generated in this manner contributes to endothelial dysfunction (7; 15; 22). The
sensitivity of the hypoxanthine transporter ENBT1 to superoxide produced
intracellularly by menadione may contribute to increased ROS production and overall
endothelial dysfunction through oxidative stress. Figure 7.2 proposes a model of how
ENBT1 contributes to ROS production and endothelial dysfunction.
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Figure 7.1. Changes in nucleoside and nucleobase transporter dogma.
Following the cloning of ENT1 and ENT2 it was generally accepted that ENT1 was the
primary Na-independent nucleoside transporter and ENT2 was the sole nucleobase
transporter that could also contribute to nucleoside transport. The top panel depicts
that view. Inhibitors of transport, NBMPR and dipyridamole, are connected to their
targets with red arrows.
The bottom panel depicts the current view of nucleoside and nucleobase transport in
primary human MVECs based on discoveries presented in this thesis. In place of ENT2,
ENBT1 is the sole nucleobase transporter, and is selective for purine nucleobases.
ENBT1 is also insensitive to dipyridamole inhibiton.

236

237

Figure 7.2. ENBT1 and ischemia-reperfusion injury of the microvascular endothelium.
The following schematic is a proposed model of how ENBT1 may contribute to injury of
the endothelium following ischemia-reperfusion.
During ischemia, adenosine released by surrounding cardiomyocytes accumulates in the
MVECs, via uptake by ENT1. Adenosine kinase is inactivated by ATP depletion and thus
the excess adenosine is metabolized to hypoxanthine. Without oxygen, the metabolism
of hypoxanthine cannot continue. ENBT1 mediates the efflux of hypoxanthine.
Upon reperfusion, the return of oxygen allows xanthine oxidase to metabolize
hypoxanthine to xanthine and xanthine to uric acid, producing ROS in the process. The
ROS produced attacks ENBT1, leading to decreased hypoxanthine efflux.
The resulting lack of ENBT1 function promotes increased hypoxanthine metabolism and
an increase in ROS, contributing to increased cellular oxidative stress, injury, and
possible endothelial dysfunction.
Notes: Inhibitory effect of ROS on ENBT1 is depicted by red arrow with diamond tip. The
non-functional or reduced function ENBT1 is depicted with as a red arrowless box with a
yellow starburst to suggest oxidative modification by ROS.
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7.3.2.1 Future Directions: ENT1, ENBT1, and ROS production
In Chapter 4, it was found that the intracellular superoxide generator menadione
reduced hypoxanthine uptake by a process that could be blocked by a superoxide
dismutase mimetic (Figure 4.12). While it would seem that this effect was mediated by
superoxide, no measurement of ROS was made.
Measuring ROS production, by use of fluorescent dyes, would strengthen the proposed
mechanism of reduced hypoxanthine uptake by menadione. As well, measurement of
ROS would allow the investigation of the role of ENBT1 and hypoxanthine transport on
the intracellular production of superoxide by hypoxanthine metabolism.
ROS measurement would also be useful after the mineral oil-overlay ischemia treatment
to determine a possible mechanism of action as the effects of ischemia are similar to
that of menadione treatment (Figure 4.13).
Other oxidants should also be tested on the ability to affect ENT1 and ENBT1 function.
As superoxide is rapidly converted to hydrogen peroxide or can react with NO to form
peroxynitrite, there is potential that there are additional mechanisms of oxidative stress
that could affect transport function (5; 11; 15). In fact, one recent study claimed that the
peroxynitrite donor SIN-1 reduced adenosine uptake in rat astrocytes (19). However, the
conditions of that study resulted in total adenosine accumulation rather than ENT1
mediated transport and the effects of SIN-1 on adenosine metabolism were not
addressed. Treatment of cells with stable peroxides, like tert-butyl hydroperoxide, or
with the peroxynitrite donor SIN-1 is needed to complete the profile of oxidative stress
on transporter function.
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7.3.3 New roles of ENT1 in disease
The ENT1-/- mouse has identified the contribution of ENT1 to the regulation of blood
pressure (Figure 6.2) and control of mineralization of tissues in the spine (Figures 6.46.6).
The link between ENT1 and blood pressure is not surprising, given that the ENT1
substrate adenosine is a potent vasodilator (2). However, the hypotension phenotype
raises the possibility that ENT1 may be a suitable target for the treatment of
hypertension. It may also be possible that enhanced ENT1 function contributes to the
development of hypertension, by limiting the exposure of adenosine to the vascular
lumen (10).
The hind limb paralysis and abnormal spinal mineralization observed in ENT1 -/- mice was
a serendipitous discovery. The connection between ENT1 and mineralization, especially
in such a specific manner, is not immediately clear. However, the resemblance of the
ENT1-/- mice to human patients with the condition DISH is exciting (14; 21). The cause of
DISH is currently unknown and there is no treatment option besides surgery. DISH is the
second most common form of arthritis, and the ENT1-/- mouse may prove to be an
excellent model to better understand this disease (20; 21).
7.3.3.1 Future Directions: The Role of ENT1 in Disease
Chapters 5 and 6 examined the role of ENT1 in MVECs and whole animals using ENT1 -/mice. While some changes in gene expression in MVECs were found, the impact of ENT1
to hypoxia, ischemia-reperfusion, and oxidative stress could not be completely
addressed due to difficulty in culturing ENT1-/- MVECs. Once the culturing process has
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been properly adjusted, data can be generated to complement the wild-type responses
observed in Chapter 5.
The ENT1-/- mouse had two interesting phenotypes, hypotension in young mice, and
abnormal mineralization in the spine, as discussed in Chapter 6.
The hypotension phenotype was determined with a tail-cuff system. Confirmation of the
phenotype should be performed using telemetry to obtain more natural measurements
of the course of a day. The potential of ENT1 in the treatment of hypertension can be
studied using isolated blood vessels and myograph systems.
The abnormal mineralization observed in the spine resembles the human condition
DISH. The mechanism behind the lack of ENT1 and abnormal mineralization has yet to
be determined. Altered gene expression that may contribute to the formation or
deposit of mineral in the ENT1-/- will be determined using quantitative PCR. Blood
chemistry analysis will be performed to identify possible changes in calcium or
phosphorous levels. Additionally, the specific tissue affected is currently unknown. More
in depth histological analyses need to be performed using mice at a variety of age
points. Samples from boxer dogs, who display a high rate of DISH, as well as from
diagnosed humans, for the study of ENT1 function will also help form a link between the
nucleoside transporter and the disease.
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7.4 Closing Remarks
The discoveries presented in this thesis strengthen the need to understand nucleoside
and nucleobase transporters, their expression, function, and regulation. It is evident
that these transporters are important in the microvasculature as well as overall
cardiovascular function, and even long term health.
Better understanding of ENT1 and ENBT1 at the molecular level will improve the
effectiveness of using these transporters as pharmacological targets in cardiovascular
disease, cancer, and surprisingly, pathological mineralization in the spine.
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Appendix 1: Copyright permission for Chapter 3
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Appendix 2: Copyright permission for Chapter 5
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Appendix 3: Ethics approval for usage of animals
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Appendix 4: Lack of mineralization in other joints

Unlike the spine from ENT1-/- animals (KO), joints such as knees and shoulders appear to
lack any abnormal mineralization.
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